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DNA methylation is an epigenetic modification important for the regulation of 
transcriptional activity in processes like genomic imprinting, retrotransposon silencing and 
centromeric stabilisation. It is also crucial for correct embryonic development and the 
differentiation of embryonic stem cells (ESCs) into diverse cell types. Although in mammals 
DNA methylation occurs predominantly in the symmetric CG context, it has been shown that 
certain cell types and tissues (ESCs, oocytes, primordial germ cells) have substantial amounts of 
methylation outside of the CG dinucleotide, which is asymmetric. Its presence in early 
developmental stages related to toti- or pluri-potency raises the intriguing possibility that non-CG 
context methylation may have a role in differential gene expression during those stages, 
contributing to their transcriptional plasticity. 
I investigated the distribution, dynamics and functional significance of non-CG methylation 
in early mouse development. Most methods for DNA methylation analysis are either targeted for 
the analysis of CG methylation or, in the case of bisulfite sequencing, suffer from potentially 
confounding issues. I have compared existing approaches to detect methylation outside of CG 
context and developed novel tools, namely the use of antibodies against non-CG methylation, to 
either analyse global levels of non-CG methylation, or validate its genomic distribution. With 
these, I have evaluated the role of components of the DNA methylation machinery and have 
followed the dynamic changes of non-CG context methylation throughout development. My 
analysis reveals that the highest levels of non-CG methylation in the mouse are present in the 
mature oocyte and the zygote. The enzymes responsible for establishing and maintaining its levels 
are the de novo Dnmts (3a and 3b), among which the activity of Dnmt3a2 towards CH seems 
regulated, suggesting a specific rather than an unspecific role. In ES cells, CH methylation 
correlates with active histone marks e.g. H3K4me3, and inversely with H3K27me3. The 
distribution of mCH, both in ESC naïve and primed pluripotency states, is very heterogeneous, 
while its nuclear distribution is very homogenous. mCH is physically recognised by a number of 
pluripotency factors such as Oct4 and Sox2, as well as by other DNA modification-sensitive 
proteins like MeCP2, Foxk1 and Foxk2. Moreover, mCH cannot be hydroxylated by the Tet 
family of enzymes, and repels proteins involved in the initiation of base-excision repair (AID and 
RPA), thus potentially escaping active demethylation in the zygote. In summary, my results show 










5mC - 5-methylcytosine 
5hmC - 5-hydroxymethylcytosine 
5fC – 5-formylcytosine 
5caC – 5-carboxycytosine 
ES cells, ESCs – Embryonic Stem Cells; mESCs - from mouse, hESCs – from human 
pMEFs – primary mouse embryonic fibroblasts 
WT – wild type 
CGIs (CG islands) – areas in the genome (200-500bp) with higher levels if CG dinucleotides than 
the average for the genome 
BS-seq(uencing) – next generation sequencing of bisulphite-converted DNA 
(h)MeDIP – (hydroxy)methylated DNA ImmunoPrecipitation 
ICM – Inner Cell Mass, the cells in the preimplantation embryo that give rise to the foetus 
DMR – differentially methylated region (usually associated with parental imprints) 
IAP - Intracisternal A Particle, a family of retrotransposons normally heavily silenced  
BLAST - Basic Local Alignment Search Tool 
IMR90 – human embryonic lung fibroblast cell line 
iPS cells – Induced Pluripotent Stem cells 
KD – knock-down, a targeted and specific reduction in the expression of a particular gene 
KO – knock-out, i.e a genotype having a null mutation or missing a gene 
NNA - nearest neighbour analysis, a method for quantifying the nucleotides next to a cytosine 
RdDM – RNA-directed DNA methylation, a de novo methylation mechanism in plants  
TKO – Triple Knock-Out – ES cell line missing functional Dnmt1, Dnmt3a and Dnmt3b. 
B6 (C57BL/6 J) – a common inbred strain of laboratory mouse, commonly called as ‘black 6’. 
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 1 Introduction 
 
1.1 Epigenetic DNA modifications and their role in development 
Embryonic stem cells (ES cells) have the same genome as lineage-committed cells, yet 
possess the unique properties of self-renewal and pluripotency. It is a fundamental question how 
the identical genome sequence in a multicellular organism gives rise to the huge diversity of cell 
types, each possessing different gene expression profiles and cellular functions. It is now widely 
accepted that epigenetic mechanisms play a critical role in the process of cellular differentiation 
and the maintenance of a differentiated state (Hawkins et al. 2010; Hemberger et al. 2009). 
Epigenetic modifications include chemical modifications of DNA and histones – the main 
components of chromatin, and constitute an additional layer of information which influences the 
activity of the underlying genetic information (Law & Jacobsen 2010). The addition of a methyl 
group to a cytosine base (resulting in 5-methyl-cytosine) is an epigenetic mark present in the 
DNA of all vertebrates and flowering plants, many fungi, invertebrates and protists, as well as 
many bacterial species (Goll & Bestor 2005). Another modification – 5-hydroxymethyl-cytosine 
has been known for nearly 40 years in animal DNA but it has been just recently ‘rediscovered’ 
and is still poorly characterised (Penn et al. 1972; Kriaucionis & Heintz 2010; Tahiliani et al. 
2010).  
 
1.1.1 Occurrence and distribution of DNA modifications 
In mammals, it has been long believed that DNA methylation occurs almost exclusively in 
symmetrical CG context and it is estimated that ~70-80% of all CG dinucleotides throughout the 
genome are methylated (Ehrlich et al. 1982). In plants DNA methylation occurs in three sequence 
contexts – the symmetric CG and CHG, and the asymmetric CHH context (where H is T, A or C), 
although regions enriched in CHH methylation have pretty similar methylation densities on both 
strands and show propensity for symmetrical methylation (Cokus et al. 2008). Genome-wide, 
DNA methylation in plants occurs predominantly in transposons and other repeat sequences, with 
marked enrichment in pericentromeric regions, although some is also found in the gene bodies of 
highly expressed genes (Cokus et al. 2008; Feng et al. 2010; Zhang et al. 2006; Lister et al. 




a large extent unmethylated (Zhang et al. 2006; Meissner et al. 2008; Straussman et al. 2009; 
Laurent et al. 2010; Feng et al. 2010). In mammalian genomes, methylation density is more 
uniform throughout the length of the chromosomes and the different genomic regions and slightly 
higher only in sub-telomeric regions. Moreover, methylation in CHG and CHH contexts has 
recently also been described for mammalian ES cells, with the distinction from plants that they 
are both highly asymmetrical (Lister et al. 2009; Laurent et al. 2010). 
 
1.1.2 Biological significance and role of DNA methylation 
Thirty-six years ago it was first proposed that cytosine DNA methylation in eukaryotes 
could act as an inherited epigenetic mark that activates or represses genes during cellular 
differentiation (Holliday & Pugh 1975; Riggs 1975). Since then, key roles of DNA methylation 
in mammals have been described in cellular processes such as regulation of gene activity, 
silencing of transposable elements, X-inactivation, genomic imprinting and also different 
diseases, including cancer. Altogether, DNA methylation has been shown to have a crucial role in 
the embryonic development and cellular reprogramming in mammals (Straussman et al. 2009; 
Reik 2007; Okano et al. 1999; Li et al. 1992; Feng et al. 2011).  
Very early in development, briefly after fertilisation, a genome-wide erasure of DNA 
methylation takes place, and only gametic imprints and a limited number of other sequences are 
left methylated (Figure 1) (Reik et al. 2001; Rideout III et al. 2011). This event of global 
methylation erasure is necessary for the acquisition of totipotency and then pluripotency in the 
very first stages of embryonic development (Morgan et al. 2005). Around the time of 
implantation, a round of de novo methylation takes place, which determines the methylation 
patterns of the first two embryonic lineages. At this point the epigenetic profile of the inner cell 
mass (ICM) cells is established from which ES cells are derived (Hemberger et al. 2009; Reik et 
al. 2001). The ES cell state has currently been shown to have the highest level of DNA 
methylation throughout development which drops gradually in the course of differentiation 
(Lister et al. 2009; Laurent et al. 2010). Since most of the differentially methylated regions 
(DMRs), which are by definition rich in CG-content, show an increase in methylation with 
differentiation (Laurent et al. 2010), the decrease in methylation occurring with the loss of 





Figure 1. Two phases of global DNA methylation erasure during early mammalian development. Adapted 
from (Lee et al. 2014).  
 
1.2 Occurrence of non-CG DNA modifications in different organisms and cell 
types 
Methylation of cytosine residues outside the CG dinucleotide in mammals has been 
reported as far back as the 1970s and 1980s (Salomon & Kaye 1970; Harbers et al. 1975; Sneider 
1980; Grafstrom et al. 1985). The first quantitative investigation of the ratio of all four 
methylated CN dinucleotides, however, was only published in 1987, in DNA from human spleen 
(Woodcock et al. 1987). The reported methylation percentage per context was much higher for 
CG dinucleotides (37.9% mCG/all CG), with merely 2% each for CA and CT, and 1.1% for CC 
context. However, the absolute numbers of methylated cytosines were 45.5% for mCG, and the 
remaining 54.5% of methylated cytosine was in CH context (21% CA, 22% CT and 11% CC, 
respectively), meaning it was actually higher in overall than mCG. These values, however, have 
not been subsequently confirmed. Since then, non-CG methylation in human cells has been 
reported in different instances, either in exogenous DNA integrants, or in different endogenous 
regions of the genome such as repeat sequences, origins of replication or gene coding sequences 
(Toth et al. 1990; Clark et al. 1995; Woodcock et al. 1997; Tasheva & Roufa 1994a; Tasheva & 





Further in 2000, the first investigation on ES cells established that non-CG methylation 
accounts for a quarter of the total methylation in the mouse ES cell genome, decreasing to less 
than 6% in differentiated tissues, while the overall amount of CG methylation increases (Figure 
2) (Ramsahoye et al. 2000).  
 
 
Figure 2. Percentage of CN methylation in the mouse. ES cells (black bars), tissues (white bars) and Dnmt1 
null ES cell lines (grey bars).A. mCG; B. mCA; C. mCT, and D. mCC. Since all values are normalised for CG 
methylation, the amount of non-CG methylation can be estimated roughly as a quarter of the total. 
Adapted from (Ramsahoye et al. 2000). 
 
These results have been confirmed by the reports of Lister et al. and Laurent et al. ten years 
later, who describe similar figures and arrive at similar conclusions for non-CG methylation in 
human ES cells (Lister et al. 2009; Laurent et al. 2010). With high resolution bisulphite 







quarter (24.5%) of all methylated cytosines in ES cells are in a non-CG context. This amount is 
reduced to 0.02 % in foetal lung fibroblasts (Figure 3) and also decreases upon differentiation of 
the same ES cell line (Lister et al. 2009; Laurent et al. 2010).  
In addition, analysis of the same primary foetal lung fibroblasts (IMR90) induced to 
pluripotency (iPS cells) reveals restored non-CG methylation at the same loci as in control ES 
cells, suggesting that the presence of asymmetric non-CG methylation is characteristic of an 
embryonic stem-cell state. While CG methylation shows high consistency of methylated loci 
throughout the cell population, and most of the CG loci are 80-100% methylated, CHG and CHH 
loci are methylated only in 10-40% of the ES cell population (Lister et al. 2009).   
 
 
Figure 3. Percentage of methylation in human ES cells (H1) and differentiated fibroblasts (IMR90). The 
overall amount of non-CG methylation in ES cells (purple and orange) is 24.5% and it disappears in 
fibroblasts while CG methylation stays roughly the same as shown by the total number of analysed 
cytosines (4.7 x 107 in hESCs and 4.5 x 107 in IMPR90). Adapted from (Lister et al. 2009). 
 
The more recently described DNA modification in mammals, hydroxymethylation of 
cytosine (5hmC), also shows a significant fraction in an asymmetric and non-CG context in 
mouse ES cells (Ficz et al. 2011).  
Non-CG methylation has also been observed in Drosophila melanogaster, where it is the 
predominant type of DNA modification, with 0.7% methylation for CT dinucleotides, 0.3% for 
CA, 0.2% for CC and only 0.1% for CG dinucleotides. DNA methylation in Drosophila is 
characteristic at low levels only for the very early stages of embryonic development (1-3 hour 
larvae), and quickly decreases to barely detectable levels with the progression of development 
(Lyko, Whittaker, et al. 2000; Gowher et al. 2000; Kunert et al. 2003; Phalke et al. 2009). Only 




methylomes (Lyko et al. 2010; Xiang et al. 2010). 
Asymmetric non-CG methylation was also described in the parasitic protozoan Entamoeba 
histolytica (Fisher et al. 2004). This is also the main type of methylation found in protists from 
the genus Dictyostelium. Although their overall levels of DNA methylation are again very low, 
with an estimated value of around 0.2% for the whole genome, methylation has been observed 
exclusively in CA, CT and CC dinucleotides (Kuhlmann et al. 2005). 
Non-CG methylation occurs commonly in plant genomes (Law & Jacobsen 2010) even 
amongst protist algae (Feng et al. 2010). In Arabidopsis thaliana, genome-wide DNA 
methylation mapping reveals levels of around 23% methylation for CG, 6% for CHG and 1.6% 
for CHH contexts (Cokus et al. 2008; Feng et al. 2010) or an overall of 45% non-CG methylation 
(Lister et al. 2008a) and even higher methylation levels were described for poplar and rice (Feng 
et al. 2010). In plants, non-CG methylation is most abundant in repeat sequences and less 
enriched in gene bodies, while gene promoters are normally not methylated in plants (Henderson 
& Jacobsen 2008). Unlike CG context, which is either unmethylated or 80-100% methylated in 
the cell population, the level of methylation between cells at individual CHH loci is lower, up to 
50%, while for CHG loci the methylation levels show high variability – between 20-100%. This 
is similar to the observations in mammalian ES cells and may indicate either that the non-CG 
methylation pattern is characteristic only for a particular cell type from the floral tissue (or ES 
cell population respectively) or that this type of methylation is more variable between the same 
type of cells (Cokus et al. 2008; Lister et al. 2008a; Lister et al. 2009).  
Non-CG context methylation has also been reported in mouse oocytes and remained 
detectable on the maternal pronucleus after fertilization, although it did not persist further than 
the 2-cell stage (Imamura et al. 2005; Haines et al. 2001). It was not found after prolonged oocyte 
culturing, in the blastocyst or cultured somatic cells. In both reports, its presence has been related 
to the amount and dynamics of CG methylation. In addition, non-CG methylation has also been 
reported in male spermatogonia (Grandjean et al. 2007), and a number of other studies have 
recently reported varying but significant levels in mammalian tissues (Lee, Jin, et al. 2010; Fuso 
et al. 2010; Yan et al. 2011). It therefore remains an open question whether mCH is a mark 






1.3 Establishment and maintenance of non-CG methylation 
Methylation on DNA is mediated by a conserved group of enzymes called DNA (cytosine-
5) methyltransferases (DNA MTs, or Dnmts for mammals). Such enzymes exist in bacteria, as 
well as higher organisms like plants and vertebrates (Goll & Bestor 2005; Jurkowski & Jeltsch 
2011). Bacterial DNA MTs have very selective sequence specificity, defined by a region termed 
‘target recognition domain’. Such a domain does not exist in eukaryotic MTs, and their target 
selection is not a function of innate sequence specificity (Goll & Bestor 2005). Less is known 
about the sequence targeting and specificity for de novo methylation in eukaryotic cells and in 
mammalian cells in particular, for both the symmetric and asymmetric sites. In plants, cytosine 
methylation in all sequence contexts is controlled by the function of several DNA-
methyltransferases – MET1, DRM1 and DRM2, CMT3 and the more recently characterised 
CMT2 (Zemach et al. 2013; Goll & Bestor 2005). MET1 is the equivalent of the mammalian 
Dnmt1 maintenance methyltransferase, which copies the symmetric CG methylation upon cell 
division. DRM1 and DRM2 are structurally related to the mammalian Dnmt3 family and 
establish de novo CG, CHG and CHH methylation at each round of DNA synthesis (Grandjean et 
al. 2007). The chromomethylase family of enzymes does not have an equivalent in mammals and 
they methylate CH-context only: CMT3 is responsible for the maintenance solely of the 
symmetric CHG methylation, while CMT2 methylates predominantly CHH context (Goll & 
Bestor 2005; Stroud et al. 2014). Thus, CHG context methylation in plants is established by the 
activities of CMT3, DRM2 and CMT2, while CHH methylation is in the competency of CMT2 
and DRM2 (Stroud et al. 2014). In mammals, experimental results regarding the enzyme 
specificity and activity for de novo methylation in non-CG sites have been controversial, maybe 
because of the high redundancy in function of the mammalian DNA-methyltransferases (Okano 
& Li 2002). Some authors even discuss the existence of an as yet unidentified de novo 
methyltransferase activity (Lorincz et al. 2002).  
In 2009 Cedar and colleagues suggested two principally distinct mechanisms for de novo 
DNA methylation of CG context sequences (Straussman et al. 2009). The first stage of global 
genomic methylation during early development they define as ‘untargeted’ methylation, which 
happens ‘by default’ and requires active protection of CG islands and other sequences meant to 
stay unmethylated. The second stage is a follow-on methylation of specific genes and individual 




marks and possibly other factors, like non-coding RNAs (ncRNAs) (Straussman et al. 2009). If 
this model would be true, then the de novo non-CG methylation should possibly be the type of 
‘targeted’ event, since a very small number of non-CG context cytosines is methylated, and at 
very specific loci (Lister et al. 2009). Recently, a stochastic model for DNA methylation has been 
proposed, whereby the methylation of each cytosine position is dynamic and determined by the 
local rates of methylation and demethylation. This model favours the targeting of de novo and 
maintenance of non-CG methylation by processes not involving a second DNA strand (Jeltsch & 
Jurkowska 2014).  
 
 
Figure 4. Domain structure and similarities of the three classes of mouse Dnmts. Adapted from (Goll & 
Bestor 2005). Details about the domains can be found in the main text. 
 
Three DNA methyltransferases are operational in mammals, namely Dnmt1, Dnmt2 and 
Dnmt3. A non-catalytically functional member of this family is Dnmt3L (Figure 4).  
 
1.3.1 Dnmt1 – the maintenance methyltransferase 
Dnmt1 was the first biochemically characterized mammalian DNA methyltransferase and it 
is known as the maintenance methyltransferase (R. Z. Jurkowska, Jurkowski, et al. 2011; Goll & 
Bestor 2005; Cheng & Blumenthal 2008). It is a large protein, built of 1620 amino acids in 
mouse and 1616 amino acids in human. Its N-terminal part has multiple domains with diverse 
functions, such as protein-binding (to Proliferating cell nuclear antigen PCNA, DNA 
methyltransferase associated protein 1 Dmap1), stability, nuclear localization, centromere 
targeting, DNA binding domains (CXXC, or cysteine-rich, and KG linker), including some 
domains with yet unclear function in Dnmt1 (BAH1 and BAH2). The C-terminal domain is the 
catalytic domain, a feature shared with all Dnmts, although it is not catalytically active in an 




Dnmt1 is ubiquitously expressed throughout mammalian development, and is the major 
methyltransferase in somatic tissues (R. Z. Jurkowska, Jurkowski, et al. 2011; Goll & Bestor 
2005). Spatially and functionally, Dnmt1 is closely associated with the replication machinery and 
has a strong processive activity on hemimethylated DNA where it transfers methyl groups to the 
newly synthesised non-methylated strand (Vilkaitis et al. 2005; Okano & Li 2002; Leonhardt & 
Page 1992). A mechanism has been proposed that the enzyme copies the methylation patterns 
from the parental methylated strand to the daughter strand and thereby maintains the mitotic 
inheritance of DNA methylation (Riggs 1975; Holliday & Pugh 1975). Dnmt1 has an 
extraordinarily strong affinity towards hemi-methylated CG sites (10-40 fold higher than for 
unmethylated CGs) (Song et al. 2011; Song et al. 2012), which greatly facilitates its role in 
maintaining pre-existing symmetric CG modifications. However, this specificity would not 
maintain asymmetric non-CG context methylation, as indeed has been suggested in some reports 
(Ramsahoye et al. 2000; Dodge et al. 2002). On the other hand, it has also been shown, that 
Dnmt1 has a self-inhibiting property, which stops it from de novo methylating entirely 
unmethylated CG sites, thus giving preference to the hemi-methylated CGs. This would mean 
that, under specific circumstances like chemical modifications or allosteric protein interactions, 
this conformationally-restricted property abrogated and de novo activity becomes once again 
possible (R. Z. Jurkowska, Jurkowski, et al. 2011). Indeed, there have been observations that 
Dnmt1-null mice and ES cells are deprived of non-CG methylation (Woodcock et al. 1998; 
Grandjean et al. 2007) or have decreased level of de novo methylation in general (Lorincz et al. 
2002). This could also be an effect of the cooperative activity of Dnmt1 with the de novo Dnmts 
(Okano & Li 2002; Lorincz et al. 2002; Fatemi et al. 2002; Kim et al. 2002; Liang et al. 2002) 
which has also been proposed for plants (Singh et al. 2008). A recent report has confirmed a 
previously detected in vitro activity of mouse Dnmt1 towards CT dinucleotides (Ross et al. 2010; 
Suetake et al. 2003). A non-processive de novo methylation activity for Dnmt1 has also been 
identified in a number of in vitro studies (Fatemi et al. 2001; Vilkaitis et al. 2005; Goyal et al. 
2006), including in non-CG (CHG) context (Lee, Jang, et al. 2010). Moreover, overexpression of 
Dnmt1, leads to the methylation of previously unmethylated sequences (Takagi et al. 1995; 
Vertino et al. 1996; Biniszkiewicz et al. 2002). Indeed a firm role in setting up de novo 
methylation marks in cooperation with the Dnmt3s has recently been fully recognized for Dnmt1 
(Jeltsch & Jurkowska 2014). However, to what extent it possesses a Dnmt3-independent de novo 




Functionally, Dnmt1 is indispensable for mammalian development. Dnmt1-KO mice have 
variably decreased methylation levels, and embryonic lethality shortly at E10 (Li et al. 1992). 
Mutations in Dnmt1 cause loss of imprints (Li et al. 1993) and misregulation of X chromosome 
inactivation (Beard et al. 1995; Sado et al. 2000), apoptosis in affected cells including PGCs 
(Takashima et al. 2009; Jackson-Grusby et al. 2001) and general genomic instability leading to 
chromosomal aberrations (Chen et al. 1998). Interestingly, embryonic stem cells lacking Dnmt1 
are viable and show no growth or morphological abnormalities, despite their strongly reduced (by 
60%) level of DNA methylation (Li et al. 1992). These cells, however, die when induced to 
differentiate and have high rates of mitotic recombination (Chen et al. 1998). Dnmt1 is also 
implicated in multiple types of cancers, where its loss, on one hand, contributes to the genomic 
instability and higher mutation rates (Gaudet et al. 2003; Eden et al. 2003), while on the other its 
overexpression is crucial to maintain the high division rate and survival characteristic of cancer 
cells (Gravina et al. 2013; Chen et al. 2007; Robertson et al. 1999).  
Dnmt1 is known to have a wide and varying number of interaction partnerships. In addition 
to the previously listed, relevant partners are the de novo Dnmts 3a and 3b, the methylated DNA 
binder MeCP2 and its obligatory maintenance methylation partner Np95 (Uhfr1) (R. Z. 
Jurkowska, Jurkowski, et al. 2011).  
Dnmt1 has several isoforms – the main ones being the ubiquitous somatic isoform 
(Dnmt1s) and the oocyte isoform (Dnmt1o), which is shorter at the N-terminus and is much more 
stable and long lived, accumulated in very high levels in the oocyte (Goll & Bestor 2005; R. Z. 
Jurkowska, Jurkowski, et al. 2011).  
 
1.3.2 Dnmt3 – the de novo methyltransferase family 
The two catalytically active members of the Dnmt3 family are two closely related MTs 
which share very high homology – Dnmt3a and Dnmt3b (Masaki Okano et al. 1998). They are 
considered the mammalian de novo Dnmts (Aoki et al. 2001), which establish the DNA 
methylation patterns during early development (Reik 2007). They are smaller proteins than 
Dnmt1, again with an N-terminal regulatory domain and a C-terminal catalytic domain. Although 
the catalytic domain is highly conserved, their N-terminal domains are unrelated, which speaks of 
potentially non-redundant functions. All of the Dnmt3 members possess an ADD domain 




(P) and tryptophanes (W). The ADD domain is the main protein interaction platform, binding 
with transcriptional factors and multiple classes of chromatin modifying activities and binding 
proteins (Goll & Bestor 2005; R. Z. Jurkowska, Jurkowski, et al. 2011; Freitag & Selker 2005). 
In addition, the ADD domain prevents binding to an H3 tail with di- or trimethylated in lysine 4 
(K4me2/3), and facilitates the binding of unmethylated H3K4 tails (Ooi et al. 2007; Otani et al. 
2009; Zhang et al. 2010). H3K4me2 and me3 are marks of actively transcribed chromatin, 
particularly associated with promoters and transcription start sites (TSS), and the expression of 
tissue specific genes (Lauberth et al. 2013; Pekowska et al. 2010; Barski et al. 2007). The PWWP 
domain is important for the localisation of the Dnmt3s to heterochromatin by binding to the 
H3K36me3 mark, and thus facilitating methylation of nucleosomal DNA (Dhayalan et al. 2010). 
The Dnmt3s also interact with Np95 (Uhrf1) which connects them to the H3K9me3 and 
heterochromatin (Arita et al. 2012).  
Unlike Dnmt1, both Dnmt3s have a strong affinity towards unmethylated DNA (Gowher & 
Jeltsch 2001). In vitro as well as in vivo both enzymes show a strong affinity towards CG 
dinucleotides (Masaki Okano et al. 1998), although substantial activity has been reported towards 
non-CG cytosine residues as well (Dodge et al. 2002; Suetake et al. 2003). While Dnmt3b shows 
a higher non-CG activity in vitro (Gowher & Jeltsch 2001; Aoki et al. 2001), in vivo results 
implicate Dnmt3a as more important for establishing the patterns of non-CG methylation (Lee, 
Jang, et al. 2010; Mund et al. 2004; Lyko et al. 1999; White et al. 2002). It has been reported that 
unlike Dnmt1, the Dnmt3s exhibit strong preferences for the flanking sequence around the CG 
site, which limits their methylation activity (Handa & Jeltsch 2005; R. Z. Jurkowska, Siddique, et 
al. 2011; Lin et al. 2002). Both Dnmt3s oligomerise in either hetero- or homodimers or together 
with Dnmt3L (R. Jurkowska et al. 2011). It is interesting to note, that their overall in vitro 
activity in not very strong, and is weaker than the de novo activity of Dnmt1. Nevertheless, they 
are the main de novo methylatransferases, and their activity cannot be compensated for by 
Dnmt1.  
Both Dnmt3a and Dnmt3b have isoforms, some of which are active, and others are shorter 
inactive forms (Aoki et al. 2001; R. Z. Jurkowska, Jurkowski, et al. 2011; Goll & Bestor 2005). A 
specific shorter isoform of Dnmt3a, called Dnmt3a2 is functional in germ cells and early 
embryogenesis, at the times of the two major phases of de novo establishment of methylation. It 
is expressed from an intronic promoter and lacks a part of its N-terminus, but is as active as 




the ‘euchromatic’ Dnmt3a due to its cellular localization (Chen et al. 2002). Dnmt3b also has a 
number of isoforms, potentially regulated in a developmental fashion. Interestingly, all the 
isoforms expressed in ES cells (Dnmt3b1, -3b6, -3b7 and -3b8) contain conserved catalytic 
domains, which differ from the isoforms expressed in somatic tissues (Dnmt3b2, -3b3, -3b4 and -
3b5). Dnmt3b1 and 3b2 are the main active forms, although 3b3 and 3b6 have recently been 
shown to have an enzymatic activity as well. Notably, none of the Dnmt3s is expressed very 
highly in somatic tissues, although their expression is detectable in most, but their peaks in 
expression are found in early development (R. Z. Jurkowska, Jurkowski, et al. 2011).  
The non-catalytic member of the family is the Dnmt3L (Dnmt3-like), which lacks the 
PWWP domain, and key parts of the catalytic domain (Aapola et al. 2000; Hata et al. 2002; 
Che´din et al. 2002). It is expressed only in the germ line and early development (Lucifero et al. 
2004; Salle et al. 2004) and binds to both Dnmt3a and Dnmt3b, but not directly to the DNA 
(Suetake et al. 2004). The CG methylation activity of Dnmt3a is 20-fold higher in partnership 
with Dnmt3L (Kareta et al. 2006). It has proven essential for the de novo methylation in germ 
cells (Hata et al. 2002; Bourc’his et al. 2001; Webster et al. 2005; Bourc’his & Bestor 2004; Hata 
et al. 2006) and it has been proposed, that it recruits the Dnmt3a2 isoform to specific loci 
unmethylated at H3K4 via the ADD domain (Ooi et al. 2007; Otani et al. 2009; Jia et al. 2007). It 
is not known whether Dnmt3L also recruits the de novo Dnmt3s at non-CG sites, but both early 
male PGCs (E16.5) and maturing oocytes (GVOs) have elevated levels of non-CG methylation 
(Seisenberger et al. 2012; Shirane et al. 2013). In ESCs, where there is no need to establish 
imprinted regions, Dnmt3L releases the catalytic Dnmt3s from heterochromatin and targets them 
to gene bodies of housekeeping genes. It also reduces the extent of DNA methylation on bivalent 
promoters, by competing for the formation of functional hetero-duplexes with the catalytic 
Dnmt3s (Neri et al. 2013).  
Much like Dnmt1, both Dnmt3a and 3b are critical for the early phases of mammalian 
development. Dnmt3b knockout embryos die around E9.5, despite that their global methylation 
levels are higher than in the Dnmt1 knockout, while Dnmt3a knockout embryos develop to term 
and die shortly after birth (Okano et al. 1999). In contrast, Dnmt3L knockout mice are perfectly 
viable and without any discernable morphological abnormalities (Hata et al. 2002). Male mice, 
however, are sterile, due to impaired spermatogenesis (Bourc’his & Bestor 2004; Webster et al. 
2005), and female mice cannot deliver viable pups as they die before midgestation (Bourc’his et 




silencing of repetitive elements during spermatogenesis. In these processes, it partners with 
Dnmt3a which delivers the catalytic activity, and during this developmental timeframe Dnmt3b is 
dispensable. On the contrary, later in development Dnmt3b seems to cooperate with Dnmt1 for 
the maintenance of methylation, and conditional knockout MEFs for Dnmt3b and not 3a, have 
decreased global levels of methylation, accompanied by genomic instability and chromosomal 
aberrations (Dodge et al. 2005). Mouse ESCs mutant for 3a or 3b show mild global 
demethylation, showing that both Dnmt3s play a role in the maintenance during that stage (Chen 
et al. 2003; Okano et al. 1999).  
 
1.3.3 Dnmt2 – the enigmatic Dnmt 
The function and biological roles of Dnmt2 have been less well characterized and are both 
controversial and enigmatic in comparison with the rest of the mammalian Dnmts. Dnmt2 is the 
most conserved and widely distributed member of the Dnmt family, with orthologues found in 
dozens of organisms ranging within all evolutionary kingdoms (Figure 5) (Goll & Bestor 2005; 
Ponger & Li 2005; Schaefer & Lyko 2010b). Moreover, in most protists, fungi, nematodes and 
insects, Dnmt2 is the only Dnmt family protein encoded in their genomes and, in some of them, 
the only DNA methyltransferase at all. Dnmt2 is also the only mammalian DNA 
methyltransferase with orthologues found in bacteria – the genus Geobacter (Goll & Bestor 2005; 
Ponger & Li 2005).  
When Dnmt2 was first described in 1998 by Okano and colleagues, it did not show any CG 
de novo methylation activity in vitro. Dnmt2 null ES cells displayed normal de novo CG-
methylation activity towards endogenous and exogenous virus DNA and thus it was concluded 
that Dnmt2 was a non-essential DNA-methyltransferase (M Okano et al. 1998).  
Further research has shown that a Dnmt2 orthologue is responsible for the methylation of 
isolated cytosine residues in the early stages of embryo development in Drosophila 
melanogaster. The expression of the enzyme is developmentally regulated and strictly 
corresponds to the time frame of methylation occurrence in the fly genome (Kunert et al. 2003; 
Lyko 2001; Lyko, Whittaker, et al. 2000). Moreover, the preferred dinucleotide targets are CA 
and CT (0.4% methylation on average), without a consensus sequence specificity, while less 
preference has been shown towards CC and CG (0.1% on average) (Lyko, Ramsahoye, et al. 




mammalian embryogenesis (Ramsahoye et al. 2000), when Dnmt2 is also expressed, this raises 
the possibility that Dnmt2 may be a non-CG methyltransferase – a CT/A-specific 
methyltransferase, and the earlier attempts to demonstrate its activity on DNA (M Okano et al. 
1998) may have been misled by their focus on CG (Kunert et al. 2003; Lyko 2001). 
It has been subsequently shown that both human and mouse Dnmt2 orthologues form 
covalent complexes with DNA, suggesting an active catalytic function (Liu et al. 2003; Dong et 
al. 2001). Further research has proved in vitro the DNA methylation activity of the human 
Dnmt2, albeit very low, and again demonstrated its high affinity towards non-CG dinucleotides in 
comparison to the other de novo Dnmts (Hermann et al. 2004). Overexpression of mouse Dnmt2 
in Drosophila shows a weak but significant DNA methylation activity and a strict specificity 
towards non-CG (Mund et al. 2004).  
 
 
Figure 5. A schematic of the 
evolutionary conservation of 
Dnmt2-like proteins in protists, 
plants, fungi and animals. 
Phylogenetically related 
orthologues have been retrieved 
for 65 species and total 108 
protein sequences. Adapted from 
(Schaefer & Lyko 2010b). 
A Dnmt2 orthologue was later shown to be responsible for the asymmetric methylation 
observed in the genome of Dictyostelium. In this group of protists, the Dnmt2 orthologue DnmA 
is the only DNA methyltransferase encoded in their genome and has a high similarity to its 
mammalian counterpart (Katoh et al. 2006). No obvious sequence context for the enzyme 
specificity has been identified but all the methylated cytosines are within non-CG dinucleotides 




After continued lack of evidence for an in vivo DNA methylation activity of Dnmt2 in 
mammals, it was clearly and reproducibly demonstrated that Dnmt2 enzymes originating from 
human, mouse, Drosophila and Arabidopsis can successfully and very specifically methylate an 
aspartic acid transport RNA – tRNA
Asp
 (Goll et al. 2006; Jurkowski et al. 2008; Hengesbach et al. 
2008; Schaefer et al. 2009). It appears that the anticodon loops of different Dnmt2-encoding 
species have conserved sequences, while the tRNA
Asp
 in Caenorhabditis elegans and 
Saccharomyces cerevisiae, who do not have Dnmt2 homologues, have diverged in their 
anticodon sequence (Goll et al. 2006). The in vitro experiments with purified Dnmt2 enzyme, 
however, do not exclude the possibility that in vivo other factors may facilitate an activity 
towards DNA, since it has already been shown that Dnmt2 can bind and form stable covalent 
bonds with DNA (Dong et al. 2001). Moreover, it has been demonstrated that Dnmt2 utilizes a 
DNA methyltransferase mechanism to methylate the tRNA
Asp
 and is not a classical RNA-
methyltransferase (Jurkowski et al. 2008). Recently is was also shown by comparative structural 
analysis that DNA was the original substrate of the ancestral Dnmt2 enzyme, and the adaptation 
to an RNA substrate occurred subsequently (Jurkowski & Jeltsch 2011). These facts leave the 
question open for a possibility that in vivo Dnmt2 has some remaining low activity on DNA, or 
that this activity could be stimulated under particular circumstances.  
 
1.3.4 Other protein and chromatin factors in DNA methylation 
Studies in Neurospora, Arabidopsis and Drosophila have shown that mutations in 
homologues of the Su(var)3-9 histone-3-lysine-9 methyltransferase (H3K9 MT) result in reduced 
levels of DNA methylation (Kunert et al. 2003; Tamaru et al. 2003; Jackson et al. 2002; 
Weissmann et al. 2003), and this is especially the case with non-CG methylation (Law & 
Jacobsen 2010). This has led to the notion that histone methylation may promote DNA 
methylation as an evolutionary conserved pathway existing in mammals too (Freitag & Selker 
2005). Indeed, de novo DNA methylation in mammals has been shown to decrease in Suv39h 
null mutants, mainly at repeat sequences (Peters et al. 2003; Lehnertz et al. 2003; Martens et al. 
2005; Fuks et al. 2003). Similar observations have been made for another mammalian H3K9 MT, 
G9a, which is necessary to recruit Dnmt3a and Dnmt3b for triggering de novo methylation at 
gene promoters during cellular differentiation (Feldman et al. 2006; Dong et al. 2008; Epsztejn-




members of the mammalian H3K9 MT family – EZH1 and SETDB1 (Li et al. 2006; Vire et al. 
2006). It has been shown that the interactions of the Dnmts with the H3K9 MT G9a involve 
domains independent of their histone methyltransferase function, and thus mutations in their 
histone methyltransferase function (and lack of H3K9me3 respectively) do not affect the 
methylation on DNA. This suggests that DNA methylation is not dependent on the histone 
methylation per se, but rather on the recruitment function of the histone methyltransferases. 
(Cedar & Bergman 2009).  
Interestingly, an orthologue of SETDB1 in Drosophila melanogaster (dSETDB1) has been 
shown recently to bind methylated CA sequences and recruit Dnmt2 to target loci for DNA 
methylation and silencing (Gou et al. 2010).  
The most studied protein, which does not belong to the Dnmt family but is closely related 
to DNA methylation, is Np95 (or Uhrf1). It is an E3 ubiquitin ligase which has a role in 
chromatin modification, replication-linked DNA methylation maintenance and the DNA damage 
response (Mistry et al. 2008; Nishiyama et al. 2013). It has been described to work tightly with 
Dnmt1 to facilitate its function in the maintenance of pre-existing CG methylation, similarly to 
the way in which Dnmt3L works together with the Dnmt3s. Np95 binds specifically to 
hemimethylated DNA and loss of function mutations lead to severe loss of DNA methylation 
(Sharif et al. 2007; Bostick et al. 2007). Np95 has also been shown to interact with Dnmt3a and 
Dnmt3b, which may suggest a role for Np95 in de novo methylation as well (Meilinger et al. 
2009).  
LSH1 (lymphoid-specific helicase 1 or HELLS) is a chromatin-remodeling factor also 
shown to have a role in the maintenance of DNA methylation. Although Lsh-KO mice develop 
normally, their genomes are heavily demethylated, both at repeats and at single copy genes 
(Dennis et al. 2001). Lsh-deficient cells are found to have reactivation of repeat expression, at 
pericentric satellites and LTR elements, but not at single copy genes (Huang et al. 2004; Dunican 
et al. 2013; Yu et al. 2014). This suggests that chromatin structure and DNA methylation are 
directly related and interdependent. 
 
1.3.5  Non-coding RNA pathways in the regulation of DNA methylation 
It is well established that all de novo methylation in plants as well as the maintenance of 




RNA-directed DNA methylation (RdDM), in cooperation with histone modifying enzymes 
(Jackson et al. 2002; Chan et al. 2004; Chan et al. 2006). Non-CG methylation in plant drm1 
drm2 cmt3 triple-KO Arabidopsis thaliana mutants can be recovered by sequence-specific 
signals, dependent on the siRNA pathway and H3K9 methylation (Chan et al. 2006). Thus, plant 
non-CG methylation shows a different recruitment behaviour from CG methylation, which 
cannot be recovered in a met1 mutant after backcrossing to wild type, demonstrating different 
potential of utilising non-CG methylation for gene regulation (Henderson & Jacobsen 2008). 
siRNAs are also involved in chromatin remodelling in Saccharomyces pombe (Verdel 2004; 
Noma et al. 2004), which however, do not have DNA methylation. Knockouts of RNAi pathway 
genes in Arabidopsis and S. pombe lead to a loss in asymmetric DNA methylation or H3K9 
methylation at repetitive loci, respectively (Cam et al. 2005; Volpe 2005; Zilberman et al. 2004). 
The current knowledge about the mechanism of RdDM in plants, however, involves a number of 
plant-specific proteins (Matzke et al. 2009), making it unclear whether a similar mechanism 
exists in mammals.  
In the protist Dictyostelium dependence of asymmetric DNA methylation on RNAi 
pathway has also been suggested. DNA methylation was reduced and, as a result, gene expression 
of particular genes elevated in KOs of a number of proteins involved in the yeast RNAi pathway 
(Kuhlmann et al. 2005). This observation is particularly noteworthy, since the enzyme 
responsible for the DNA methylation in protists is a high-homology orthologue of the 
mammalian Dnmt2, while DRM2 in plants is homologous to the Dnmt3 family in mammals 
(Katoh et al. 2006).  
Interestingly, in mammals, it has been suggested that Suv39h-dependent DNA methylation 
of satellites could be initiated by a Dicer-mediated mechanism in which RNA-duplexes from the 
satellite sequences, after processing, are targeted back to the pericentromeric regions in the 
nucleus to initiate heterochromatisation (Cedar & Bergman 2009; Fukagawa et al. 2004; 
Sugiyama et al. 2005; Kanellopoulou et al. 2005). Knocking out Dicer in mouse ES cells leads to 
a loss of DNA methylation and H3K9 methylation at centromeres (Sugiyama et al. 2005; 
Kanellopoulou et al. 2005) and an aberrant accumulation of satellite transcripts (Fukagawa et al. 
2004). It has also been shown that siRNAs bind Dnmt3a (Weinberg et al. 2006) and endogenous 
siRNAs complementary to retrotransposons are abundantly expressed in mouse oocytes (Tam et 
al. 2008; Watanabe et al. 2008). Moreover, synthetic RNA can target complementary DNA 




process of targeting chromatin modifications to the correct sequences (Weinberg et al. 2006; Kim 
et al. 2006; Morris et al. 2004). Indeed non-coding RNAs seem involved in recruiting DNA and 
histone methylases at imprinted loci and during X-chromosome inactivation (Law & Jacobsen 
2010; Nagano 2010; Zhao et al. 2008)) but also at non-imprinted autosomal loci (Tufarelli et al. 
2003). There is recent evidence that piRNAs are involved in de novo methylation in primordial 
germ cells (PGCs), acting upstream of the Dnmts (Aravin et al. 2008; Kuramochi-Miyagawa et 
al. 2008). 
Quite the opposite, Imamura et al. have reported that overexpression of an antisense RNA 
in rat induced CG-island demethylation and non-CG methylation on the sense strand of the 
sphingosine kinase 1 gene (Sphk1) (Imamura et al. 2004). In line with this, it has recently been 
reported that Dnmt1 interacts with non-coding RNAs from the CEBPA locus and this blocks its 
activity, leading to demethylation of CEBPA. Moreover, it has been suggested, that this 
mechanism is functional at numerous loci genome-wide (Di Ruscio et al. 2013).  
 
1.4 Removal of non-CG methylation 
The removal of 5mC has been a heavily investigated topic in the last fifteen years and it is 
currently known that a few mechanisms are involved in this process. 
The removal of the methylation mark can either be through passive or active mechanisms. 
A few reports have claimed that the levels of non-G context methylation are dynamic, and imply 
that it can therefore be subject to active or passive removal (Imamura et al. 2005; Fuso et al. 
2010; Haines et al. 2001). The passive demethylation is replication-dependent, and it occurs in 
highly proliferating cells (Franchini et al. 2012). It is based on an impeded maintenance of 
methylation, usually associated with down-regulation of Dnmt1 or Np95 (Kagiwada et al. 2013), 
or their physical exclusion from the nucleus and the replication foci (Lee et al. 2014; 
Seisenberger et al. 2012). This results in a passive ‘dilution’ of the 5mC marks through the cycles 
of replication. This type of demethylation would particularly affect non-CG context methylation, 
because it does not have a known mechanism of maintenance, and would either need to be 
actively established de novo after each course of replication, or is bound to be passively 
quantitatively reduced.  
There is more than one mechanism known for active demethylation (Bhutani et al. 2011; 




of 5mC in a replication independent manner (or at least cell division independent). Therefore this 
type of demethylation can also occur in non-replicating cells (Kohli & Zhang 2013). Active and 
regulated demethylation has already been suggested for non-CG context in the myogenin gene 
during muscle differentiation, although the mechanism has not been investigated (Fuso et al. 
2010). One group of mechanisms involve the DNA repair machinery of the BER pathway (base 
excision repair) and proteins like AID (Activation-induced (cytidine) deaminase),UNG2 (or 
UDG2) (Uracil-DNA glycosylase) and potentially TDG (Thymidine-DNA glycosylase) (Santos 
et al. 2013; Hajkova 2010; Popp et al. 2010). This mechanism relies on cytosine deamination by 
AID, followed by a short- or long-patch repair by the glycosylases – UNG2 in case an 
unmethylated cytosine is targeted by AID (to form uracil), and TDG in case a methylated 
cytosine is targeted by AID (to form thymidine) (Franchini et al. 2012). The in vivo significance 
of the first pathway (deaminating unmethylated cytosines to uracil) is not yet fully validated, 
however it seems a very plausible mechanism, since fertilized oocytes maternally deleted for 
TDG do not show any impairment in the active demethylation of the paternal pronucleus (Santos 
et al. 2013). In addition, the substrate affinity of AID is around 10-fold weaker towards 
methylated or hydroxymethylated cytosines in comparison to unmethylated cytosine (Nabel et al. 
2012). The conserved recognition target sequence for AID is WRC (where W is A or T, and R is 
A or G), and since this sequence does not have any specificity for cytosine context, the 
expectation is that it should equally affect both types of DNA methylation – CG and non-CG. 
Interestingly, the highest sequence preference of UNG2 is towards uracils followed by an A or T, 
and the least preference is for U followed by a G (Doseth et al. 2012).  
 
Another pathway for active demethylation is through the chemical modification (oxidation) 
of the methyl group on 5mC. A recently identified family of three enzymes, the Ten-eleven 
translocation methylcytosine dioxygenases or Tets (Tet1, Tet2 and Tet3) are responsible for 
oxidising 5mC to 5hmC, 5fC and 5caC (Figure 6) (Tahiliani et al. 2010; Ito et al. 2011). 
Although this is not a physical removal of the methylation, the effect of oxidising the methyl 
group chemically reverses the effect of methylation by neutralising its strong hydrophobic and 
strand duplex stabilising effect (Thalhammer et al. 2011). A mechanism to maintain the 5hmC 
mark has not yet been reported (Lee et al. 2014; Shen & Zhang 2013), and therefore the oxidation 
derivatives of 5mC are either passively diluted in the course of cell division, or removed by the 




has been shown that TDG, in addition to recognising T:G mismatches, has an in vitro activity on 
5fC and 5caC (not 5hmC) and has therefore been proposed to act downstream for their active 
removal (He et al. 2011; Maiti & Drohat 2011). Another possibility is a recently reported in vitro 
property of the Dnmt enzymes to remove oxidised methylation derivatives and thus contribute to 




Figure 6. A structural comparison of the three members of the Tet family of oxygenases. A domain outline 
(upper panel) and a multiple alignment of the conserved catalytic domain (lower panel) between human, 
mouse, and the bacterial oxygenases, which served for their original identification in mammals (adapted 
from Shen and Zhang, 2013).  
 
It is currently not known if the Tet enzymes have any context limitations for their oxidation 
activity on 5mC, although it is very clear that they strongly affect CG context - it is the 
predominant context of sperm and hence the male pronucleus, which is affected by global 
genome-wide hydroxylation shortly after fertilisation (Santos et al. 2013). The possibility that Tet 
enzymes might be able to discriminate between mCG and mCA would be worth investigating.  
 
1.5 Biological role of CHH and CHG methylation 
DNA methylation in the symmetrical dinucleotide has long been appreciated as a requisite 




defence and transcriptional regulation. Silencing of transcription is achieved by methylation of 
CGIs and repeat sequences (Reik 2007), while gene body methylation is often associated with 
higher gene expression (Seisenberger et al. 2012; Ball et al. 2009; Lister et al. 2009; Laurent et al. 
2010). In contrast, the biological significance of non-CG methylation, has so far remained 
elusive. 
The role of CH methylation has been best characterised in plants, where cytosine 
methylation in non-CG sequence contexts is tightly linked to inactive chromatin and 
transcriptional gene silencing (Volpe et al. 2010; Stroud et al. 2014). This includes 
pericentromeric repeats (macro- and minisatellites), DNA type and retrotransposons, telomere 
repeats and some single copy genes, generally conferring genome stability (Cokus et al. 2008; 
Lister et al. 2008a; Vrbsky et al. 2010). Early studies on the drm1 drm2 cmt3 triple-KO 
Arabidopsis thaliana, which lacks CH context methylation, have shown distinct phenotypes and 
developmental defects in mutant plants, suggesting that non-CG methylation is implicated in the 
regulation of developmentally important genes (Chan et al. 2006). The presence of non-CG 
methylation on repeat sequences within the gene promoter of the SDC gene (SUPPRESSOR OF 
drm1 drm2 cmt3) has later been shown to silence gene expression and its absence was enough to 
cause the drm1 drm2 cmt3 developmental phenotypes (Henderson & Jacobsen 2008). Recently, 
the varying decrease in levels of non-CG methylation in drm1, drm2, cmt3 and cmt2 mutants has 
been implicated in the transcriptional derepression of transposable elements (TEs) in a 
quantitative fashion (Stroud et al. 2014). Interestingly, a fraction of protein coding genes were 
also found silenced by non-CG methylation, although under the control of only CMT3 and 
DRM2, and not CMT2. These observations validate that non-CG methylation in plants acts 
primarily as a repressor of transcription. Moreover, the 24-nt siRNAs, which target the de novo 
methylation, are strongly dependent on non-CG methylation through a possible self-reinforcing 
loop mechanism that involves H3K9 methylation, which in itself depends largely on non-CG 
methylation and controls the biogenesis of the siRNAs. At the same time, global loss of non-CG 
methylation in plants induces histone acetylation, not only in transcriptionally derepressed TEs 
and genes, but in a genome-wide fashion, leading to relaxation of chromocentres and overall 
decompactisation of heterochromatin. Thus, non-CG methylation is of crucial importance for 
plant genomes to maintain a condensed heterochromatic state (Stroud et al. 2014).    
In Dictyostelium, similarly to plants, non-CG methylation has been found in two 




unexpressed state (Kuhlmann et al. 2005). After depletion of DNA methylation using Dnmt2-null 
cells their expression levels rose and mobility of Skipper within the genome was restored. 
Interestingly the non-CG methylation of Skipper in the wild type genome was localized only 
within the coding sequences and only on the antisense strand. In DIRS-1 the methylation was 
found in the control LTR region but also on the antisense strand only (Kuhlmann et al. 2005).  
In Drosophila, the Dnmt2-mediated asymmetric methylation has been suggested to play a 
role in the maintenance of retrotransposon silencing and telomere integrity during early 
embryonic development. Depletion of DNA methylation in Dnmt2 null strains causes enhanced 
expression of retrotransposon sequences and loss of subtelomeric repeat clusters (Phalke et al. 
2009; Schaefer & Lyko 2010a). Nevertheless, complete depletion of asymmetric methylation in 
the fly genome by RNA interference does not have any detectable consequences for embryonic 
development (Kunert et al. 2003). This is consistent with the lack of phenotypic effects in 
Su(var)3-9 mutant fly strains (Tschiersch et al. 1994), which have been shown to lack DNA 
methylation almost completely (Kunert et al. 2003). However, overexpression of mouse Dnmt3a 
in Drosophila leads to severe developmental defects or lethality, attributed to disruption in cell 
cycle progression and abnormal chromosome condensation (Lyko et al. 1999; Weissmann et al. 
2003), which indicates that, nevertheless, DNA methylation or the lack of it may have a 
functional role in Drosophila (Lyko 2001). This is also suggested by the strong conservation 
between Dnmt-2 mediated DNA methylation in Drosophilids and Anopheles mosquitoes over 
more than 250 million years of evolution (Marhold et al. 2004).  
Recently, a role of non-CG hydroxymethylation has been proposed in the regulation of 
alternative splicing in honey bees, since both 5mC and 5hmC have been observed in gene bodies, 
but only 5hmC in introns (Cingolani et al. 2013).  
In mammals, no definitive roles have been ascribed for non-CG methylation at present, 
which is not surprising given the limited reports, which are available.  
Gowher and Jeltsch (2001) hypothesised at least three possible roles for non-CG 
methylation . First, it could have a role in epigenetic gene regulation for specific targets. Second, 
it could contribute to global genome silencing in the early stages of development, in advance of 
the establishment of heterochromatic marks. And third, it could function to activate Dnmt1 for de 
novo methylation of specific sequences (Gowher & Jeltsch 2001). In light of later discoveries 
more roles could be hypothesised or envisioned but these three certainly still remain valid.  




methylation maps shows twice as high non-CG methylation density within gene bodies, 
compared to other genomic sequences, with the highest density in exon sequences. Surprisingly, 
significant enrichment of asymmetric non-CG methylation and of hydroxy-methylation was 
found on the antisense strand of the non-CG enriched sets of genes (Lister et al. 2009). Moreover, 
strand-specific RNA-seq analysis in those sets of genes showed that highly expressed genes 
contain threefold higher non-CG methylation density than non-expressed genes (Lister et al. 
2009). Another interesting observation by Lister et al. (2009) is the mosaicism of methylation in 
non-CG sites within the ES cell population, where 85% of the sites were methylated only in a 
fraction of the genomes (10-40%), unlike CG methylation where 77% of mCG sites were 
methylated in 80-100% of the genomes. This striking heterogeneity of asymmetric methylation in 
the ES cell population may point to differences in the epigenomes of individual ES cells, which 
may be linked to the unique set of epigenetic marks each cell gains before the process of 
differentiation sets off (Lister et al. 2009). The difference in the amounts of non-CG methylation 
in human ES cells and fibroblasts suggests it may have a role in the origin and maintenance of the 
pluripotent lineage (Lister et al. 2009). 
A possible role for non-CG methylation in telomere silencing has been suggested by 
Gonzalo et al. (2006), who showed that in ES cells lacking either Dnmt1 or Dnmt3a and 3b 
together, telomeric sequences have an increased frequency of recombination between sister 
chromatids. This suggests that DNA methylation may also be required to maintain the ends of 
chromosomes in a heterochromatic state, in order to prevent recombination at telomeres, which 
could lead to translocations, genomic instability and aneuploidies (Gonzalo et al. 2006). 
Telomere sequences lack the canonical CG dinucleotides, so this effect would be completely due 
to non-CG methylation.  
Non-CG methylation has also been observed in some origins of replication and has been 
suggested to play a role in the mechanism of origin licensing (Tasheva & Roufa 1994a; Tasheva 
& Roufa 1994b). Interestingly, the CA, CC and CT methylation was not observed in replication 
arrested G0 cells and seemed dynamically regulated during the cell cycle. The cytosines rapidly 
demethylated when cellular growth and DNA replication were arrested in an exponentially 
growing replicating cell culture, and they quickly remethylated when the arrest was reversed 
(Tasheva & Roufa 1994a; Tasheva & Roufa 1994b).  
The occurrence of non-CG methylation has been observed in human cancer cells compared 




hence genomic instability (Kouidou et al. 2005; Kouidou et al. 2006), although, generally, non-
CG methylation is believed not to be characteristic for cancer cells (Dyachenko et al. 2010). This 
raises the possibility that, being abundant in ES cells, non-CG methylation may be a also feature 
of cancer stem cells (Dyachenko et al. 2010).  
 
To summarise, non-CG methylation does not yet have a confirmed role in mammalian 
cells. Having in mind that its peak in appearance is very early in development and it correlates 
with gene bodies of highly expressed genes, it is not very likely that it has a common origin or 
function with the plant non-CG methylation (Dyachenko et al. 2010).  
 
1.6 Techniques for the analysis of non-CG context methylation 
1.6.1 Methods for DNA methylation analysis – an overview 
Epigenetics is a relatively young scientific field, and many of the methods it employs are 
also young and novel, a number of them having been developed within the last 10 years (Table 1). 
The current methods used for the analysis of DNA methylation have been broadly divided into 
three groups, based on their leading principle of methylation detection: methods involving 
bisulphite treatment of DNA, methods based on affinity or 5mC binding properties, and methods 
based on enzyme digestion (Table 1) (Zilberman & Henikoff 2007; Laird 2010). There is a fourth 
group of techniques, used for the direct detection of global amounts of 5mC in a digested DNA 
sample – such as high pressure liquid chromatography (HPLC), mass spectrometry (MS), and 
capillary electrophoresis, as well as the thin layer chromatography (TLC) based methods (direct 
digestion or in nearest neighbour analysis – NNA) (Woodcock et al. 1987; Nyce et al. 1986; 
Grafstrom et al. 1985; Mund et al. 2004). This group has regained its significance in recent years, 
especially in regard to the identification and analysis of novel DNA modifications like hydroxy- 
and formyl-cytosine (Kriaucionis and Heintz 2010; Tahiliani et al. 2010; Booth et al. 2012), but 
also for global analysis of 5mC levels (Ficz et al. 2013; Oda et al. 2013; Senner et al. 2012; J. 
Wang et al. 2014; Barciszewska et al. 2014; Zhang et al. 2014). More recently, several nano-
techniques have been developed which are not widely used yet, discussed in detail elsewhere 




Table 1. A summary of methods for analysing DNA methylation.  MS-REA = Methyl-sensitive restriction endonuclease 
assay (Bird & Southern 1978; Cedar et al. 1979), MSP = Methylation-specific PCR (Herman et al. 1996), MCAM = 
methylated CG island amplification and Differential methylation hybridization methods (DMH): HELP = HpaII tiny 
fragment enrichment by ligation mediated PCR, MMASS = Microarray-based methylation assessment of single 
samples (reviewed in (Laird 2010), RLGS = Restriction landmark genomic scanning (Kawai et al. 1993), LUMA = 
Luminometric methylation assay (Karimi et al. 2006), COBRA = Combined bisulphite restriction analysis (Xiong & Laird 
1997), MethyLight = Methylation sensitive qPCR (Eads et al. 2000), Ms-SNuPE = Methylation-sensitive single 
nucleotide primer extension (Gonzalgo & Jones 2002; Wu et al. 2008), RRBS = Reduced representation bisulphtie 
sequencing (Meissner et al. 2005), BS-seq/WGBS = Whole genome bisulphite sequencing (Lister et al. 2008b), PBAT 
= Post-bisulphite adaptor tagging (Miura et al. 2012), MIRA = Methylated CG island recovery assay (Rauch & 
Pfeifer 2005), IF = Immunofluorescence, MeDIP = Methylated DNA immpunoprecipitation (Weber et al. 2005; Down 
et al. 2008), HPLC = High pressure liquid chromatography (Grafstrom et al. 1985), TLC = Thin layer chromatography 
(Harbers et al. 1975), MS = mass-spectrometry, NNA – Nearest neigbour analysis (Grafstrom et al. 1985), MS-SSCA 
= Methyl-sensitive single strand conformation analysis 
 Colour coding: red = CG-context biased, orange = no context information, green = information on all 
contexts, i.e. useful for non-CG context methylation; * Discussed in text 
Methods Established Context non-CG useful  





MSP 1996 No 
RLGS 1993 No 
Array-based (MCAM, HELP, MMASS, etc) 2002 - 2008 No 
LUMA 2006 Maybe* 
Bisuphite (BS) conversion-based methods 
BS-conversion, cloning and Sanger sequencing 1992 All contexts Yes 
COBRA 1997 CG-context No 
MethyLight 2000 No context No 
Bisulphite pyrosequencing 2003 CG- context No 
Ms-SNuPE (array-based: EpiTYPER) 2002 (2008) CG- context No 
Illumina bead arrays (Infinium, GoldenGate) 2006 - 2009 CG-bias Maybe* 
RRBS (MspI-digest) 2005 CG-bias Maybe* 
MethylC-seq (BS-seq,WGBS) 2008 
All contexts 
Yes 
PBAT 2012 Yes 
Affinity-based (Antibody or 5mC binding proteins) 




5mC IF 2002 No 
MIRA  2005  
MeDIP (+seq) 2005 (2008) No (Maybe*) 
MeCAP-seq  2010 CG-bias No 
Other methods 
HPLC, TLC, capillary electrophoresis, MS 1900s No context No 
Nearest Neighbour Analysis (NNA)  1961 All contexts Yes 





As emphasised in Table 1, the classical analysis of DNA methylation has been primarily 
focused on the context of CG methylation. As such, many of the methods developed to date 
enrich for this type of methylation either by sequence-specific restriction enzymes (MspI/HpaII, 
Xma/SmaI, MaeII, BstUI) or with 5mC recognition proteins (like MBDs, MeCP2), and hence fail  
to provide information for other cytosine contexts (Table 1) (Laurent et al. 2010; Laird 2010; 
Zilberman & Henikoff 2007). Most of the remaining techniques including the chromatography-, 
mass spectrometry- and antibody-based methods, detect total 5mC per DNA sample, and 
therefore do not provide any context information. The same is the situation with the methyl-





C (R being A or G) does not account for the context of 
methylation 3’ of the cytosine base (Zilberman & Henikoff 2007; Laird 2010). 
For this reason, none of these techniques is suitable for the analysis of non-CG context 
methylation. The most suitable techniques, used historically for the identification of non-CG 
methylation, have been the locus specific bisulphite conversion and sequencing and the NNA 
analysis (Araujo et al. 1998; Clark et al. 1995; Grafstrom et al. 1985; Ramsahoye et al. 2000). 
More recently, bisulphite conversion has been coupled with high depth next generation 
sequencing (>10-fold genome coverage) to yield whole genome data on the distribution of non-
CG methylation (Lister et al. 2009; Shirane et al. 2013; Lister et al. 2013). In addition, some 
other methods can potentially be used to indirectly derive data for non-CG context methylation, 
for example the asymmetric peaks detected in MeDIP datasets may correspond to non-CG 
context methylation (Ficz et al. 2011). CG-biased methods like the RRBS or the Illumina bead 
arrays (Table 1) can also contain information on non-CG context methylation, although they are 
both designed around enrichment for CGIs (Ziller et al. 2011). Lastly, another restriction 
enzyme-based method – LUMA – originally described for the MspI/HpaII enzyme pair (Karimi 
et al. 2006), has recently been modified to work with the enzymes AjnI/Psp6I for the estimation 
of global CCWGG (W = A/T) methylation (Barrès et al. 2009; Yan et al. 2011).  
 
It therefore seems that, in addition to the overall research focus on CG methylation, the 
current scarcity in understanding about a potential biological function of the non-CG context 





1.6.2 BS-seq and the analyses of non-CG methylation 
Bisulphite conversion followed by DNA sequencing is the only technique to date which 
provides base pair resolution data for DNA methylation and has established as the ‘gold standard’ 
to identify presence and distribution of both CG and non-CG methylation. It has, however, been 
suggested that its validity for non-CG context should be confirmed in parallel via another 
independent technique (Laird 2010). The data output from this analysis is the absolute level of 
methylation for each individual cytosine for a sequence, therefore false positives will contribute 
to the individual methylation value. Conversion artefacts have called into question the validity of 
a non-CG positive signal (Rein et al. 1997; Harrison et al. 1998), and in the classical bisulphite 
Sanger sequencing approach have been dealt with via strict rules for the design of PCR primers 
(Henderson et al. 2010; Warnecke et al. 2002). In NGS, these rules cannot be applied. I will focus 
briefly on a few factors related to the NGS analysis of non-CG context methylation, which point 
to the limitations of this technique in a few different ways, and are important to take into 
consideration.  
 
1.6.2.1 Genomic coverage and depth 
The degree of CG methylation in mammals is on average 70-80% for the CG dinucleotide 
(Ehrlich et al. 1982; Goll & Bestor 2005). Although this value is quite high, in order to estimate 
the correct percentage of methylation in a given cytosine position, between 10 and 20 sequences 
(clones) of the same position are standardly used. For regions with lower methylation status, 
more than 10 clones would be needed in order to correctly estimate the methylation percentage. 
When it comes to next generation sequencing (NGS), the usual depth for low coverage datasets is 
between 3- and 5-fold – they are regarded as useful for low resolution comparative analysis of 
multiple organisms or cell lines in CG context, and for global genomic elements only, but are not 
adequate for the evaluation of individual cytosine positions (Feng et al. 2010). Deeper ‘high 
resolution’ analysis, which provides correct information on individual CG calls, requires above 
15-fold average depth per position, reaching even more than 30-fold in present day (Lister et al. 
2009; Li et al. 2010; Stadler et al. 2011). Non-CG context methylation is on average below 25% 
per cytosine position, meaning that even higher depths would be needed in order to achieve 
similar level of accuracy as for the CG-context analysis. This situation is almost analogous to the 




hydroxyl-methylcytosine (Huang et al. 2012). Therefore, so far only the high resolution datasets 
have proven informative for the analysis of non-CG context methylation (Lister et al. 2011; 
Stadler et al. 2011; Shirane et al. 2013), making the NGS approach financially intractable at 
present for a routine genome-wide analysis of non-CG context DNA methylation.  
 
1.6.2.2 Computing power 
The depth of coverage required for data reliability directly leads to the next specificity of 
non-CG context analysis in NGS datasets and this is the capacity of the computing facilities. The 
higher the depth, the longer it takes to calculate methylation in individual positions or even in 
genomic features, and the more server memory and processing power need to be utilised. In 
addition, the distribution of CG context in mouse genome Build 37 used in this study, is only 
1/25
th
 of the genomic cytosine content or only 4% from the total cytosine, making it only a 
fraction of the individual frequencies of the other three cytosine contexts – 36% for CA, 35% for 
CT and 25% for CC (see Table 0). This means that all calculations performed for non-CG context 
will require roughly 20-fold more processor power and time, than the same analysis performed 
for the CG context. These requirements create restrictions owing to the extended capacity for 
computing power and accompanying cost per sample.  
 
1.6.2.3 Bisulphite conversion efficiency 
For long, the amount of non-CG positive calls served to determine conversion efficiency in 
a treated DNA sample, and thus served as an internal control and not a methylation signal in 
itself, preventing the need to use actual unmethylated controls (Genereux et al. 2008; Chhibber & 
Schroeder 2008). Bisulphite conversion of cytosine has a high chemical efficiency; however it 
never reaches 100% (Harrison et al. 1998). Good efficiency values lie above 95%, usually aiming 
for above 98-99% of the total unmethylated cytosine content. Due to the repressed representation 
of CG in mammalian genomes (4%, as discussed above), conversion artefacts are mostly seen in 
non-CG context (the remaining 96% of cytosine), and they are often dispersed as individual false 
positives throughout the whole genome (Warnecke et al. 2002). Therefore a single false positive 
value in a high depth dataset is not very likely to affect the evaluation of CG-context methylation 
with an average of 70% per position. This is not the case for non-CG context methylation, where 




calls, amounting for 5-20% on average per position. For this reason, authors often apply different 
‘filters’ to exclude possible false positives from the final analysis – the most common being to 
exclude all reads containing more than 3 positive calls in non-CG context from the final data 
analysis (Lister et al. 2009; Lister et al. 2011), or defining a cutoff value below which the 
methylation signal is considered as conversion ‘noise’ (Raddatz et al. 2013). However it is not 
known how much of what is real signal is filtered out and how much is actual artefact, and what 
proportion of the artefacts actually remain in the validated data. This is because no alternative 
method currently exists which can identify DNA modifications at a single base resolution without 
bisulphite conversion. With the development of nanopore sequencing for the analysis of DNA 
modifications (such as the technology offered by Pacific Biosciences) (Flusberg et al. 2010; 
Coupland et al. 2012) this might be possible to do in the near future. 
 
1.6.2.4 Amplification bias  
It is well documented that due to DNA polymerase sequence preferences, there is a 
detectable bias towards CG context in the non-bisulphite converted whole genome NGS datasets 
accompanied with a much lower representation of AT-rich DNA regions (Quail et al. 2012; 
Oyola et al. 2012). AT-rich genomes have therefore proven difficult to amplify, a problem that 
can be extrapolated to the bisulphite-converted whole genome (WGBS) datasets in particular, 
which become highly AT-rich after conversion, irrespective of the original base composition of 
the sequenced genome. Commercial suppliers compete to engineer polymerases that show less 
context preference, but the issue still hasn’t been fully resolved (Oyola et al. 2012) (see also 
KAPA HiFi Uracil + leaflet at http://www.bio360.net/z/KAPABiosystems/). Therefore, highly 
methylated and unconverted CG-rich regions are unlikely to suffer from this problem but will be 
amplified preferentially, contributing to CG-bias and potential overestimation of the total number 
of positive methylation signals. The cytosine-rich but hypomethylated sequences including CH 
context, on the other hand, will certainly be greatly affected by this bias, with reduced 
representation and sequencing depth, necessary to complete an accurate analysis. However, 
whether those biases really affect bisulphite-converted datasets in this way, however, has not 






1.6.2.5 DNA degradation 
It is well documented that the treatment of DNA with sodium bisulphite is a chemically 
aggressive process and leads to high levels of DNA degradation, i.e. loss of input material 
(Grunau et al. 2001; Shiraishi & Hayatsu 2004). This has for a long time dictated the amount of 
starting material used for bisulphite analysis, making it very difficult to produce methylation data 
from biological sources with very low cell numbers (Miura et al. 2012; Smallwood & Kelsey 
2012). To date there is no comprehensive research into contexts of base sequence degradation 
during bisulphite mutagenesis. A recent study has shown that the degradation is triggered at the 
cytosine, and is a direct consequence of the bisulphite attack, contradicting earlier suggestions 
that it was due to an acidic attack on the purines (Tanaka & Okamoto 2007; Piperi & 
Papavassiliou 2011). It is therefore an open question whether the overall cytosine content in DNA 
is affected by the chemical attack to a larger extent than the other three bases, and whether the 
surrounding sequence context or methylation status would have an influence.  
 
1.6.3 Additional tools facilitating DNA methylation analysis 
Molecular tools such as methylation-sensitive restriction enzymes, anti-methylcytosine 
antibodies and methyl-binding proteins have been widely used for the development of a wealth of 
techniques as discussed in 1.6.1., although the broadly used and commercially available 
restriction enzymes target specifically CG context. A limited number of studies have used 
enzymes like the BstNI (BstOI) and AjnI together with their methylation-sensitive counterparts 
EcoRII or Psp6I to characterize methylation in CCWGG context (Woodcock et al. 1987; 
Franchina & Kay 2000; Barrès et al. 2009). Some studies have used the MspI enzyme and its 
sensitivity to the first cytosine in the CCGG sequence (Crowther et al. 1989), but considering the 
fact that CC methylation is the lowest observed non-CG context methylation in mammals, this 
tool is not very useful. Another group of restriction enzymes are the methylation-conditional 
endonucleases, like the McrBC (Sutherland et al. 1992), which digest only methylated DNA. 




C (in which R is A or G) the 
enzyme is naturally targeted to highly methylated regions (such as DMRs). It has been used for 
the degradation of highly methylated DNA (enrichment of unmethylated DNA) (Lippman et al. 
2004; Rollins et al. 2006) or for the detection of 5mC (Gowher et al. 2000). Although the 




methylation, the lack of identified non-CG DMRs and the inability to distinguish between CG 
and non-CG, the properties of this enzyme do not seem relevant for the detection of non-CG 
methylation.  
In 2011 another group of methylation-specific restriction enzymes has been characterized 
and named after its main component - the MspJI family of restriction endonucleases (Cohen-
Karni et al. 2011). All of the group members cleave 9 bp (on the forward strand) and 13 bp (on 
the reverse strand) downstream of their recognition motif, and while half are enriching for CG-
context, the other half are enriching for all methylation contexts or even mCA or mCT (RlaI). 
Therefore, this group of enzymes might be useful for the analysis of non-CG methylation and is 
worth investigating.  
Other methylcytosine enrichment tools, like the well-studied and widely used methyl-
binding proteins (MBDs, MeCP2) bias towards CG context and especially highly methylated 
CGIs (Bock et al. 2010; Zilberman & Henikoff 2007; Robinson et al. 2010). The antibodies 
generated against methylcytosine on the other hand, do not differentiate the sequence context, 
and will not be useful for non-CG analysis, unless a way to ‘subtract’ the CG information is 
applied. There are currently no known proteins which specifically bind to methylated non-CG 
context.  
Additional tools utilised for studying DNA methylation include the enzymes responsible 
for generating it - the DNA methyltransferases. Apart from the widely used eukaryotic 
methyltransferases, bacterial enzymes have also become an extremely useful tool – the best 
known of which is the M.SssI methylase (Renbaum et al. 1990). This enzyme methylates 
cytosines exclusively in the CG dinucleotide, and has therefore proven very useful to study CG 
methylation. It is usually used for in vitro DNA methylation – vectors, short fragments or 
genomic DNA – in order to analyse the properties of CG-binding proteins, or restriction 
enzymes, or often as a positive control (a calibrator) in different techniques (Goll et al. 2006; 
Laurent et al. 2010; Guo et al. 2011). It is also a common tool to study nucleosome positioning 
and genome organization (Fatemi et al. 2005; Gal-Yam et al. 2006; Miranda et al. 2010) and has 
been used for targeted CG-methylation and gene repression (van der Gun et al. 2010). Bacterial 






1.6.4 Technological perspectives 
As is the situation with the recently discovered novel types of DNA modifications 
(Kriaucionis & Heintz 2010; Ito et al. 2011; He et al. 2011; Tahiliani et al. 2010), new techniques 
may need to be developed or old techniques adapted through the use of new molecular tools, in 
order to achieve comprehensive characterization of non-CG methylation, beyond the mere 
‘sequencing after bisulphite treatment’ analysis. Recent advances regarding hydroxy-
methylcytosine (hmC) and formylcytosine (fC) have shown that additional understanding about 
the localisation, dynamics and biological functions of each novel modification must be paralleled 
by the development of unique techniques for its analysis and detection (Ficz et al. 2011; Booth et 
al. 2012; Raiber et al. 2012; Yu et al. 2012). In this regard, it becomes clear (Table 1) that the 
development or use of a few types of molecular tools can provide access to a variety of 
methodological possibilities for such in-depth analysis; and these are: 
 Context-specific anti-5mC antibodies  several quantitative and descriptive techniques 
are based on the use of antibodies 
 Non-CG context 5mC binding proteins or restriction enzymes  nearly half of the 
existing current techniques employ the use of such proteins for CG context 
 Methyltransferases methylating exclusively non-CG contexts would also help teach us 
more about the nature of these modifications and their functional significance 
 
Therefore, in order to achieve the aims of this work, alongside the use of the classical DNA 
methylation techniques, it is important to explore novel opportunities - modify existing methods 
or develop molecular tools for the accurate characterisation of non-CG context methylation. 
 
 
1.7 Aims and hypothesis 
In mammalian development, each cell lineage acquires a unique set of epigenetic marks 
during differentiation. The epigenetic profile of each lineage represents a complex combination 
of histone marks and DNA modifications, as well as chromatin interacting factors, which work 
together to define the gene expression profile of the lineage. Although there is some plasticity of 




lineage specification and restoration to pluripotency requires removal of these modifications in 
the germline and early embryo (Hemberger et al. 2009). While this pattern is well established for 
some histone modifications and DNA methylation in the symmetric CG context, the opposite has 
been shown for the overall distribution and abundance of asymmetric non-CG methylation in ES 
compared to differentiated cells (Lister et al. 2009; Laurent et al. 2010; Ramsahoye et al. 2000). 
 
As a summary, non-CG methylation is a poorly characterized phenomenon in mammals, 
typical for their very early stage of development, and proposed to have a role in pluripotency 
(Lister et al. 2009; Ziller et al. 2011). Since pluripotent cells are a model of the ICM component 
of the preimplantation stage mammalian blastocyst (Nichols et al. 2009), then its accumulation is 
a brief event in the course of development and its peak coincides with the wave of global 
genomic methylation occurring in the blastocyst post fertilization. In the context of the currently 
proposed two stages of CG methylation (Straussman et al. 2009), its appearance falls within the 
first phase of global untargeted CG genome methylation, which occurs around the ES cell stage – 
the phase with the highest density of methylation in the genome. Its distribution is very 
heterogeneous in the ES cell population and its enrichment is highest in actively expressed genes, 
and particularly in the antisense strand of the exons (Lister et al. 2009).  
 
In addition, non-CG methylation is evolutionarily more conserved than CG methylation 
and in organisms like Drosophilids it is also characteristic only for the very early stages of 
development (Lyko, Ramsahoye, et al. 2000; Lyko 2001). The conservation of this pattern of 
distribution up to mammals indicates a possibility for an important conserved role in those very 
early stages of development. I therefore hypothesised a role of non-CG methylation in the 
establishment and maintenance of a pluripotent cell state, possibly through a role in regulation of 
gene expression. It is important to note, that DNA methylation per se has been claimed non-
essential for the self-renewal capability of pluripotent cells (Tsumura et al. 2006), while it is 
absolutely crucial for their ability to differentiate (Schmidt et al. 2012). Therefore, the role of 
non-CG methylation might be expected in the latter, where creating intra-population methylation 







I propose to investigate this hypothesis by addressing the following questions: 
 
1) What is the genomic distribution of non-CG methylation in ES cells, and its wider 
dynamics during key developmental stages in the mouse? 
2) How is the asymmetric methylation established de novo and maintained; are there 
dedicated Dnmts involved in this process (like Dnmt2), what are the individual 
contributions of Dnmt3a and Dnmt3b? 
3) Does non-CG methylation have a role in transcriptional regulation in ES cells and 
does that influence their pluripotency state? 
4) If necessary, can the development of novel tools and techniques facilitate in depth 
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 2 Materials and methods 
 
2.1 Cell lines and culture 
The cell lines and tissues used in these studies where derived or obtained by the host 
laboratory for use in epigenetic studies. Mouse lines derived de novo from strategically relevant 
genetically modified loci were generated under licensing in keeping with the Animals Scientific 
Procedure ACT 1986 and under Home Office permission to Prof Wolf Reik. Human cell lines, 
embryonic stem cells (hESC) were obtained as a gift and used under the relevant MTAs. 
The J1 ES cell line (129S4/SvJae) was purchased from ATCC (Cat. SCRC-1010); the E14 
ES cell line has been derived from the E14 cell line strain 129P2/OlaHsda and is a long standing 
reagent in the host laboratory. The Dnmt2 KO, Dnmt3a and 3b single and double KO ES cells, the 
Dnmt1/3a/3b-KO and Np95-KO (129/Ola derived) are J1 or E14 derived and a gift from Masaki 
Okano (M Okano et al. 1998; Okano et al. 1999; Tsumura et al. 2006), the Dnmt1
s/s
-KO line is a 
gift from En Li (Lei et al. 1996), and the Dicer-KO lines are a gift from Neil Brockdorff, 
University of Oxford (Nesterova et al. 2008). The tamoxifen inducible Dnmt3a/4b-DKO ES cells 
are a kind gift from H. Koseki, RIKEN Center for Integrative Medical Sciences Laboratory for 
Developmental Genetics.  
All wild type (WT) and Dicer-KO cell lines were grown on a -irradiated pMEF feeder 
layer while all Dnmt-pathway KO lines were grown on gelatine. All ES cell lines were cultured at 
37C and 5% CO2 in complete ES medium (DMEM 4500 mg/L glucose, 4 mM L-glutamine and 
110 mg/L sodium pyruvate, 15% foetal bovine serum, 100 U of penicillin/100 µg of streptomycin 





) (Ficz et al. 2011). Naïve mES cells were grown in serum-free N2B27 meduim (Cat. 
DMEM/F12: GIBCO 21331; Neurobasal: GIBCO 21103; N2: Stem Cells SF-NS-01-005; B27: 
GIBCO 17504-044), supplemented with 10
3
 U/ml LIF, 1 mM Mek inhibitor PD0325901 and 3 
mM Gsk3b inhibitor CHIR99021 (Ficz et al. 2013).  
Primary mouse embryonic fibroblasts were derived from E13.5 embryos (C57BL/6J x 
CBA/Ca F1 x F1, called further for short ‘F1’) and cultured for 1 to 3 passages in DMEM 4500 
mg/L glucose, 4 mM L-glutamine and 110 mg/L sodium pyruvate, 10% foetal bovine serum, 100 
U of penicillin/100 µg of streptomycin in 100 mL medium, 50 M -mercaptoethanol.  
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H9 hES cells were cultured and provided by Peter Rugg-Gunn (Babraham Institute) and 
IMR90 human lung fibroblasts (ATCC, Cat. CCL-186) - by Tamir Chandra (Reik lab).  
DNA from C57BL/6 J (B6) ES cells TMBD10, B6 pMEFs and AID-KO pMEFs (Popp et 
al. 2010) as well as from iPS cells derived from those MEF genotypes was provided by Inês 
Milagre (Reik lab). 
 
2.2 Mouse tissues 
DNA from B6 adult mouse tissues was kindly provided by Tim Hore (Reik lab). DNA 
from C57BL/6 J (B6) E11.5 and adult forebrain and hindbrain, as well as E11.5 placenta, were 
provided by Heather Burgess (Reik lab). B6 E19.5 placenta was provided by Myriam Hemberger 
(Babraham Institute).  
Mouse embryos and oocytes were collected by Fátima Santos according to standard 
procedures (Hogan et al., 1994) and were derived from C57BL/6J animals. 
 
2.3 Molecular Biology  
2.3.1 Isolation of DNA and RNA from cells and tissues 
Genomic DNA from ES cell lines was extracted using Qiagen kits: All Prep DNA/RNA 
kit, Qiagen DNeasy Blood and Tissue kit and QIAmp DNA micro kit and stored in EB buffer 
(Qiagen) or RNAse free water (Qiagen). All genomic DNAs were quantitated by Quant-iT™ 
PicoGreen® dsDNA Assay Kit on a CytoFluor II microplate reader (PerSeptive Biosystems) and 
stored at -20°C.  
RNA was extracted either with the Qiagen All Prep DNA/RNA kit or using QIAzol® 
(Qiagen). Total RNAs were quantitated with NanoDrop® ND-1000 Spectrophotometer and 
stored at -20°C or -80°C.  
 
2.3.2 Bisulphite conversion of genomic DNA 
Genomic DNA was treated with sodium bisulphite using any of the following kits: Qiagen 
Epitect Bilulfite Kit (FFTP protocol), Imprint DNA Modification kit from Sigma-Aldrich (1-step 
or 2-step) and EZ DNA Methylation™ Kit (Zymo Research) according to manufacturer’s 
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instructions. The following minor modification was applied: the temperature incubation 
programme in the Qiagen kit was doubled (i.e. 10 hours instead of 5 hours in total). Conversion 
with 9 M ammonium bisulphite was performed at 70°C for 30 minutes as described (Hayatsu et 
al. 2004).  
 
2.3.3 Amplification (PCR) of major satellite  
One µg of bisulphite converted genomic DNA was diluted 1:100 and 5 µl of the dilution 
subjected to amplification with HotStart Taq (Qiagen) in 50 μl volume, 200 nM primer, 200 μM 
dNTPs, 2 mM MgCl2, 1.0 unit of enzyme. Amplification was done with an initial step at 94°C 
for 15 minutes followed by 35 cycles of 20 seconds at 94°C, 20 seconds at 55°C, and 20 seconds 
at 72°C, with a final step at 72°C for 3 minutes. The amplified DNA was loaded on a 2% agarose 
gel, the 370bp band excised and purified with a Qiagen Gel Extraction kit according to kit 
instructions. The fragments were cloned and sequenced as described in 2.3.4.  
 
2.3.4 T-A cloning  
For sequencing of bisulphite converted DNA regions of interest, PCR fragments were 
cloned into pGEM-T using the pGEM-T Easy Vector Kit from Promega. Ligations were 
performed in 10 μl volume at 4C overnight. Invitrogen’s Subcloning Efficiency DH5α 
Competent Cells or One Shot Top 10 Chemically Competent E.coli were used for transformation 
and all steps were performed according to the manufacturer’s instructions using 5μl of the 
pGEM-T ligation reaction. For each transformation, 100 μl and 900 μl of the transformation 
mixture were plated out onto LB plates containing 100 μg/ml ampicillin, for selection, and 40 μl 
of a 40 mg/ml X-gal solution, spread over the plate, for blue/white selection. Plates were 
incubated at 37C overnight (o/n).  
Colony screen was performed via PCR with the M13 primer pair (Appendix Table 12). 
White colonies were picked from the LB-Ampicillin plates with a 10μl pipette tip and transferred 
into a PCR tube containing the PCR reaction mix. The PCR reaction mix was prepared using 
Roche’s Taq DNA Polymerase (25 μl volume, 300 nM primer, 200 μM dNTPs, 1.25 units 
enzyme). Amplification was carried out with an initial step at 94°C for 10 minutes followed by 
35 cycles of 30 seconds at 94°C, 30 seconds at 55°C, and 30 seconds at 72°C, with a final step at 
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72°C for 10 minutes. Ten μl of the PCR reaction mix were loaded on a 2% agarose gel to verify 
the expected band size, 5 μl of the remaining PCR mix was sent for sequencing. 
 
2.3.5 Sanger sequencing  
Sanger sequencing was carried out by the company Beckman Coulter Genomics. For 
bisulphite converted DNA, the sequencing results were analysed with QUMA (Kumaki et al. 
2008) and visualised by a custom-made R script (from Miguel Branco). 
 
2.3.6 Synthesis of M13 fragments 
PCR of M13 fragments – either unmethylated or enriched for methylcytosine or hydroxy-
methylcytosine, was performed using a standard dNTP mix (Bioline), or modified dm5CTPs 
(10 mM, NEB) or d5hmCTPs (100 mM, Bioline) instead of dCTPs. The PCR reaction mix was 
prepared using Dream Taq DNA Polymerase from Fermentas/Thermo (50 μl volume, 200 nM 
primer, 200 μM dNTPs, 1.25 units enzyme). Amplification was carried out with an initial step at 
95°C for 2 minutes followed by 35 cycles of 30 seconds at 95°C, 20 seconds at 57°C, and 30 
seconds (C, 5hmC) or 5 minutes (5mC) at 72°C, with a final step at 72°C for 7 minutes.  
All M13-derived PCR fragments have been further purified with Qiagen PCR Purification 
kit or Thermo GeneJet PCR Purification kit, quantitated by Quant-iT™ PicoGreen® dsDNA 
Assay Kit on a CytoFluor II microplate reader (PerSeptive Biosystems) or on an Agilent 2100 
Bioanalyzer system, and stored at -20°C. One μl of each PCR product was checked on a standard 
DNA resolving 2% agarose gel to ensure amplification was successful. A full list of the oligos 
and the different fragments are presented in Appendix Table 12 and Appendix Table 13.  
 
2.3.7 Next generation whole genome bisulphite sequencing (BS-seq, WGBS) 
The amount of input material for WGBS was approximately 300 ng genomic DNA spiked 
with a 2 kb PCR fragment from M13mp18, 1:10 000. The DNA was fragmented via sonication 
with a Covaris E220 instrument with the 300 bp programme, in a total volume of 50-85 µl. Early 
Access Methylation Adapter Oligos (Illumina) were ligated to the fragmented DNA with the 
NEB Next DNA Library Prep Master Mix Set for Illumina, according to the manufacturer‘s 
instructions and purified after each step with Agencourt® AMPure® XP beads. Half of the 
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eluted adapter-ligated DNA was kept as a backup, the other half was subsequently bisulphite 
converted as described in 2.3.2. The bisulfite-treated DNA was eluted in 20 μl RNAse free water 
(Qiagen). Again, half of the eluted DNA was kept, the other half was amplified using PfuTurbo 
Cx Hotstart DNA Polymerase (Agilent Technologies): volume 50 μl, 300 μM dNTPs, 400 nM 
primer, 2.5 units enzyme, with an initial step at 98°C for 30 seconds followed by 15 cycles of 
98°C for 10 seconds, 65°C for 30 seconds, and 72°C for 30 seconds, followed by a final 
elongation step at 72°C for 5 minutes. In some instances indexed adapter-specific primers for 
Illumina were used from the iPCRtagT system (Quail et al. 2012). Each library was checked on 
an Agilent 2100 Bioanalyzer system, for average fragment size and concentration, and 
subsequently quantitated via KAPA Library Quantification Kit (KAPA Biosystems). 
Paired-end 100 bp next generation sequencing (NGS) was performed on an Illumina HiSeq 
system at the facility at the Wellcome Trust Sanger Institute (WTSI).  
 
2.3.8 Reduced representation bisulphite sequencing with MspJI (meRRBS) 
The amount of input material was 150 ng intact genomic DNA. The DNA was digested 
with MspJI enzyme for 4 hours at 37°C adapting manufacturer’s instructions (NEB) for 18 µl 
reaction volume. NEB Next kit Klenow exo- (1 µl), dNTP mix (0.2 mM) and dATP (2mM) were 
added directly to this mix for end repair and A-tailing and incubated for 40 min at 37°C, and then 
inactivated at 75°C for 15 min. Methylated adapters (Illumina) were added to the mixture 
(100 nM), together with 2 µl T4 Ligase (NEB Next kit), 1 mM ATP and incubated overnight at 
4°C. Successful adapter ligation was tested via a test PCR: volume 50 μl, 0,5 μl DNA, 300 μM 
dNTPs, 400 nM primer P1 and P2 (Illumina), 2.5 units Phusion DNA Polymerase and Phusion 
High-Fidelity PCR Buffer 5x (NEB Next kit), with programme conditions as described in 2.3.7. 
The amplified libraries were run on a 2% agarose gel.  
The adapter-ligated DNA was bisulphite converted with the Sigma Imprint DNA 
Modification kit using the 2-step protocol according to manufacturer’s instructions and eluted in 
20 μl RNAse free water (Qiagen). Half of the eluted DNA was kept as back up, the other half 
was amplified with KAPA HiFi HotStart Uracil+ 2x Ready Mix (KAPA Biosystems): volume 
50 μl, 10 μl DNA, 200 nM PCR primers PE 1.0 and 2.0, with an initial step at 98°C for 45 
seconds followed by 15 cycles of 98°C for 15 seconds, 65°C for 30 seconds, and 72°C for 30 
seconds, and a final elongation step at 72°C for 1 minute. Each library was barcoded with 
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indexed adapter-specific primers from the iPCRtagT system (Quail et al. 2012). The libraries 
were purified with Agencourt® AMPure® XP beads, processed as described for BS-seq in 2.3.7 
and sequenced at the WTSI.  
 
2.3.9 Mass spectrometry 
Mass spectrometry was performed by David Oxley, Head of the BI mass spectrometry 
facility. Genomic DNA was first quantitated by Quant-iT™ PicoGreen® dsDNA Assay Kit and 
digested into single nucleosides overnight at 37°C with a DNA Degradase Plus™ (Zymo 
Research) according to manufacturer’s instructions. Variable amounts between 300-1000 ng 
were used for the digestion depending on sample availability. They were then submitted to the 
BI mass spectrometry facility, where 50 pg per sample was analysed by LC-MS/MS on a 
Thermo Q-Exactive mass spectrometer coupled to a Proxeon nanoLC. Three replicates of each 
sample were analysed and the amounts of C, 5mC and 5hmC were quantified in fmoles.  
 
2.3.10 In vitro DNA methylation assays 
The in vitro DNA methylation was performed with 0.5 – 1.0 µg of genomic DNA (TKO 
ES) or M13-derived PCR fragments (see Appendix Table 13) with either M.SssI (NEB) or 
M.CviPI (NEB), according to the manufacturer’s instructions. The reactions were incubated for 2 
hours at 37°C, the DNA purified with GeneJet PCR Purification kit (Thermo) and quantitated by 
Quant-iT™ PicoGreen® dsDNA Assay Kit on a CytoFluor II microplate reader (PerSeptive 
Biosystems). 
 
2.3.11 Nearest Neighbour Analysis (NNA) 
The nearest neighbour analysis was performed following the published protocol 
(Ramsahoye 2000) with the following modifications. One µg of DNA was digested o/n at 37°C 
with 10 units of FokI (gDNAs) or DpnII (PCR fragments) and 10 units of RNAse A, purified 
with Qiagen QiaQuick PCR purification kit, and eluted in 30 µl dH2O. The DNA was quantified 
with PicoGreen® dsDNA Assay as in 2.3.1 and labelled with 1 U Klenow (Invitrogen) and 
10 µCi 
32
P-dNTP (PerkinElmer NEG502A) as in the original protocol. The labelled DNA was 
precipitated with 100% ethanol/ 3 M sodium acetate at -20°C for minimum 1 hour, and the pellet 
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resuspended in micrococcal nuclease digestion mix with 0.2 units MNAse (Pharmacia Biotech) 
and 2 µg PDE II (Sigma-Aldrich) for 4 hours at 37°C. After digestion 0.5 µl was spotted onto a 
glass backed cellulose plate (Merck) and TLC performed as in original protocol.  
 
2.3.12 Luminometric Methylation Assay (LUMA) 
The originally published protocol was followed closely for this assay (Karimi et al. 2011). 
Two hundred (200) ng of DNA were digested o/n with either of the following: MspI, HpaII 
(Fermentas), AjnI, Psp6I, Bsp19I (SibEnzyme) together with one control enzyme: EcoRI, CviaII 
or Tsp509I (NEB) using temperatures and buffer conditions as advised by the manufacturer. The 
digestion was simultaneous when temperature requirements were the same, or in two steps if 
they were different. The digested DNA was analysed on the Pyrosequencer at the Department of 
Physiology, Development and Neuroscience (PDN) by Mitsutero Ito. 
 
2.3.13 Gene synthesis 
Gene synthesis was performed using the GeneArt® Gene Synthesis platform by Life 
Technologies (available on http://www.lifetechnologies.com). The DNA sequence was reverse 
translated from the protein sequence and AttB1 and AttB2 sequences flanking the gene were 
added in order to facilitate downstream Gateway cloning. All genes were received in a Gateway 
entry vector.  
 
2.3.14 Gateway cloning 
The cloning was performed according to the instructions in the Gateway Technology Rev 
1.0 user manual. In brief, the gene of interest was cloned into a pDONR vector via a BP reaction 
containing 10 µl of 50 ng vector with gene of interest, 150 ng pDONR vector, and 2 µl BP 
Clonase™ II enzyme mix in TE buffer pH 8.0, incubated 1 hour at 25°C, terminated with 
Proteinase K digest and transformed into One Shot ® Top10™ Chemically Competent E. coli 
Cells (Invitrogen).  
Transformation was done according to the manufacturer’s instructions, i.e. incubation on 
ice for 30 minutes, heat-shock by incubating at 42°C for 30 seconds, incubation with 250 µl of 
S.O.C. Medium at 37°C for 1 hour with shaking. 10 µl and 100 µl of each transformation were 
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plated out onto kanamycin selective (100 µg/ml) pre-warmed agar plates.  
After selecting colonies, mini-prepping plasmid with Qiagen Mini Prep kit and digesting 
diagnostically with restriction enzymes to verify the correct insert size, the second Gateway sub-
cloning reaction was performed – LR reaction. The 10 µl mix contained 180 ng pDONR with 
gene of interest, 100 ng pQLinkHD vector, and 2 µl LR Clonase ™ II enzyme mix in TE buffer 
pH 8.0. It was incubated 1 hour at 25C, terminated with Proteinase K digest and transformed into 
One Shot ® Top10™ Chemically Competent E. coli Cells (Invitrogen) as described above and 
plated onto selective pre-warmed plates containing 100 µg/ml ampicillin.  
Plasmid was mini-prepped from selected colonies with the Qiagen Mini Prep kit according 
to manufacturer’s instructions, and digested diagnostically with restriction enzymes to verify the 
correct insert size. The plasmid preps with correct insert size were sent for Sanger sequencing to 
Beckman Coulter Genomics using PQE-REV and PQE-FOR primers (Appendix Table 12) to 
verify correct sequence before downstream applications.  
 
2.3.15 Antibody concentration 
I have used both Amicon centrifugal filters (Millipore) and Protein G agarose (Innova 
Biosciences) for concentrating the hybridoma supernatants. A 100K cut-off Amicon filter was 
used which will allow the filtration of proteins less than 100 kDa, but will retain IgG which has 
around 160 kDa. First, 10 ml of supernatant were concentrated 20 x with the Amicon Ultra-15 
Centrifugal Filter at 4,000 x g for 21 minutes at 4ºC to a final volume of 500 µl. The column 
filter was ‘washed’ with PBS to collect the proteins immobilized on the membrane and the final 
volume made up to 700 µl. Thus the final concentration of the supernatant was ~14-fold.  
The Protein G resin was pre-washed twice with PBS, 40 µl were added to each concentrate 
and incubated at 4 C overnight. The supernatant was kept as a concentrate of the original 
hybridoma supernatant, and the resin with the bound IgG was washed twice with PBS. The 
bound antibody was eluted with 20 µl 50mM Glycine, pH 1.9, and after mixing, was 
immediately added to a vial with 2 l of 1M Tris-HCl, pH 8.0; 1.5M NaCl; 1mM EDTA; 0.5% 
sodium azide which brings the pH up to ~7.5. The elution step was repeated two more times with 
the same volumes, each fraction kept separately.  
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2.3.16 DNA ELISA assays 
For the direct DNA coating assay, varying amounts of DNA were diluted in 50 mM acetate 
buffer pH 5.0, denatured at 99ºC for 5 min, incubated immediately on ice for 10 min and loaded 
on the plate in decreasing dilutions, 50 µl/well. For quantitative comparison between samples 
OliGreen
TM
 was added at a 1:800 dilution to the buffer and the amount of DNA imaged on a 
PHERAstar FS instrument (BMG Labtech) at 485nm excitation and 525nm emission. 
For the avidin-biotin ELISA assay, the following conditions were used: 100 µl of 
250 ng/well NeutrAvidin (Pierce/Thermo Scientific) were incubated in 50 mM Carbonate buffer 
pH 9.6 for 1 hour at 37ºC or overnight at 4°C, followed by 1 hour at 37ºC incubation of 50 µl of 
10 ng/well biotin-labelled oligonucleotides in PBS. 
The subsequent steps of both assays are the same: blocking for 1 hour at 37ºC or overnight 
at 4ºC with 2% BSA in PBS, incubation with a mix of primary and secondary antibodies for 1-2 
hours at 37ºC – the dilutions of the primary antibody are specified for each experiment in the 
results section, usually 1:2000, while the secondaries were used at 1:5000-1:10 000. The signal 
was developed with a 1 x TMB substrate solution (eBioScience) at RT, for 1 – 15 min and 
stopped with 1N sulphuric acid. For quantitative comparison between samples, the assay was 
developed with the chemiluminescent SuperSignal ELISA Femto Maximum Sensitivity 
Substrate (Pierce/Thermo Scientific). In both cases the signal was measured with a PHERAstar 
FS instrument. All assays were performed with flat bottom medium binding 96-well microplates 
(Greiner).  
For the DNA binding experiment with recombinant WT and R111G MeCP2 ds 
oligonucleotides were used. Equimolar amounts of F and R oligos (F is 5’-biotinylated) were 
incubated at 99°C for 5 min and then allowed to re-anneal at RT for 1 hour. They were attached 
to the avidin plate as described above, using 40 ng/well. After the blocking, an additional 
binding step was performed with MeCP2 for 60-90 min at RT in the following binding buffer: 
0.1% BSA, 0.5 mM DTT, 1 mM EDTA in 1x PBST. The rest of the protocol is the same as 
described above, but the antibody binding was performed in the binding buffer at RT. The result 
was developed with 1 x TMB substrate solution (eBioScience). The recombinant MeCP2 WT 
and KO proteins were kindly provided by Prof Sir Adrian Bird (University of Edinburgh). All 
antibodies used are described in Appendix Table 14. 
 
2: Materials and methods 
44 
 
2.3.17 Immunofluorescence and cell imaging 
Cells were either grown directly on sterile cover slips or cytospun onto microscope slides 
with a Shandon Cytospin 2 Centrifuge for 3 minutes at 300 rpm. They were fixed in 2% PFA for 
30-60 minutes at room temperature, washed in PBS and permeabilised in PBS 0.5% Triton X-
100 for 1h at room temperature (RT). After washing, they were blocked in PBS 0.05% Tween-
20, 1% BSA (BS) for 1h at RT or overnight at 4C and subsequently incubated 1 hour at RT or 
overnight at 4°C with a primary antibody in BS (see Appendix Table 14). After 30-60 minutes of 
washing, the cells were incubated with 1:500 BS dilution of a secondary fluorescently labelled 
antibody (Life Technologies Molecular Probes) for 30 minutes at RT in the dark. Cells stained 
for DNA modifications had an extra step of 2N HCl treatment for 30 minutes after 
permeabilisation, as described (Ficz et al. 2011), and an extra permeabilisation step with 2% 
PFA for 10 min if this was performed together with staining for a protein. After 30 minutes 
washing the cells were stained with DNA stain (DAPI or YOYO) and mounted with Vectashield 
(Vector) or SlowFade Gold (Molecular Probes).   
The slides were imaged with either: 1) Zeiss 510 META Point scanning confocal equipped 
with Zeiss510 META Digital microscope camera AxioCam, 2) Olympus FV 1000 System 
confocal and 3) Nikon A1R MP Multiphoton Confocal Microscope, at 40x and 63x 
magnifications. Super resolution images were taken by Simon Walker on a Nikon SIM/STORM 
microscope. 
Staining and imaging of oocytes and embryos was performed by Fátima Santos as 
published (Santos et al. 2013).  
 
2.3.18 Preparation of metaphase spreads 
Metaphase chromosome spreads were prepared as described (Novo et al. 2013) with slight 
modifications. WT ES cells were treated with 0.05 µg/ml colcemid for 30 minutes at 37°C. After 
harvesting they were incubated with hypotonic solution (8g/l NaCitrate, 75 mM KCl) for 20 min 
at 37°C and fixed with freshly prepared ethanol/acetic acid 3:1 at -20°C overnight. Metaphase 
chromosomes were spread onto glass slides and air-dried overnight. Air-dried slides were 
rehydrated and fixed in 2% PFA, and processed further as in 2.3.17.  
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2.3.19 cDNA synthesis from total RNA 
All total RNA preparations before cDNA synthesis were treated two times with DNA-
free™ DNAse Treatment and Removal kit (Ambion) following the manufacturer’s instructions 
(2-step treatment). cDNA synthesis was performed from 100-500 ng RNA with the RevertAid 
First Strand cDNA Synthesis kit (Fermentas) or SuperScript III First Strand Synthesis System 
(Invitrogen, Life Technologies) following manufacturer’s protocol; random hexamers were used 
for gene expression or satellite analysis, and strand specific satellite oligos for the strand-specific 
major and minor satellite analysis (Appendix Table 12). 
 
2.3.20 Quantitative PCR (qPCR) for gene expression 
qPCR was set up manually or with Bravo Automated Liquid Handling Platform (Agilent 
Technologies). cDNA preparations for manual preparation were diluted 1:50 - 1:100 times in 
RNAse-free water (provided with kit) and 5 µl per sample were used in triplicate for each 
quantitative real-time PCR reaction. For automated set up, cDNA was diluted 1:7 – 1:30 fold and 
2.5 µl per sample were used for each qPCR reaction. The reactions were set up using either 
Brilliant II or Brilliant III Ultra-Fast SYBR Green QPCR Master Mix (Agilent Technologies), or 
Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen, LT). qPCR was performed on 
Mx3005P
TM
 (Stratagene) and C1000 Touch Thermal cycler 384 Real Time System (BioRad), the 
cycling conditions are outlined in Table 2. Primer pair efficiencies were calculated with the 
BioRad CFX Manager from a standard dilution curve for each master mix, and sample 
expression values were normalised for each pair.  
 
Table 2. qPCR programmes outline. 
 Brilliant II Brilliant III Platinum 
Annealing - - 50ºC for 2 min 
Hot start 95ºC for 10 minutes 95ºC for 3 minutes 95ºC for 2 minutes 
Denaturation 95ºC for 30 seconds 95ºC for 8 seconds 95ºC for 3 seconds 
Annealing  58ºC for 30 seconds - - 
Polymerisation 72ºC for 30 seconds 60ºC for 15 seconds 58ºC for 30 seconds 
Number of cycles 40  40 40  
Melting curve Yes Yes Yes 
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For primer pairs with similar efficiencies, the ratios between Ct values of target genes were 
normalized relative to the Ct of a reference gene (Schmittgen & Livak 2008). All samples were 
normalised to at least one reference gene (Hspcb and Atp5b for gene expression), and 
subsequently to the value of the relevant study control. All primer sequences are listed in 
Appendix Table 12. 
 
2.3.21 Dot blot for measurement of total 5mC or 5hmC 
DNA was denatured at 99C for 5 minutes and spotted onto Hybond-N+ nitrocellulose 
membrane (GE Healthcare). The membrane was UV cross-linked and incubated overnight with 
10% non-fat milk and 1% BSA in PBT (PBS + 0.1% Tween20) at 4C followed by >1 hour 
incubation with either 1:250 anti-5mC or 1:500 anti-5hmC antibody (see Appendix Table 14). 
Membranes were washed 4x with PBT, incubated for 30 minutes with HRP-conjugated anti-
mouse or anti-rabbit antibodies (GE Healthcare; 1:10,000 in blocking solution), washed with 
PBT, and developed using the ECL Plus detection system (GE Healthcare). The membranes 
were exposed to a high performance chemiluminescence film (Hyperfilm
TM
 ECL, Amersham). 
 
2.3.22 Methylated DNA Immunoprecipitation assay (MeDIP) 
For the 5-methylcytosine context-specific quantitative MeDIP-Seq experiments, 1.0 µg of 
genomic DNA was used as input material. Fragmentation was performed on a Covaris E220 
instrument with the 150 bp programme, in a total of 85µl. For end repair, A-tailing and adapter 
ligation of the input material, the NEB Next DNA Sample Prep Master Mix Set for Illumina was 
used, as described in 2.3.7. Each input sample was barcoded with Illumina TruSeq adapters as 
indicated in Appendix Table 15. All reactions were cleaned up using AMPure XP beads 
(Agencourt) and eluted in a final volume of 30-50μl with buffer EB (Qiagen). All adapter-
attached samples were quantitated on an Agilent 2100 Bioanalyzer system and subjected to a test 
PCR reaction for verification of the efficiency of adapter ligation (as in 2.3.8, but with NEB Next 
2x Phusion mix).  
Equal amounts of the measured input material from the DNAs of interest were then mixed, 
denatured at 99°C for 10 minutes in a heating block and immediately put on ice to prevent re-
annealing. After 10 minutes, 1:10 µl of 10x IP buffer (100 mM Na-Phosphate pH 7.0, 1.4 M 
NaCl, 0.5% Triton X-100) and 1:100 µl of a mouse monoclonal antibody against 5meCA or 
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5meCG (Reik lab, Babraham Institute) were added. Samples were incubated with the antibody at 
4°C for two hours on a rotating wheel. To capture the DNA-immuno-complex, 40  μl of 
Dynabeads Protein G (Novex/Life Sciences) were washed and blocked for two hours at 4°C with 
PBS-BSA 0.1%, and added to the DNA-antibody IP mix. After a further incubation at 4°C for 
two hours, the beads were collected with a DynaMag
TM
-2 Magnet (Life Technologies) and the 
supernatant taken out. After three washes at RT with 1x IP buffer, the beads were resuspended in 
200 μl proteinase K digestion buffer (50 mM Tris pH 8.0, 10 mM EDTA, 0.5% SDS. After this, 
35 μg of proteinase K (Roche) was added and the samples were incubated at 55°C for 30 minutes 
using a shaking heating block at 800 rpm. The beads were collected with the magnet, the bound 
fraction was taken out and cleaned up with Agencourt® AMPure® XP beads, eluted in 20 μl 
RNAse free water (Qiagen). For enrichment of adapter-ligated fragments, PCR was performed 
with NEB Next 2x Phusion mix: volume 50 μl, 5 μl DNA (pulled down or input), 200 nM 
TruSeq PCR primers 1.0 and 2.0, programme conditions as in 2.3.7 for 12 cycles for mCA and 
mCG pull-downs and 6 cycles for the input material.  
The amplified libraries were purified with Agencourt® AMPure® XP beads, processed as 
described for BS-seq in 2.3.7 and sequenced at the WTSI.  
 
2.3.23 Protein binders pull down from nuclear extract  
The protein pull down from ES cell nuclear extracts was performed by our collaborator 
Michiel Vermeulen as described (Spruijt et al. 2013). 
 
2.3.24 Tet1 oxidation assay  
Recombinant active Tet1 protein was purchased from Active Motif. Equimolar amounts of 
F and R oligos (F is 5’-biotinylated) were incubated at 99°C for 5 min and then allowed to re-
anneal at RT for 1 hour. The oxidation reaction was performed as instructed by the manufacturer, 
in 10 µl reaction volume: 200 ng DNA, 2.5 µg Tet1 in 50 mM HEPES pH 6.8, 50 µM 
Fe(NH4)2(SO4)2, 2 mM ascorbate and 1 mM α-ketoglutarate, and incubated for 3 hours at 37°C.  
A quarter of the reaction volume (2.5 µl, 50ng oligos) were diluted in 200 µl of EB buffer 
(Qiagen) and denatured at 99ºC for 5 min, incubated immediately on ice for 10 min and loaded 
on a pre-coated with NeutrAvidin polystyrene plate in 6x dropping dilutions with EB buffer, 
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50 µl/well. The rest of the ELISA was performed as in 2.3.15, incubated with either the anti-mC 
or anti-hmC antibodies (Appendix Table 14), and developed with the chemiluminescent 
SuperSignal ELISA Femto Maximum Sensitivity Substrate from Pierce/Thermo Scientific.  
 
2.3.25 FACS-sorting of ES cells  
J1 ES cells were grown on feeder cells in standard serum + LIF conditions as described in 
2.1, in 6 x 15 cm dishes to 60-70% confluence. Prior to FAC-sorting, they were trypsinised and 
incubated in dense concentration on 2 x non-gelatinised 15 cm dishes for 35 min for the feeders 
to attach. They were then spun at 300g x 3 min and washed in 1 x PBS, resuspended in 5 ml cold 
70% ethanol and incubated for 3 hours at 4°C. They were then washed in 5 ml PBS and 
incubated for 10 min at RT, spun and resuspended in 1 ml PBS and sieved through a 40 nm 
filter. After 10 min at RT 80ul of 0.5 mg/ml PI + 0.6% Igepal-630 were added to the cells and 
left for 2 hours at RT in the dark or o/n at 4°C.  
Where indicated, EdU pulse labelling was performed for 15 minutes at 37°C at 20 µM 
final EdU concentration, followed by harvesting and cell fixation in 70 % ethanol.  
The cells were sorted with a FACS Aria system and the sorts kept at 4°C prior to further 
manipulation.  
 
2.3.26 Whole Genome Amplification (WGA) 
Whole genome amplification was carried out with Qiagen REPLI-g Mini kit, following 
manufacturer’s instructions. For mouse gDNA, 380ng of starting material were used, yielding 
~12ug of WGA DNA, while for human gDNA - 90ng starting material was used, yielding 
~7.4ug WGA DNA. The WGA DNA was used without further purification, from a 1:10 working 
stock, and further dilutions towards its final applications.  
 
2.4 Bioinformatics 
2.4.1 Data mapping 
In all the various analyses of genome-wide datasets, the mouse NCBIM37 genome build 
was used as the reference genome. Data mapping was carried out by Felix Krueger, Simon 
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Andrews or Phil Ewels (Bioinformatics Facility, Babraham Institute) using Bowtie (Langmead et 
al. 2009) or Bismark (Krueger & Andrews 2011). Mapped reads were further analysed with the 
SeqMonk software developed by Simon Andrews 
(http://www.bioinformatics.babraham.ac.uk/projects/seqmonk/) and custom-made R and 
Perl scripts. 
 
2.4.2 FastQC analysis of raw and mapped reads data 
Each NGS dataset generated in this study was subjected to a raw data quality analysis with 
the BI-developed tool FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc) by 
the staff at the BI Bioinformatics facility. Additional FastQC analysis of the mapped reads of 
selected published datasets was performed by Felix Krueger and the further analysis for the 
bisulphite degradation study was carried out by the student. 
 
2.4.3 Repeat consensus analysis 
The repeat analysis for mouse satellites and other repeats was carried out by Felix Krueger, 
including the telomere degradation analysis. A similar pipeline was performed for unconverted 
MeDIP data, as well as for the WGBS-seq and MspJI meRRBS datasets. Depending on the type 
of library, either Bowtie or Bismark were used to align the trimmed raw reads against a 
consensus repeat sequence for each repeat class. The alignments were performed with high 
stringency allowing for only one base mismatch (n=1). For MeDIP data, the percentage of reads 
aligning to a repeat sequence was scored, separated by strand, and for BS-Seq data the 
methylation results were assessed for each cytosine from the consensus sequence. The 
methylation analysis was done by the student in SeqMonk: a custom-made genome was used for 
each repeat consensus, probes were generated for each base as read position, and methylation 
was calculated as percentage of methylated calls versus total cytosine calls for each probe. The 
data was exported and analysed further in Excel and visualised with GraphPad Prism 6.0.  
 
2.4.4 Analysis of MeDIP and WGBS datasets 
The feature and global methylation analysis was carried out with SeqMonk by the student. 
Phil Ewels helped with calculating cytosine content and context distribution in selected features 
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used for the analysis of MeDIP and MspJI data. 
For SeqMonk analysis of MeDIP-seq data, tiling probes were created for every 500bp 
without overlap. Feature probes coordinates were extracted from the NCBIM37 annotation, 
except for promoters which were determined as spanning -1000 to +200 around the transcription 
start site and CG islands were annotated based on published coordinates (Illingworth et al. 2010). 
Feature read numbers were normalized to the total read number per dataset. Extreme outlier 
probes with a log2 value above 10 were excluded from further analysis as they likely represent 
mapping artefacts (Ficz et al. 2011). Highly asymmetric peaks were selected (‘Forward-biased’ 
and ‘Reverse-biased’) on regions covered by at least 10 reads, and strand to strand ratio higher 
than log2 value of 0.5, meaning one strand has to be at least three times more represented than 
the other. Peak enrichment was normalized to the unbound and represented directly or as log2 
enrichment.  
For BS-seq analysis, probes were generated over selected genomic features in SeqMonk 
and methylation was calculated as a percentage of positive (methylated) calls versus all calls for 
each individual probe, and then averaged for the feature. Initial filtering of outliers was 
performed as for MeDIP-seq, and those regions were excluded from further analysis.  
The analyses over high depth WGBS datasets (Lister et al. 2009; Stadler et al. 2011) were 
carried out by Felix Krueger or Simon Andrews (BI Bioinformatics) with custom-made scripts. 
 
2.4.5 Analysis of ChIP datasets 
ChIP (Chromatin Immuno-Precipitation) data peak calling was performed by the student 
with the MACS peak caller (Zhang et al. 2008) integrated in SeqMonk, and peak coordinates 
exported for further analysis. Whole cell extract (WCE) or Input datasets (provided with 
published ChIP datasets) were used for normalisation for the MACS peak calling. Outlier peaks 
with high read coverage potentially due to sequencing artefacts were removed. For mCA or 
mCG enrichment, the ChIP peaks were overlayed with mCA or mCG peak coordinates and 
enrichment was calculated by the ‘Quantitation trend plot’ feature over either mCA or mCG in 
SeqMonk.  
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2.4.6 In silico digestion 
In silico digestion of the mouse genome by restriction enzymes was performed by Felix 
Krueger.  
 
2.4.7 MspJI-RRBS base-calling  
The base-calling was carried out by Felix Krueger. The justification for strand and read 
usage and final ‘true positive’ call selection, was carried out by both the student and Felix 
Krueger, based on the nature of MspJI digestion and library read generation. As a result, after 
adapter trimming, only position #16 from read 2’s were selected as ‘true positive’ methylation 
calls for further analysis (read 1’s contained an error of the unspecifically digested 5’ ends). The 
rest of the analysis was performed as described in 2.4.4 for WGBS.  
 
2.4.8 WRC sequence analysis 
The AID consensus sequence (WRC) analysis was carried out by Simon Andrews (Head, 
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 3 Genomic distribution of non-CG methylation: a classical approach 
 
3.1 Introduction 
At the time of starting this project, only one study had attempted a detailed investigation of 
the whole genome distribution of this type of methylation, and it was done in human cell lines 
(Lister et al. 2009). In order to approach the question for its biological relevance in the mouse as a 
model animal, a good starting point was to analyse the non-CG 5mC genomic distribution in the 
mouse, and Lister’s data could provide a good point of comparison, since it is done on embryonic 
stem cells and fibroblasts. Another important factor for my analysis, though, have been the 
existing scepticism and doubts within the scientific community, related to a possible artefactual 
nature of the non-CG context methylation, and the fact that it had traditionally been used for 
estimation of conversion efficiency, and not as an actual signal in itself (Harrison et al. 1998; 
Araujo et al. 1998; Laird 2010; Genereux et al. 2008). In order to move this ongoing discussion 
further, it therefore seemed necessary to not only analyse existing non-CG methylation signals in 
the genome, but to address the issues around BS-conversion artefacts and the limitations of the 
existing techniques, finding ways to validate the real non-CG 5mC signals.  
As discussed in 1.6, the techniques to study non-CG methylation are quite limited; however, 
a few have been successfully used to obtain qualitative and quantitative information of the 
cytosine neighbouring context and they are: bisulphite (BS) conversion and sequencing, nearest 
neighbour analysis (NNA) and a CCWGG modification of the LUMA technique. They seemed 
good candidates to provide both quantitative data on the global levels of genomic non-CG 
methylation (with LUMA and NNA), and also to obtain details on the genomic distribution of 
non-CG methylation in ES and differentiated cells (with BS sequencing). It is important to 
remind, however, that the genome wide BS-seq technique has to date been used to analyse non-
CG genomic distribution only on high depth sequencing datasets (min 10-fold coverage) (Lister et 
al. 2009; Laurent et al. 2010; Shirane et al. 2013; Lister et al. 2013), which were not an option for 
this study. Because of the different concerns raised in 1.6 regarding the use of bisulphite 
conversion and the feasibility of low depth BS-seq datasets to deliver valid results for non-CG 
context, it was necessary to also address these issues and evaluate the suitability of the approach.  
In addition, it was appropriate to employ and analyse other genome-wide data like datasets 
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of mouse ES cell lines obtained with MeDIP-seq, which have been available in the lab, to 
indirectly assess the distribution of asymmetric methylation, as has been suggested previously 
(Ficz et al. 2011).  
 
3.2 Aims  
1. To analyse indirectly genome-wide distribution of asymmetric methylation in mouse 
ES cells from the available MeDIP-seq datasets and validate the feasibility of using 
this approach 
2. Perform a direct analysis of the genome-wide distribution of asymmetric methylation 
in mouse ES cells and differentiating primary embryonic fibroblasts (pMEFs) with 
whole genome low coverage BS-seq data and use that to validate the MeDIP-seq 
approach  
3. Investigate the feasibility of using the low resolution BS-seq approach by addressing 
1) conversion artefacts and 2) DNA degradation and amplification sequence biases 
4. Assess global genomic levels of non-CG methylation in WT mouse ES cells, pMEFs 
and tissues using NNA and CCWGG-LUMA  
 
For the purpose of the genome-wide analysis carried out in this and the following chapters 
cytosine methylation will be presented in three sequence contexts – CG, CHG and CHH, where 




3.3.1 Non-CG methylation in MeDIP-seq 
One way to assess the patterns of genome-wide DNA methylation is to first enrich for the 
methylated fraction of the genome and subject only this portion of the genome to high throughput 
sequencing. This strategy might have considerable advantages specifically for low levels of 
methylation like in the non-CG context, and does not have the disadvantage of a chemical 
treatment and incomplete conversion. As discussed in 1.6 (Introduction), the two most commonly 
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used techniques rely on pulling down methylated DNA using either a methyl-DNA binding 
protein (MBD – MBDCap, MeCP2 – MeCAP) (Serre et al. 2010; Brinkman et al. 2010) or an 
antibody against 5-methylcytosine (MeDIP) (Weber et al. 2005; Down et al. 2008). The 
MBDCap/MeCAP recognise CG context only, while the MeDIP recognises methylated cytosine 
in any sequence context (Zilberman & Henikoff 2007; Robinson et al. 2010; Bock et al. 2010), 
making it a more appropriate enrichment technique for this study. There are clear advantages of 
this method over the BS-seq: only a small fraction of the genome is sequenced which leads to 
high coverage over all methylated regions, highly important for the non-CG context; and this is 
achieved with a relatively small sequencing effort, which could enable sample multiplexing. The 
downside of including an enrichment step, however, is that any direct quantitative information is 
lost and precise levels of methylation cannot be assessed as for BS-seq.  
Since the MeDIP technique does not provide information on individual bases, on their 
neighbouring context and methylation status (the pulled down sonicated DNA fragments have an 
average length of 250bp), in order to be able to interpret this data, I have to look at 
asymmetrically represented genomic regions, which could be a sign of asymmetric methylation. 
In order to fulfil this requirement one of the DNA strands has to be pulled down more than the 
other, because of the asymmetric nature of non-CG methylation in mammals as discussed in 1.2 
(Guo et al. 2013; Ziller et al. 2011). To validate this approach, I looked at the ratio of pulled down 
reads from several repeat classes using published repeat consensus sequences (listed in Appendix 
Table 16). The raw reads were aligned to the consensus sequence and the proportion of forward 
and reverse strand reads estimated in a number of MeDIP datasets (a schematic of the paired end 
technology which preserves original strand information is presented in Appendix Figure 71). I 
compared a WT mES cell line (J1) with a panel of differentiated samples: embryonic bodies (EB) 
derived from the J1 ES line, primary mouse fibroblasts (pMEFs) and sperm, together with an 
unmethylated control of a Dnmt3a/3b/1-KO ES cell line (TKO), which were already available in 
the lab and subsequently published (Ficz et al. 2011). The TKO line does not have any 5mC 
(Kaneda et al. 2004; Raddatz et al. 2013) and has been widely used as a negative control in 
methylation studies. I tested four repeat classes; for three of them (LINE1 5’UTR, SINE1B and 
IAP LTR1a) the strand representation was very symmetric, while the major satellite repeat 
showed a very strong strand asymmetry - the reverse strand was pulled down several-fold higher 
than the forward strand (Figure 7A). The unexpected observation was that the strand asymmetry  










 Forward Reverse GC Skew 
Major 14% 23% 9% 
SINE1B 28.6% 32.7% 4% 
LINE1 26.6% 33.3% 7% 





Figure 7. Analysis of MeDIP strand asymmetry. A. Asymmetric strand representation of repeats in the 
MeDIP pulled down DNA fraction in a panel of ES cell lines and tissues. B. Percentage of cytosine 
distribution between the two strands of each repeat consensus. C. Percentage of reads in the MeDIP 
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was strongest in the unmethylated TKO sample, suggesting that this can be merely an artefact and 
not a consequence of underlying asymmetric methylation. I calculated the cytosine content and it 
showed that the major satellite also has a cytosine strand asymmetry and the pulled down reverse 
strand is the cytosine-rich strand, composed of 65% more cytosine than the C-poor forward strand 
(Figure 7B). The remaining three analysed repeats have overall higher C-content or a relatively 
uniform cytosine distribution on both strands. Another important point is that the satellite repeat 
itself constituted a large fraction of the total reads in most MeDIP datasets, pointing out to a 
potential amplification artefact (Figure 7C), especially in that the pull down ratios do not reflect 
directly the samples’ methylation levels – the sperm sample (very methylated) has a low satellite 
proportion while the relatively unmethylated Np95-KO had pulled down as much as the WT 
samples.  
I decided to validate this result with a classical targeted bisulphite sequencing. I designed 
individual primer pairs for the amplification of bisulphite converted forward and reverse strands, 
which become non-complementary after bisulphite conversion and require separate amplification 
(see Appendix Table 12). These oligos yielded several sizes of major satellite bands for J1 ES cell 
and TKO gDNA (as a conversion control) and I cloned the band which spans for one and a half 
satellite consensus repeat – ~370bp. The results are shown in Figure 8. Both strands showed 
presence of non-CG methylation (in the CA context), which was more pronounced on the reverse 
strand (2.1% reverse vs 0.88% forward, conversion rate 99.71% as determined by the TKO). 
These findings therefore confirmed that there is an existing link between asymmetrically pulled 
down DNA strands and asymmetric methylation, although from the findings in Figure 7A and B, 
we know that there also is a clear link, between cytosine content and asymmetric strand 
enrichment in the MeDIP datasets.  
 
To further address those issues and test the MeDIP approach, I performed a genome-wide 
feature analysis on ES cell lines with variable methylation levels – J1, E14 (WT), Np95-KO 
(reduced maintenance methylation) and TKO. Plotting the percentage of symmetric and 
asymmetric peaks for each dataset revealed that the less methylated genomes like the Np95-KO 
and the TKO had more asymmetric peaks, this value reaching almost 100% in the TKO (Figure 
9A). 
 





Figure 8. Bisulphite conversion and cloning of major satellite single repeat.  J1 ES cell line forward strand 
(left upper) and reverse strand (right upper); the span of one unit is shown, with a coloured legend for 
each context. Lower panel – a quantitative representation of methylation positions and their methylation 
values for the satellite monomer on both strands; Note: the values on the reverse strand are not negative! 
 
I then looked at the peak overlap with selected genomic features with coordinates obtained 
through SeqMonk directly from Ensembl Genome Browser. Some features, not available on 
Ensembl, such as ‘Introns’, ‘Intragenic regions’, ‘Promoters’ etc were custom made in SeqMonk 
as explained in 2.4.4. I calculated the number of peaks per feature, and normalised this to the 
unbound DNA fraction, to the cytosine content of each feature (which correlates to its length), and 
to the total number of reads per dataset. The results showed that the TKO unmethylated control 
had the highest relative enrichment for some of the features, but not for others (Figure 9B). Those 
features were mainly simple repeats like microsatellites and telomere repeat, which are very likely 
to be artefacts, especially given how C-rich they are – 50% for telomeres and some C-containing 
microsatellites. I therefore removed from the analysis the repetitive features where the negative 
control shows more than two-fold higher enrichment than the input (value of 1.0 is equal to 
input).  
5’                                                                                3’ 1 unit 
234bp 
J1 Major satellite repeat: Reverse strand 
5’                                             3’ 1 unit
234bp 
J1 Major satellite repeat: Forward strand CG, CA, CT, CC 
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Figure 9. MeDIP-seq symmetric and asymmetric peak analysis. A. Percentage of symmetric and asymmetric 
peaks in the MeDIP-seq datasets included in this analysis. B. Feature analysis of peak enrichment, 
normalized to the unbound fraction, to peak counts per dataset and to the cytosine content of each feature 
(reflecting its genomic size). Each dataset represents pooled data from two biological replicates, published 
































































I then analysed further the remaining features representing them as a log2 of the values in 
Figure 9C, so that the enriched regions would appear as positive and the depleted as negative 
values along the Y axis (Figure 10). The results showed that the asymmetric feature enrichment 
pattern follows the pattern of the symmetric peaks, but with much lower values, showing that 
either both peak types reflect the CG methylation, or that the pattern of asymmetric methylation 
follows the pattern of CG methylation. Indeed (Ficz et al. 2011) have shown (fig. 3a and c) that a 
high proportion of the CG-enriched peaks are asymmetric (referred to in the paper as ‘biased’ 
from ‘strand biased’). The highly enriched features in WT ES in Figure 10A, such as exons, and 
introns, indeed have also been reported as enriched by the authors (Ficz et al. 2011, 
supplementary materials), while the CGIs, promoters, intergenic sequences, LTRs and LINEs are 
less enriched (Figure 10A). In addition, my results showed that some RNA loci were enriched 
over the background, the SINEs were also enriched in both peak fractions as well as the non-
promoter CGIs were enriched in the symmetric methylation as expected. Interestingly, the 
mapped satellite units did not show enrichment, which is probably due to the initial data filtering. 
Only the snRNA and tRNA loci showed a higher enrichment in the asymmetric fraction, however 
the TKO showed similar enrichment, pointing to a potential artefact. Comparing the asymmetric 
peak distribution of WT and methylation compromised ES cell lines (Figure 10 B and C) revealed 
that the asymmetric fraction in general had very low enrichment in most features in comparison to 
the symmetric peaks. This means that those asymmetric peaks followed the dynamics of the 
asymmetric peaks of the unbound fraction to which they were normalised, and therefore most 
likely reflect amplification biases rather than real asymmetric methylation.  
The fact that the completely unmethylated genome of the TKO yield many reads from the 
antibody pull down, which are exclusively asymmetric, shows that the pull down artefacts would 
manifest as asymmetric peaks. The unbound control on the other hand, which should represent an 
unbiased genomic sample, also shows around 45% of asymmetric peaks, while it is expected to 
have entirely symmetric unbiased strand distribution. This shows that alongside the antibody pull 
down artefacts, there are, in addition, polymerase amplification artefacts, potentially created by 
the known polymerase bias discussed in 1.6.2.4. As shown in (Ficz et al. 2011, fig. 3c), the 
composition of the asymmetric peaks is very rich in CH cytosines, which could explain both the 
antibody unspecific C-affinity pull down, in the absence of its endogenous 5mC target, and also  










Figure 10. Feature enrichment of asymmetric and symmetric peaks, normalized to unbound genomic 
fraction. A. Comparison of the enrichment of symmetric and asymmetric peaks in WT ES cells. B, C. 




























































the polymerase preference to over-amplify C-rich regions. As shown in Figure 10 B and C, the 
asymmetric peaks which were not pull down artefacts overrepresented in the TKO samples, 
disappeared after normalisation to the unbound fraction and do not show any high specific feature 
enrichment.  
Taken together, the results from the MeDIP-seq data analysis show that it is very likely that 
a high proportion of the asymmetric peaks are pull-down or amplification artefacts, while another 
proportion indeed reflects existing underlying methylation, predominantly in CG context. A 
proportion of the asymmetric peaks undoubtedly reflect non-CG methylation, as confirmed by 
bisulphite analysis, which however would be impossible to track among the artefacts and the 
asymmetric CG methylation peaks. Therefore, the MeDIP-seq datasets generated with a general 
5mC antibody, although containing both CG and non-CG methylation, as expected, are not 
suitable for the exclusive analysis of non-CG methylation.  
 
3.3.2 Low resolution BS-seq datasets: non-CG BS-conversion artefacts  
In order to characterise the distribution of non-CG methylation, an affordable technique 
should be available, which can be applied to a large number of samples and not have the 
limitations of cost and computing power of the high coverage BS-seq datasets. I therefore focused 
my next analysis on low coverage BS-seq datasets, generated previously in the lab (Seisenberger 
et al. 2012; Popp et al. 2010), together with datasets sequenced for this project (Raddatz et al. 
2013). I first quantitated total methylation calls in the CG, CHG and CHH contexts. Filtering was 
applied for outliers – regions with very high read coverage, which could be either amplification 
artefacts, or reads from the major satellite units mapping to regions of interspersed repeat 
sequence, which do not actually belong to the particular locus. No filtering was applied for the 
exclusion of methylated cytosine calls as it was done in (Lister et al. 2009) due to the low 
coverage, and because the initial purpose of this study was to evaluate the contribution of 
conversion artefacts to the analysis of non-CG context methylation in low resolution datasets. The 
first results showed a higher amount of total CHG and CHH methylation in ES cells (36%) 
consistent with expectations. The primary mouse fibroblasts (pMEFs) contained less but 
nonetheless considerable amount of 5mC in non-CG context (22%) compared to the published 
human (0.02%) data (Lister et al. 2009) (Figure 11A).  
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Figure 11. Methylation levels in CG, CHG and CHH contexts in low coverage BS-seq datasets and 
conversion artefacts. A. total proportion of positive calls in each context for the whole dataset normalised 
to total read count. B. CHG and CHH methylation as percentage of each context. C. Global levels of 
methylation per context presented as a percentage of total cytosine content for each dataset. D. Cytosine 
conversion efficiency after bisulphite treatment of the WT J1 and TKO ES samples as measured by a mass 
spectrometer (LC/MS) and BS-seq. E. Contribution of false positive calls (unconverted cytosine) to ‘global’ 
methylation after bisulphite treatment as measured by LC/MS. F. Applying various mapping stringencies 
and non-CG filtering for two datasets changes the estimate of non-CG but not of CG methylation; “n” is 
the number of allowed mismatches, and |30/31 is the number of consecutive bases for which the mismatch 
rule is applied. Standard conditions used in our facility’s pipeline are n = 1 mismatch per 31bp (length of 
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Similar results were observed when 5mC calls were calculated as a percentage per context - 
the methylation in pMEFs is still around half of that in ES cells (Figure 11B). To address the 
question whether this is a real estimate, or the direct result of a conversion artefact, I sequenced 
the methylome of the Dnmt3a/3b/1-KO ES cell line (TKO), which has no methylation (Raddatz et 
al. 2013). An M13 2kb PCR fragment was spiked in as an additional conversion control as 
advised in (Krueger et al. 2012). The total levels of CHG and CHH positive calls in both the TKO 
ES DNA (1.38%) and the M13 DNA (1.6%) were comparable and slightly higher than the pMEF 
DNA (1,25%), confirming that those levels of non-CG methylation can be attributed entirely to 
false positive calls (Figure 11C). I then measured by mass spectrometer the level of unconverted 
cytosines of bisulphite-treated J1 and TKO genomic DNA, and the amount of unconverted 
cytosine in both samples was between 1 and 2 % of the total, confirming the observed false 
positive levels in the TKO and M13 samples from BS-seq (Figure 11D). Thus the incomplete 
conversion contributes significantly to the false discovery rate of BS-dependent platforms where 
the unconverted cytosines will be interpreted as methylated cytosines and add up to more than 
20% to the total 5mC value (Figure 11E). Lastly, we tried enhancing the alignment stringency of 
the low coverage BS-seq datasets and applied filtering of non-CG context as described (Lister et 
al. 2009). The results showed that any change in mapping conditions and filtering, affected 
dramatically the methylation values in both CHG and CHH context, but not the levels of mCG 
(Figure 11F). This points to an additional issue that the non-CG context positive calls, real or 
artefactual, can be manipulated by the data processing parameters. The real methylation values are 
also affected by this, as seen in (Figure 11E), where the E14 sample almost ‘loses’ its non-CG 
methylation with more stringent mapping parameters.  
 
In search for possible validation approaches of the low level methylation signal in non-CG 
context in base resolution datasets, I looked at C>T transitions (or single nucleotide 
polymorphisms, SNPs) in non-CG context between the C57BL/6 J (B6) genomic annotation used 
for mapping and the sequenced J1 mES cells of the 129S4/SvJae mouse strain. If is known, that 
methylated cytosines cause higher rates of C>T transitions, which contribute to disease and in the 
context of evolution have led to the depletion of CG in mammalian genomes (Cooper et al. 2010).  
Therefore sites of C>T SNPs could be mapped and used to validate positions of real methylation 
as opposed to conversion artefacts. My analysis revealed that C>T transitions in the CG context 
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were indeed comparatively higher methylated (83% versus 74% average CG methylation) (Figure 
12A). Among C>T SNPs in CH contexts, CA showed the highest 5mC value (3.6% out of 2.9% 
on average), which was a too low difference, however, to be reliably used as a validation marker. 
Curiously, post-mutation calculations revealed that methylated CG sites give rise to CA sites after 
deamination, which in its turn give rise to TA sites, providing a plausible explanation of the 
predominance of AT content (~60% for mammals, Appendix Table 11) in the genomes of 
organisms possessing CG DNA methylation (Figure 12B).  
 
A.    
 
B.    
 
Figure 12. C>T transitions in all four cytosine contexts. A. Average percentage of methylation for each 
context in J1 mESC compared with polymorphic C>T transition sites between C57BL/6J (NCBIM37) and 
129S4/SvJae mouse strains. B. A calculation, demonstrating why CA context is not proportionally reduced 
in the mouse genome as CG, despite its increased C>T transition rate.  
 
I also explored the opposite possibility – if SNPs could contribute to artefacts in the 
methylation calls, undistinguishable from the conversion artefacts we observe in BS-seq. The 
effect of SNPs on methylation calling can contribute in three ways:  
1) False negatives (when a T is actually a T rather than a converted cytosine); 
2) Give wrong context in the case of G>H transitions, where methylated CGs could give 
false rise in CH methylation; 
Somatic methylation level
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3) Mapping mismatches – if a large number of SNPs occur on one sequencing read, such 
reads will be excluded from analysis by the stringent mapping parameters. 
 
I explored the first two possibilities. False C>T transition negatives would be exactly 
1,699,651 sites out of 1,068,292,058 cytosines in the genome or 0.16% of all cytosines, which 
will not affect the result of final methylation. Regarding the false positives, (C)G>(C)H transitions 
are 528,608 sites out of a total of 42,685,558 CG sites, or the decrease in CG methylation due to 
transitions will be 1.24%. There are 1,025,760,420 cytosines in CH context, making CG>CH 
transitions 0,052% of CH context. Given that around 70% of CG context is methylated in mESC, 
this will mean that around 0.036% of CH calls will appear methylated due to wrongly mapped CG 
sites. This makes around 1/40
th
 of the observed conversion artefacts.  
 
In summary, the conversion efficiency of bisulphite-based techniques has always been a 
main question for non-CG methylation because the ‘real’ signal looks like the conversion artefacts 
– sparsely distributed, individual values, with low % per position, and in non-CG context 
(Warnecke et al. 2002). A small amount of those artefacts is due to wrongly mapped methylated 
CG sites from the 129 genome, which correspond to CH context in the B6 genomic annotation. 
The current results suggest one should be extremely cautious when interpreting global non-CG 
context methylation data from low resolution BS-seq datasets. How this affects the actual analysis 
of non-CG methylation for genomic features has to be further assessed.  
 
3.3.3 Distribution of non-CG methylation in low resolution BS-seq datasets 
Despite the high levels of false discovery rate contributing to the global amounts of cytosine 
methylation, which makes the analysis of individual cytosines impossible, a global analysis of the 
annotated genomic features and unmappable repeat classes as for MeDIP-seq in 3.3.1, was 
nevertheless worth attempting.  
I therefore first set to validate the repeat alignment results from the MeDIP analysis in 3.3.1 
and repeated the same alignments for bisulphite converted DNA for two pairs of pluripotent and 
differentiated samples (J1 ES and pMEF (Seisenberger et al. 2012), and E14 ES, Np95-/- ES and 
E13.5 Fetus (Popp et al. 2010). Since non-CG methylation should be more prevalent in 
pluripotent cells we would expect to see a higher value in the ESC than in lineage committed cells 
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A. Major satellite   
   
B. Minor satellite   
   
C. SINE1B   
   
D. IAP LTR1a   
   
Figure 13. Non-CG methylation in mouse repeat sequences. The individual cell lines are given in figure 
legends – pluripotent cells are marked with ‘red’, differentiated with ‘blue’, DNA methylation-KO ES in 
‘green’; GC context (left), CHG context (middle) and CHH context (right). A. Major satellite repeat; B. 
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(Ramsahoye et al. 2000). I included in the analysis all repeats previously analysed in 3.3.1 
together with the minor satellite and LINE 3’ UTR consensus (see Appendix Table 16). The 
results confirmed the presence of non-CG methylation in the major satellite, again mostly on the 
reverse strand (strand information not given on figure), and surprisingly it was also present in the 
differentiated cells, although potentially to a lower extent (Figure 13 A, red vs blue colour). The 
minor satellite, SINE1B and IAP LTR1a showed lower amounts of non-CH methylation and, 
unlike the major satellite, it was present exclusively in the ES cells and not in the differentiated 
samples (Figure 13 B-D, red vs blue colour). There was no striking strand bias in those repeats 
and the figure omits strand-specific information, showing a summed up methylation from both 
strands along the length of each consensus. 
Another interesting point from this analysis is the largely preserved non-CG methylation in 
Np95-/- ESCs, which maintains the pattern of the WT ES cells and not the lineage committed 
cells, despite that the CG methylation is heavily reduced. In the case of minor satellite and 
especially the IAP LTR1a we see slightly higher non-CG methylation levels than in the WT 
ESCs, which could lead to the speculation for a compensation mechanism over the lack of CG 
methylation. This could in fact be observed in all four repeats, because the highest levels of non-
CG methylation are detected within the ‘gaps’ of CG methylation – as if the low levels of non-CG 
methylation were compensating for the lack of methylateable CG sequence in that region. 
However not all ‘gaps’ were compensated for, meaning some sequences potentially required a 
higher level of compensation than others, suggesting this might be biologically meaningful. 
 
These results looked quite promising regarding the capacity of low coverage WGBS 
datasets for the assessment of repeat classes, for the LINE1 sequences, and I therefore I used the 
recently published mouse ES cell high depth dataset by (Stadler et al. 2011) as a comparison. The 
results are presented in Figure 14. The data for J1 and E14 WT ES cells from both datasets show a 
very coherent overlap (‘red’ vs ‘black’ on the figure). The interesting observation about LINE1 
UTRs is that both of them have a few conserved individual CH positions with very high levels of 
methylation, which is a rarity for CH context, while they do not show larger stretches of low level 
non-CG methylation characteristic of other repeats. This result is strikingly reproducible and 
accurate in all datasets, the positions are conserved in all datasets and do not resemble a 
conversion artefact. Interestingly, in the 5’UTR those values are higher for the pMEF than the ES 
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cells, which also have only 30-50% CG methylation while the MEFs are fully methylated in CG. 
This observation highlights that the levels of non-CG methylation tract the levels of CG 
methylation for the same region, again pointing to a potential ancillary role to the main CG 
methylation, and not necessarily only in ES cells. The levels of mCH therefore seem region 
specific, rather than cell specific, and it will be important to define where it occurs in the different 
cell types and what differences in its role the different locations might determine. The 3’ end of 
the 3’ UTR is excessively CH-rich and therefore those levels must be a result of bisulphite 
degradation and amplification bias over unconverted DNA.  
 
 
A. LINE1 5’ UTR   
   
   
B. LINE1 3’ UTR   
   
Figure 14. Non-CG methylation in mouse LINE1 sequences. Shown are low coverage J1 (red) and pMEF 
(blue) (Seisenberger et al. 2012), and high coverage mES datasets (Stadler et al. 2011) (black) – the 
latter in two groups as ‘GAII’ and ‘HiSeq’, depending on the Illumina machine used. A. LINE1 5’ UTR. B. 
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To summarise, the initial analysis of low depth BS-seq datasets on repeat consensus 
sequences yielded very good results. In both groups of comparative repeat analysis, the agreement 
between two different sets of datasets generated by different groups, show very good 
reproducibility, despite differences in coverage and depth. The results from the lower coverage 
datasets were entirely comparable with high depth datasets. This is not a surprise given that this 
analysis utilises alignment of multiple raw reads to a repeat consensus sequence, which gives a 
very high depth of alignment even in low-resolution datasets.  
 
 
I proceeded with assessing the methylation of unique (non-repetitive) or non-unique but 
annotated genomic sequences (like the rRNA loci or pseudogenes). I chose a selection of features 
and calculated the relative methylation levels for each of the three contexts – CG, CHG and CHH. 
As seen in Figure 15, the levels of CG methylation (upper panel) are entirely as expected, with 
every feature highly methylated between 60-80%, apart from CGIs, transcription start sites (TSS) 
and CGI-containing promoters. In both CHG and CHH contexts however, the distinction between 
methylated and unmethylated features is not as dramatic and fluctuates around the genomic 
average and the TKO incomplete conversion value (Figure 15, middle and lower panel). This 
result shows that the positive calls in non-CG context are distributed more or less evenly among 
the features and do not enrich in any particular genomic locations. However, high depth analyses 
have revealed enrichment in gene bodies and some repeats in human and mouse (Lister et al. 
2009; Ziller et al. 2011). In addition, unmethylated CGIs are not expected to have CH 
methylation, because they are protected from methylation. This means that the amount of 
information in the low coverage datasets is not enough to provide robust and adequate evaluation 
of CH methylation, and the majority of observed positive calls are actual false positives resulting 
from incomplete bisulphite conversion. Incomplete conversion has no reason to be enriched in one 
feature over another, and therefore is expected to be uniformly distributed along the whole 
genome, a result in keeping with our observation in Figure 15. 
 
Thus, high depth repeat analysis from low coverage datasets is entirely valid for both CG 
and CH methylation, while feature analysis in CH context is dominated by artefacts and is not 
reliable.  






Figure 15. Methylation in genomic features in J1 ES and pMEFs in CG (upper), CHG (middle) and CHH 
(lower) contexts. The genomic false discovery rate per context of the TKO estimated in Figure 11 is added 
to each graph for clarity. 
 
 
As a last test, I decided to verify a published observation, rather than use the low coverage 
datasets for identifying novel patterns of mCH localisation for which I cannot be 100% certain if 
the result is valid. It has been reported that non-CG methylation was observed at replication 
















































































3: Genomic distribution of non-CG methylation: a classical approach 
72 
 
origins, as it did not persist once the cells entered a replication arrest (Tasheva & Roufa 1994b). I 
have therefore decided to validate this observation, and check if I would detect more non-CG 
methylation in mouse ES cells than in pMEFs at origins in the low resolution BS-seq datasets. I 
used published annotation of replication origins for mouse for chromosome 11 to analyse 
methylation calls in cell type specific origins of ES cells and pMEFs (Cayrou et al. 2011).  
 
A                                          B 
       
 
Dataset 5mC calls All C calls 
J1 CG 2,03 2,76 
MEF CG 2,08 2,76 
CG GA 31,57 43,41 
CG HiSeq 46,49 62,49 
J1 CHG 0,35 11,22 
MEF CHG 0,19 11,68 
CHG GA 4,86 189,59 
CHG 
HiSeq 6,76 247,32 
J1 CHH 0,59 29,08 
MEF CHH 0,43 26,27 
CHH GA 11,27 503,24 
CHH 
HiSeq 16,95 674,32 
 
Figure 16. Methylation in mouse replication origins for chromosome 11.  A. Average cytosine coverage per 
feature for low coverage J1 and pMEF and high coverage mES from (Stadler et al. 2011) – note that this 
data is split in two and appears as ‘GA’ and ‘HiSeq’, depending on the Illumina machine it was performed. 
B. Context methylation analysis in ES and pMEF specific replication origins (vertical axis groups) in J1 and 
MEFs (horizontal axis); the methylation ratios are binned in groups as shown in figure legend, and each 
group represented as a percentage of the total. Anne Segonds-Pichon, BI Bioinformatics helped for the 
statistical analysis. 
 
However the cytosine coverage per origin of the low resolution BS-seq datasets was not 
enough for a statistical validity of the results (Figure 16A) and we had to perform the analysis on 
the high depth mES cell datasets (Stadler et al. 2011). The difference between CHG and CHH 
methylation in ES cells and pMEFs was not statistically significant to conclude that ES cells have 
more non-CG methylation in replication origins, for both cell type specific origin groups (Figure 
16B). 
p=0.055 p=0.094 
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3.3.4 Bisulphite treatment and DNA degradation 
It has previously been reported that the unmethylated cytosine is the primary base targeted 
for degradation by bisulphite (BS) (Tanaka & Okamoto 2007), but so far no comprehensive study 
has been carried out to investigate whether this degradation bias affects the uniform genomic 
coverage of BS converted sequencing data. If indeed the unmethylated cytosines are the main 
source of DNA degradation, then we might expect a lower representation of C-rich regions in the 
datasets and a higher representation of highly methylated regions versus unmethylated regions 
(Figure 17A). This can, on one hand, lead to an overestimation of global genomic methylation 
levels (because the total cytosine pool is reduced), and on the other, can potentially have a 
negative effect on the coverage and depth of non-CG rich regions, which are two crucial 
parameters for its correct evaluation as discussed in 1.6.2 (Introduction) (Figure 11A). 
I therefore set to answer the following questions: 1) Whether cytosine rich regions are 
indeed preferentially degraded by the BS treatment; 2) Whether cytosine modifications affect the 
degree of BS induced degradation; 3) Could this lead to any real biases in WGBS data.  
 
A  B  
  
Figure 17. Bisulphite-induced degradation of DNA. A. A schematic representation of the expected 
consequences from the biased degradation in a cytosine-rich (upper) and highly methylated (lower) 
environments. B. DNA yield after bisulphite conversion of a C-rich and C-poor DNA PCR fragments shows 
higher degradation of the C-rich DNA. 
 
For this purpose, I combined analysis of synthetic PCR fragments as well as of WGBS 
datasets. In order to address the first question I used two DNA fragments from the sequence of the 
M13 bacteriophage – one with 15% cytosine (‘C-poor’ fragment, R3) and the other with 35% 
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cytosine content (‘C-rich’ fragment, R5), the mapped mouse genomic average being 20.90% (see 
Appendix Table 13 for M13 sequences and Appendix Table 11 for genomic representation of 
cytosine contexts). I bisulphite treated both fragments with two widely used kits – Epitect and 
Imprint (see 2.3.2), and measured the recovered DNA on an Agilent Bioanalyser high sensitivity 
DNA chip (Figure 17B). The results with both kits were very similar and the average recovery of 
the C-poor fragment was around 4-fold higher, meaning the cytosine content indeed affected the 
level of degradation.  
 
I then looked at published WGBS datasets, where, due to the known polymerase AT-rich 
regions fail (Quail et al. 2012; Oyola et al. 2012) this problem might be further intensified. I first 
analysed the total cytosine content of a selection of published datasets, to see if the ratio of 
cytosine in the mapped sequences matches the genomic content, or is reduced. Due to the 
conversion of cytosine to uracil and then thymine after amplification, I summed the total cytosine 
and thymine content from each dataset’s FastQC quality reports, and compared that to the 
genomic ratio. A non-converted ‘Input’ MeDIP-seq sample was used as a control dataset, which 
fully matched the genomic ratio (Figure 18A left). All of the analysed datasets, published by 
different labs and converted with a variety of BS conversion kits, showed a lower C + T content 
than the expected genomic value. I then looked into specific genomic C-rich sequences to 
investigate if this effect is seen at a regional level. I chose the telomeric repeat, as a unique and 
extreme case of continuous stretch of C-rich DNA, which is 100% asymmetric in its cytosine 
content – one strand represents the tandem repeat [CCCTAA]n (50% cytosine), while the 
complementary [TTAGGG]n strand is completely depleted of cytosine. Since the 6-mer tandem 
repeat can be quite degenerate (personal observations in the course of work), we looked for reads 
containing either one 12-mer stretch (2 telomeric units) or four of the single unit sequences, not 
necessarily in tandem. Both results showed a complete absence of the C-rich strand from the 
datasets, both in its converted and unconverted form (Figure 18A, right). Some datasets contained 
low levels of the converted TTTTAA -version of the [CCCTAA] consensus, which is very likely 
to be a native TTTTAA genomic sequence which cannot be filtered out but is not necessarily the 
converted telomere repeat. A very similar result was observed for a second tandem repeat - the 
major satellite consensus, which is also asymmetric in its cytosine content, although not as 
extreme as the telomere (14% cytosines on the forward strand and 23% on the reverse strand).  

















































































p < 0 .0 0 0 1










































B  C  
  
Figure 18. Biased degradation of C-rich DNA after bisulphite treatment. A. Cytosine depletion in 
published BS-seq datasets – left: decrease in total measured C + T (T is included because the majority of 
cytosines are converted to T’s); right: telomere strands representation in a number of published datasets; 
Datasets used: MeDIP Input (Raiber et al. 2012), E14 serum and 2i (Ficz et al. 2013), J1, pMEF and PGC 
d16.5f, and d16.5m (Seisenberger et al. 2012), mES and NP (neuronal progenitor) cells (Stadler et al. 
2011), H1 hESC, IMR90, iPS_19.11 and iPS_6.9 (Lister et al. 2009), PBC (peripheral blood cells) (Li et al. 
2010), hES (WA09), hES > fibro and fibroblasts (Laurent et al. 2010), Arabidopsis (Lister et al. 2008b). B. 
Biased representation of C-rich and C-poor major satellite strands in a WGBS datasets after heat or 
alkaline denaturation in BS-conversion protocols. C. Affected coverage of CGIs due to the biased cytosine 
degradation in low (mouse) and high (human) coverage datasets (Lister et al. 2009; Popp et al. 2010). 
 
The result showed that the reverse C-rich strand represented only 1% of the total reads 
mapping to satellite in the J1 dataset, the forward strand taking 99% of all mapped reads (Figure 
18B). For both the telomere and satellite repeats however, it is clear that the C/G strand 
asymmetry will create an AT -asymmetry after BS-conversion, which will render the T-rich (ex-
C-rich) strand in a much less favoured position in regard to DNA polymerases, in addition to the 
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degradation, creating this extreme bias where the C-strand is virtually missing. I therefore looked 
also at CG-islands (CGIs), which should have a more uniform CG content on both strands. Both 
for human and mouse ESC datasets, one of which high depth and the second - low depth dataset, 
the coverage of the CGIs was lower than the genomic average (Figure 18C).  
 
To summarise, all results so far pointed towards a cumulative coverage bias in BS-seq 
datasets towards C-low sequences and reduced coverage and depth of unmethylated C-rich 
sequences, as a result of the interplay between bisulphite induced degradation of DNA and 
polymerase bias. 
 
I next addressed the effect of methylation on BS-induced degradation. I used again the M13 
bacteriophage fragments, this time with methylated or hydroxymethylated dNTPs against the 
unmethylated control fragments, and treated them with the same two BS-conversion kits (Figure 
19A). Although the quantitation of DNA on the Agilent bioanalsyer is based on of fluorescent 
DNA intercalating dyes, which show a marked preference for unmethylated versus methylated 
DNA (Ioannou et al. 2010), the summarised result from both kits showed that, both methylated 
and hydroxymethylated probes recovered better and suffered less degradation, as expected from 
(Tanaka & Okamoto 2007). 
It was then important to see how much this affects WGBS datasets and the interpretation of 
our results. For this purpose, I sequenced the completely unmethylated gDNA from a 
Dnmt1/3a/3b triple-KO (TKO) ES cell line and an in vitro methylated DNA from the same 
sample. I used a bacterial GC-methylase M.CviPI (NEB), which methylates around 20% of 
cytosines in the mouse genome in all contexts, according to our in silico digestion calculations 
and the genomic occurrence of the GC dinucleotide presented in Appendix Table 11. After NGS 
of all samples the C + T content of the methylated TKO data (meTKO) was higher and closer to 
the genomic expected value, than the value in the unmethylated sample (Figure 19B). However, a 
comparison with WT mESC lines converted with the same kits, and containing only around 3.5% 
of total genomic 5mC, showed that the WT mouse genome was behaving much like the 
unmethylated sample and 3.5% of biological 5mC did not make a difference for the levels of 
global degradation it suffered. This meant that the susceptibility to degradation of native 
biologically methylated mammalian gDNA was as high as for a completely unmethylated DNA.  


















































































Figure 19. Effect of DNA modifications on the extent of DNA degradation by bisulphite. A. DNA yield 
after bisulphite conversion of unmodified and 5mC- or 5hmC-modified C-rich and C-poor DNA PCR 
fragments. B. Decrease in genomic cytosine content in selected WGBS datasets by total measured C + T (T 
is included because the majority of cytosines are converted to T’s) - in vitro 20% methylated TKO (meTKO), 
unmethylated TKO and WT ES DNA (3.5% mC). C. Mass spectrometry measurement of total cytosine 
decrease in bisulphite treated TKO and WT ES DNA. D. Extent of cytosine decrease (in percent) from the 
WT and TKO gDNA measured by mass spectrometer and normalized to T content to account for the 
column losses from BS purification. E. Change in global methylation in WT ES cells with and without 
bisulphite conversion measured by mass spectrometer. F. Coverage of each dinucleotide pair in the WT 
E14 (mCG=80%) and TKO (mCG=0%) datasets (value normalized to CA = 1). 
 
However, since the effect of cytosine degradation is surely paralleled by the shown 
polymerase bias against AT-rich sequences, in order to verify that the observed result was an 
effect of the bisulphite degradation bias and not merely the polymerase bias, I repeated the 
experiment with a quantitative measurement on a mass spectrometer (LC/MS) (Figure 19C). The 
initially observed decrease in cytosine content was around 15-20%, but after normalisation to 
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loss from the input content (Figure 19D). This however contributed to an 8% of increase in the 
total methylation levels measured in the J1 gDNA before and after BS-conversion, showing that 
the degradation of unmethylated cytosine indeed leads to an overestimation of global genomic 
5mC levels (Figure 19E). To see how affected further this will be in WGBS datasets, I assessed 
the extent of polymerase preference on GC-rich sequences by plotting the coverage of all four CN 
dinucleotides for two datasets – methylated and unmethylated. Three of the dinucleotides convert 
entirely into AT-sequences, and all three have 30% lower coverage than the unmethylated CG 
dinucleotide, which has an even increased coverage with further 30% in the WT mESC with 80% 
CG methylation level. Interestingly, we did not observe a higher coverage depth in the WT dataset 
in the CA context, which is the second highest methylated context in ES cells (Stadler et al. 
2011). This shows that CA methylation levels are not high enough to cause a bias, and the CA 
context suffers as harsh degradation as the rest of unmethylated CT and CC contexts in both WT 
and unmethylated gDNA. The polymerase bias can however reach quite high levels in CG-rich 
regions. 
 
3.3.5 Measuring global levels of non-CG methylation in the mouse genome 
As outlined in 3.2 Aims it is important to be able to assess global genomic levels of non-CG 
methylation in my pluripotent and differentiated samples of interest. There has been conflicting 
evidence for the presence of non-CG methylation both in pluripotent, but also in various 
differentiated cell types or tissues, and it is not very clear if it is limited to the pluripotent state or 
a more general phenomenon.  
The total genomic methylation in mouse ES cells is variable between 3-4% of total cytosine 
(Ficz et al. 2013), and this value is lower for human DNA (Ehrlich et al. 1982). mCH methylation 
constitutes a sizable proportion of the total methylation in ES cells, accounting for approximately 
one quarter of the total 5mC (Ramsahoye et al. 2000; Lister et al. 2009). To test this, I used two 
published techniques to estimate global non-CG methylation: luminometric methylation assay 
(LUMA) for CCWGG, and nearest neighbour analysis (NNA).  
I have investigated which alternative enzymes would be useful to increase the sensitivity or 
change the specificity of both techniques, in addition to the published ones, and the results from 
an in silico digest and calculations are summarised in Appendix Table 17 and Appendix Table 18. 
 




The principle of NNA is described in Figure 20.  
 
  
Figure 20. A schematic representation of the NNA method. 
 
To cut the long story short, I have digested WT ES gDNA samples with FokI, and 
completed the procedure as described (Ramsahoye 2000) with a few modifications outlined in 
2.3.11. In order to be able to identify which spot belongs to which base, including the modified 
cytosine bases, I also synthesised by PCR and digested a group of M13 fragments which after the 
digest with DpnII yielded one particular base and could serve as standards. However the results 
showed double spots rather than the expected single spot, both on 1D and 2D TLC (Figure 21). 
On the same figure it is also shown what the 2D TLC result from the NNA digestion should be, 
and even the positions of the fragments are not identical. Several discussions with TLC 
technology representatives and personal communication with Bernard Ramsahoye were unable to 
help resolve the reason for this result, and I was therefore not able to utilise this classical 
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Figure 21. Results from the nearest neighbor analysis.A. 1D TLC, B. 2D TLC (upper) and a representation 
of what the result should look like (lower panel). 
 
3.3.5.2 LUMA 
The CCWGG version of LUMA was published recently (Yan et al. 2011), and the 
possibility to use this assay for non-CG context looked quite promising, given the possibility for 
high throughput analysis of multiple samples and the simplicity of the assay. A downside of this 
technique is the limitation that only CHG methylation can be studied, and in particular in the 
CCWGG context, but taking in mind that the CHG methylation predominates over CHH 
methylation in ES cells according to several reports (Lister et al. 2009; Ziller et al. 2011; Lister et 
al. 2011), this technique seemed quite appropriate. Another potentially limiting point is the use of 
a Pyrosequencer, but this equipment nowadays is available in many research institutions.  
Together with the classical assay based on the MspI/HpaII CCGG digestion (Karimi et al. 
2006) I tried the CCWGG version with AjnI/Psp6I and also a Bsp19I – a CCATGG cutter, 
sensitive to 5mC according to SibEnzyme (personal communication). The principle of the LUMA 
assay is shown in Figure 22. Digestions were carried out as described in 2.3.12 closely following 
the published protocol (Karimi et al. 2011).  





Figure 22. A schematic principle of the LUMA assay.Borrowed from Karimi et al. 2006. 
 
The assay worked well overall – the pyrograms showed the expected profiles, the chosen 
enzymes worked well and showed clean signals (peaks) in individual test runs (not shown) and in 
double digests (Figure 23A). Calculating the CG methylation worked as described and gave good 
results, both for mouse and human gDNA samples (Figure 23B). A standard curve for CG 
methylation, produced with a M.SssI methylated PCR fragment, gave good linearity (Figure 23C), 
although it did not reach 100% methylation, because of an inefficient M.SssI activity – the 
maximum methylation of the fully methylated fragment was measured repeatedly around 65% 
(not shown).  
The assay for CCWGG however showed inconsistent results, despite changing enzymes 
(PspGI vs Psp6I) and digestion buffers. A panel measurement of a selection of ES cell samples 
with varying methylation levels is shown on Figure 24A. The values unfortunately do not reflect 
the actual methylation levels of the samples according to expectations, and some values are highly 
negative, even for samples, which should be positive for CHG methylation. The result for the 
Bsp19I was similar (not shown). I therefore performed an in vitro digest with AjnI and Psp6I on a 
synthetically CCWGG methylated oligonucleotide sequence as in Yan et al. 2011. I tested all 
combinations of fully, hemi- and unmethylated fragments, and the result showed that AjnI did not 
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fully digest unmethylated or methylated DNA, with even less digestion of the hemimethylated 
DNA. It is not clear why it inefficiently digests the hemi-methylated fragments, but it may be due 
to the strand asymmetry. It is interesting to note that there also seems to be a difference in the 
extent of digestion between the two hemi-methylated fragments, the forward ‘F’ one being 









Figure 23. LUMA assay results.A. Pyrograms for the different digestions tested; each peak corresponds to 
a ‘filled up’ by the DNA polymerase position in the restriction sequence, which releases light and generates 
quantifiable signal. B. CCGG methylation in mouse (J1, E14)) and human (H9) ES cells and fibroblasts 
(pMEF and IMR90). C. Measurement of in vitro M.SssI-methylated DNA fragment (65% 5mC), mixed with 





























































Figure 24. CCWGG LUMA trial.A. Methylation measurement of a panel of mouse and human cell lines 
with variable amounts of 5mC; the resulting percentages however do not correspond to methylation levels. 
B. In vitro digestion of oligonucleotides with AjnI and Psp6I, visualized on a 6% TBE polyacrylamide gel. U 
is ‘unmethylated’, H is ‘hemimethylated’ respectively on the forward or reverse strand, M is ‘methylated’. 
 
We know that CHG methylation in mammals is mostly asymmetric, therefore situations in 
actual gDNA would be more similar to the hemi- and unmethylated oligos, and not the fully 
methylated. It therefore seems that the enzyme pair AjnI/Psp6I is not as reliable and appropriate 
for CCWGG as MspI/HpaII is for CCGG, especially that in CCWGG context we are looking for 
much lower amounts of methylation than in CCGG. Yan et al. did not demonstrate a digest of 
hemi-methylated fragments and they also use different equipment, which might have a better 
sensitivity (Yan et al. 2011). In conclusion, the CCWGG version of the LUMA technique was not 
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The results from the genomic analysis so far show, that even with the well established 
‘classical’ techniques, the process of genome-wide or global analysis of non-CG methylation is 
not as straightforward as expected.  
The MeDIP-seq technique, although very appropriate for the enrichment of lower levels of 
methylation and could be ideal to enrich for non-CG methylated DNA, is not useful at present due 
to the wide 5mC recognition properties of the current commercially available antibody. As shown 
here and in (Ficz et al. 2011), although the asymmetric peaks can contain information on non-CG 
context, it is not possible to clearly distinguish the real signal from the artefactual noise due to the 
many pull-down artefacts and amplification biases. It is indeed possible that the observed feature 
enrichment pattern is representative of non-CG methylation and it naturally follows closely the 
pattern of the symmetric peaks in lower levels. It has already been reported that the non-CG 
methylation colocalises with CG methylation (Lister et al. 2009; Ziller et al. 2011) meaning there 
is a chance that we wouldn’t observe anything different from CG even without the noise. 
However those assumptions are not sufficient to validate the current MeDIP-seq approach.  
Other well established techniques such as BS conversion and sequencing appear to have 
some limitations in regard to non-CG context, especially used together with NGS, which make 
them less than ideal for the analysis of this type of methylation. The high depth and genomic 
coverage datasets are still the best option for whole-genome non-CG analysis (Lister et al. 2013; 
Shirane et al. 2013). On one hand they benefit from the filtering of potentially unconverted reads 
(with >3 unconverted non-CG C’s) and on the other, the standard analysis of those datasets 
includes a certain depth requirement for the analysed cytosines, typically 10-fold depth, which 
would exclude all highly degraded low coverage regions, and thus will have less false positives. 
Those datasets however require a lot of sequencing effort, which is both labour intensive and 
costly, especially if numerous samples are analysed, and at present, this cannot be a routine 
approach for many laboratories.  
Lower coverage whole-genome datasets accumulate conversion artefacts, which cannot be 
filtered out bioinformatically because of the insufficient depth and, as shown, filtering itself can 
introduce additional biases and cannot be currently validated as an approach. In this sense, the 
historical doubts about the validity of non-CG methylation and its artefactual nature (Harrison et 
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al. 1998; Araujo et al. 1998; Laird 2010), are still valid for the current low coverage NGS 
datasets, because the BS conversion has not been improved as a process, and only high 
sequencing depth enables us to validate a potential non-CG call. The most common way to 
estimate conversion efficiency through unmethylated spiked-in DNA, which gets bisulphite 
treated together with the whole sample, is useful only to an extent, given that the BS-conversion 
resistance is by nature sequence and context specific (Warnecke et al. 2002). Therefore, the 
conversion rates of one genomic sequence cannot be a guarantee for the same levels of conversion 
in another sequence or genome. To address this and also the existing speculations that the TKO 
mESC could actually possess very low levels of methylation from Dnmt2 (investigated in detail in 
Chapter 5and in Raddatz et al. 2013), I attempted sequencing a TKO library, PCR amplified 
before the bisulfite conversion, to represent a whole genome amplified (WGA) and truly 
unmethylated control. This attempt was not successful, however, due to the specificities of the 
Illumina library preparation technology, and was not repeated again for mouse BS-seq libraries. 
Nevertheless, using WGA was subsequently affirmed as an approach for all ELISA experiments 
(in Chapters 5, 6 and 7), and was also applied as a validation strategy for low methylation level 
WGBS in Patalano et al. 2015 (in preparation), where WGA was achieved via a Qiagen kit, rather 
than PCR amplification at a library level. 
In addition, the contribution of BS-degradation and amplification biases had not been 
studied until now, but also affects the analysis of CG and especially non-CG methylation. Other 
known downsides of the NGS BS-seq analysis, have been the mapping issues, especially of C-rich 
fragments, because of the lower complexity of the endogenous sequence after BS conversion 
(Krueger et al. 2012). Roughly, a quarter of the raw sequencing data, and often more than that, is 
lost and unable to be analysed just because of mapping issues. As seen in 3.3.4, although the C-
rich fragment is only 3-4 times less recovered after BS-treatment without amplification, after 
amplification and sequencing such a C-rich fragment is many-fold less represented in the dataset, 
in comparison to C-poor fragments. Thus, DNA degradation, amplification bias and mapping 
issues contribute altogether to the depletion of CH-rich sequences from WGBS datasets.  
It is useful to know well the limitations of each technique, and the current analysis shows 
that with appropriate controls and good understanding for the underlying biases, one can 
nevertheless derive meaningful data from each technique, despite its limitations. The MeDIP-seq 
technique was able to give a direction towards the presence of non-CG methylation in the major 
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satellite repeat, an observation confirmed later by (Arand et al. 2012) and reported as early as 
1975 in (Harbers et al. 1975). The low coverage BS-seq datasets proved very useful for high depth 
repeat analysis, and the presence of non-CG methylation in SINEs and LINEs has also been 
confirmed by other groups (Guo et al. 2013; Woodcock et al. 1997; Woodcock et al. 1998). IAP 
LTRs represented by the most active LTR1a did not show significant levels of non-CG 
methylation, and the lowest mCH levels were detected in the minor satellite. Although spatially 
very close to the major satellite and sharing functional roles, their methylation status is 
remarkably different – the major satellite showing high methylation in both CG and CH context, 
while the minor satellite is much less methylated in either context.  
Another aspect of the current results addresses the presence of non-CG methylation in 
pluripotent versus differentiated cells. Although all major papers analysing mCH methylation 
(Ramsahoye et al. 2000; Lister et al. 2009; Ziller et al. 2011; Lister et al. 2011) have declared 
much higher levels in pluripotent cells, and very low or virtually no presence in fibroblasts or 
adult tissues, here we see examples of regions where this generalization is not true. The major 
satellite sequence preserves non-CG methylation also in lineage committed cells, albeit decreased, 
and strikingly the levels in LINE UTRs were even higher in MEFs than in mES cells. It is 
important to note that many earlier reports have also claimed non-CG methylation in adult tissues, 
and these observations might be correct, at least for particular regions, or particular tissues. 
Therefore, although I was unable to measure directly global levels of mCH methylation in various 
cell and tissue types at this stage, my results so far do not exclude the presence of non-CG 
methylation in differentiated tissues, and do not limit it to the pluripotent state. This was also 
evident from the replication origin analysis. The existence of cell fate ‘barcodes’ has been 
hypothesised by the authors who published the origin coordinates of chromosome 11 (Cayrou et 
al. 2011) and the non-CG methylation would have been an obvious candidate for pluripotent state 
barcodes. However this doesn’t seem to be the case, at least in chromosome 11 which we have 
analysed.  
In cases like the major satellite where we have a region of high CH methylation, it would be 
interesting to know if only a selection of the tandem repeats, or those in a particular chromosome 
or nuclear area are very CH methylated and the rest are not, or rather all satellite repeats on all 
chromosomes have an even distribution of low mCH methylation. Another option could be related 
to the intrinsic heterogeneity of mouse pluripotent cells, in that some subpopulations might have 
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mCH methylation on the satellite and others not. In the DNA from a mixed pluripotent cell 
population this will appear as a lower percentage of mCH methylation for the locus, as we 
normally see non-CG methylation. It is interesting that in 3 out of the 19 sequenced clones of the 
major satellite we find 3 positive calls for mCH methylation, and such reads will be filtered out 
from the widely used filtering approach of high depth datasets, while the methylation can be 
entirely biological and not an artefact – all those three clones are very well converted elsewhere. 
This means that even with the high depth WGBS datasets real signal is inevitably being filtered 
out. On the other hand, in our M13 spike in conversion controls, we have observed BS-conversion 
resistant sequences appearing with more than 80% methylation (results not shown), and they 
would pass those filters, contributing to artefacts even in the high depth WGBS datasets. No 
doubt, defining the real and complete patterns of non-CG methylation currently remains a big 
challenge. 
 
In summary, the evaluation of the established techniques for their feasibility to deliver valid 
results for non-CG context, modifying them if necessary, or developing novel techniques, would 
be crucial for identifying its distribution, and paving the way towards more complex questions 
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 4 Novel tools and techniques for the analysis of non-CG methylation 
 
4.1 Introduction 
As shown in Chapter 3 the classical techniques for non-CG DNA methylation analysis did 
not provide satisfactory results characterising the genomic distribution and developmental 
dynamics of mCH methylation. This highlighted the need to modify the existing techniques or, 
even, develop novel tools and techniques. As discussed in 1.6 (Introduction), such tools would 
involve 1) restriction enzymes specific for the modification – either inhibited, or activated by it, 2) 
modification-specific antibodies or binding proteins, 3) enzymes or chemical treatment creating, 
modifying or removing it. However, those are much more straightforward with a chemically 
distinct modification, rather than a context specific, and many of the approaches applied for 5hmC 
and its derivatives 5fC and 5caC would not be applicable for methodological distinction of 5mCG 
from 5mCA.  
Restriction enzymes inhibited by methylation in non-CG context like the CCWGG have 
already been used in Chapter 3, with limited success. Nevertheless, it would be worth looking for 
others and testing more, if possible. The situation with restriction enzymes activated by non-CG 
context methylation, or at least not specifically by CG-context, seems more promising in the light 
of the recently described MspJI family of enzymes discussed in 1.6.3 (Cohen-Karni et al. 2011). 
One of the family members –RlaI, recognizes specifically non-CG context – S(V)
m
CW, where W 
is A or T. Half of the other members, including FspEI, LpnPI and SgrTI, recognize a 
m
CDS motif 
(D being A, G or T) and are therefore biased towards mCG because this will be the dominating 
methylation context in their recognition configuration. The remaining two enzymes – MspJI and 
AspBHI, potentially including FspEI (for its optional C
m
C preference), cut all methylated 
cytosines, without a preference for the immediate neighbouring base (
m
CNNR for MspJI and 
YS
m
CNS for AspBHI). MspJI is commercially available and this makes it a potential candidate 
for the analysis of non-CG methylation, particularly for methylation enrichment methods where it 
will enrich for 5mC in both CG and non-CG context – an improvement of the current MspI-based 
RRBS method for CG enrichment. Moreover, this enzyme was already used for the generation of 
a 5mC enriched library for a NGS genome-wide analysis without BS-conversion (Cohen-Karni et 
al. 2011).  
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Antibodies capable of not only recognising the modified base, but also distinguishing the 
surrounding neighbouring bases, have not been generated to date. A priori, it is questionable 
whether this would be possible, although there is one very early report on the generation of 
antiserum against the (phospho)AT dinucleotide (Khan et al. 1977). While this is a promising 
achievement, our criterion is much more demanding, with the need to recognise both the 
nucleotide context and modification state of the cytosine as key. Nonetheless the advantage of 
such a tool justifies an attempt to generate the antibody.  
In terms of non-restriction enzymes acting on CH context rather than CG or vice versa, the 
situation is again very challenging in comparison to the other cytosine modifications. The 
mammalian Dnmt3 family of methyltransferases, which are responsible for the de novo 
methylation, do not possess a single context preference, although they do have a target preference 
for CG (Gowher & Jeltsch 2001; Aoki et al. 2001). It would therefore be best to explore the 
possibility to find bacterial non-CG context methyltransferases, to use either as an in vitro CH 
methylation tool like the CG-specific M.SssI, or in transfection assays in the quest for a biological 
function of mCH (see 1.6.3). In terms of enzymatic modifications or the physical removal of the 
mCH mark and its stability, as discussed in 1.4 and 1.7, those have not yet been studied and are a 
matter of a separate investigation in this project, which will be discussed in more detail in Chapter 
7. In terms of non-enzymatic chemical modifications, indeed there are ways to chemically modify 
5mC (Tanaka et al. 2007), but any chemistry which works on CG context would work on non-CG 
context as well, which excludes this approach as an option for the current study.  
 
4.2 Aims  
1. To investigate the possibility for utilising new restriction enzymes sensitive to non-CG 
context methylation 
2. To develop a MspJI-based method for reduced representation genome-wide analysis 
which will enrich for methylated sequences in non-CG context (or will at the least not 
exclude them)  
3. To investigate the possibility for the development or utilisation of novel affinity tools 
for the functional analysis of non-CG methylation (antibodies) or methyltransferases 
4. To look into the possibility for developing novel methods for measuring global 
amounts of context-specific methylation with those tools  





4.3.1 Enzymes specific for non-CG context methylation 
4.3.1.1 Restriction enzymes sensitive to non-CG context methylation 
Although hundreds of restriction enzymes have been characterised, and many are 
commercially available, the enzymes recognizing cytosine-containing sequences are a small 
proportion, and most of those recognize the CG context. Table 3 shows a summary of my 
investigation, where several enzymes reported as sensitive to 5mC in non-CG context were tested 
for this project. Individual activities were tested on PCR fragments derived from the 2 kb M13 
fragment used previously (all sequences are listed in Appendix Table 13). Each digest was 
performed according to the manufacturer’s recommendations for the relevant enzyme, and 
analysed on a 2% agarose gel stained with SYBR®Safe. Most of the enzymes were sensitive to 
both 5mC and 5hmC, although many show leakiness (less than 100% sensitivity), and some were 
sensitive only to symmetric methylation on both strands, which is not likely to be physiologically 
relevant, as discussed in 3.3.5.2. The search for isoschizomers similar to MspI/HpaII, used widely 
for the analysis of CG-methylation, was unsuccessful, apart from the already known enzyme 
BstNI (Woodcock et al. 1987; Woodcock et al. 1988) which can be paired with PspGI, specific 
for CCWGG. However, as shown in 3.3.5.2, the isoschizomer counterparts of the same pair used 
for LUMA analysis (AjnI and Psp6I, SibEnzyme), failed to produce robust results for CCWGG. 
Two enzymes showed potential to form a pair for CATG, however one of them (NlaIII) showed 
leakiness and the other - some sequence preference ambiguity (CviAII), meaning they can 
potentially be used for a proof of principle analysis, but not for quantitative assays like the 
MspI/HpaII pair.  
Although all of these enzymes were analysed for their potential to use in different enzyme-
dependent applications, as seen from Table 3, the ones marked for LUMA did not prove useful 
when tested in the actual assay (3.3.5.2). The enzymes marked for MS-REA, however, can be 
used to validate locus specific methylation provided it is within the relevant recognition 
sequences, as well as the ones for NNA.  
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Table 3. Restriction enzymes sensitive to 5mC in non-CG context (in red) and their non-sensitive 
isoschizomers, where available (in black). Results are summarised based on real restriction digests and 
agarose gel electrophoresis for each individual enzyme.  
 
 
Cuts Result from test Application Similar 
CCWGG 
    BstNI CC↑WGG Cuts well C, 5mC and 5hmC MS-REA 
 MvaI CC↑WGG Not tested myself 
  PspGI ↑CCWGG does not cut, not leaky LUMA, MS-REA EcoRII 
Psp6I ↑CCWGG does not cut, not leaky LUMA, MS-REA EcoRII 
AjnI ↑CCWGG does not cut C, 5mC or 5hmC to 100% LUMA, MS-REA 
 
     CCATGG 
 
very rare combination, rarely methylated 
  Bsp19I C↑CATGG weak activity LUMA 
 NcoI C↑CATGG weak activity LUMA 
 
     CATG 
    NlaIII CATG↑ LEAKY in 5mC, less in 5hmC MS-REA FaeI 
CviAII C↑ATG slightly resistant to 5hmC NNA, MS-REA FatI 
     CTAG 
    BfaI C↑TAG weak activity 
 
FspBI 
MaeI C↑TAG LEAKY in 5mC and 5hmC MS-REA 
 
XspI C↑TAG 
Good, slightly leaky in 5hmC; but cuts 




Figure 25. MspJI family of restriction enzymes specifically cutting 5mC-containing DNA (figure from Cohen-
Karni et al, 2011). 
 
4: Novel tools and techniques for the analysis of non-CG methylation 
93 
 
Another promising group of recently described enzymes, is the MspJI group of restriction 
enzymes (Cohen-Karni et al. 2011) – they cut only if 5mC is present in the DNA, therefore they 
can be used for selective targeting of methylated sequences. One of them recognises specifically 
5mC in non-CG context (RlaI), the others are not non-CG context specific. Of this group of 
enzymes, only MspJI, FspEI and LpnPI are commercially available.  
 
4.3.1.2 Synthesis, cloning and validation of RlaI 
Since RlaI is the only enzyme in the MspJI group, which recognises 5mC in non-CG 
context, and specifically CA or CT, which are the most common non-CG contexts in mammals, I 
decided to obtain it as a tool for further analysis of non-CG methylation.  
The RlaI gene was synthesised as described in 2.3.13, the sequence was specifically codon-
optimised for expression in E. coli by algorithms in the GeneArt® platform. It was sub-cloned 
from the original entry vector into a bacterial expression vector pQLinkHD, as described in 
2.3.14. Our collaborator Tomasz Jurkowski (University of Stuttgart) performed bacterial 
expression and purification of the protein.  
The activity of RlaI was tested in a digest of the synthetically methylated oligonucleotides 
used for the LUMA AjnI/Psp6I test because the CCWGG sequence represents an RlaI restriction 
site (Figure 26). However, it only partially digested the hemimethylated oligos, which represent 
the most likely in vivo scenario, and therefore further optimisation of reaction conditions would be 
necessary in order to use RlaI for mCA analysis, which could not be performed within the 
timeframe for completing the current thesis work.  
  
Figure 26. In vitro digestion of CmCWGG-containing oligonucleotides with RlaI, visualized on a 6% TBE 
polyacrylamide gel. U stands for ‘unmethylated’, H for ‘hemimethylated’ respectively on the forward or 




M    H/F   H/R    U
RlaI +    +     +     +
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4.3.1.3 Context specific bacterial methyl-transferases 
In collaboration with Tamir Chandra (Reik lab) we identified bacterial methyl-transferases 
which show a strict DNA context specificity unlike the broader specificity of the mammalian 
native Dnmt proteins. The search for CA-specific methyl-transferase, as the most common mCH 
context in mammals (Ziller et al. 2011), led us to M.TspRI, which recognises and exclusively 
methylates the sequence motif *CASTG (where S is G or C). The M.TspRI gene was synthesised 
in the same way as described for RlaI in 4.3.1.2 but optimised for mammalian expression, and 
cloned into a vector for eukaryotic inducible gene expression as described in 2.3.14.  
Due to delays with the cloning and time constraints to complete the PhD, the M.TspRI 
ultimately was not used for transfection experiments and no further work with it is presented here.  
 
4.3.2 MspJI-based methylation enrichment RRBS (meRRBS) 
The results in chapter 3 revealed that low-resolution BS-seq datasets and MeDIP analysis 
against 5mC could not be used for genome-wide analysis of non-CG context methylation, either 
because of high conversion error masking real mCH signal, or because of the inability to 
discriminate between the 5mC contexts.  
Next generation sequencing of an MspJ1-based CG-enriched library has already been 
demonstrated successfully without bisulphite conversion (Cohen-Karni et al. 2011). This 
approach does not introduce a large proportion of false positives for the CG context, due to its 
high methylation levels, but it would for non-CG context and therefore it was not an option for us. 
We first quantitated the genomic frequency of the MspJI site (CNNR) to confirm that it was 
representative for a large fraction of genomic cytosines, including CH (Figure 27A). The high 
specificity of MspJI for 5mC and 5hmC, and not for unmodified cytosine, was also tested and 
confirmed experimentally (Figure 27B). I performed a modified protocol for classical MspI RRBS 
(Smallwood & Kelsey 2012), with a few modifications as described in Materials and methods 
(2.3.8). WT ES cell, pMEF and an unmethylated control DNA were used for pilot libraries. As a 
modification of the original protocol, special care was taken to preserve fragments smaller than 
100bp, which are not normally preserved in the classical library preparation protocols. This was 
necessary due to the specific digestion pattern of MspJI in generating small size fragments from 
symmetrically methylated regions (Cohen-Karni et al. 2011).  
 






 MspJI sites % of genomic C 
Total 205 x 10
6
 38 
CA 56 x 10
6
 10.57 
CT 61 x 10
6
 11.49 
CC 43.5 x 10
6
 8.14 




Figure 27. Characterisation of MspJI enzyme’s restriction specificity. A. Frequency of the MspJI site in the 
genome and its context distribution. B. Specificity of MspJI validated on fully unmethylated, methylated 
and hydroxymethylated substrates. 
 
The mapping efficiency of the three pilot datasets, however, was unexpectedly low (Table 
4). For comparison, the mappability of the originally published non-bisulphite converted dataset 
was also very low, most likely due to the short length of reads. For this reason the further decrease 
of mappability after conversion is not surprising, due to the highly reduced sequence complexity 
of bisulphite-converted DNA (Krueger et al. 2012).  
 
Table 4. Mapping efficiency of the MspjI meRRBS datasets, compared to the published IMR90 methylation 
enrichment dataset (Cohen-Karni et al. 2011).  
 Mapping 
efficiency 
Read number Mapped reads number Total analysed cytosines 
J1  16.1% 21.24 M 3.43 M 64,526,866 
pMEF 19.8% 19.18 M 3.81 M 79,940,702 
TKO 8.5% 14.58 M 1.24 M 25,399,827 
IMR90/NEB 32.7% 71.8 M 23.5 M ? 
 
The analysis of the meRRBS datasets included mapping of the original MspJI site, upstream 
of the end of the sequence read. For this purpose both 3’ and 5’ ends of reads were analysed, and 
the probability of a valid methylation call was calculated based on expected digestion patterns 
(Figure 28A). The prediction was that each digestion would generate two DNA ends - one 
‘specific’ 3’ end, with the target 5mCNNR site upstream, and one non-specifically cut 5’ end, 
belonging to another fragment. Thus, half of the reads will be enriched for 5mC, and the other half 
will be entirely random, thus contaminating the signal (Figure 28B).  
 










Figure 28. Strategy for calling 5mC positives from the MspJI-meRRBS reads. A. A schematic of a digestion 
pattern illustrating the generation of fragments upon MspJI digestion. B. Strategy for choosing upstream 
positions and calculating the validity of each position relative to the digestion.  




Thus analysed, the results showed high specificity, unlike the previously used approaches. 
The negative control TKO line showed barely detectable methylation ‘levels’, and the pMEF ES 





Figure 29. MspJI-RRBS positive methylation calls. (A) Total numbers in the three sequenced samples, and 
(B) proportionally in mES and pMEF.  
 
The very low mapping efficiency, however, precluded using this approach for other 
biological samples of interest. 
 
4.3.3 Development of context-specific antibodies for 5-methylcytosine 
At present, all commercially available antibodies recognise the methylated cytosine itself, 
irrespective of the surrounding context, and they cannot be used to analyse context-specific 
methylation. To address this deficit and to enable the use of all antibody-dependent methods listed 
in Table 1, I initiated collaboration with Active Motif Inc for the production of antigens against 
the two most common methylation contexts - 5mCA and 5mCG. The company has presently 
established themselves as the best on the market for producing antibodies against DNA 
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raised against the two full dinucleotides, including the modified cytosine base, the neighbouring 
base and the sugar-phosphate backbone (Figure 30).  
 
 
Figure 30. The specificity of the currently available antibody and the difference with the context-specific 
antibodies. 
 
4.3.3.1 Antigen synthesis and monoclonal antibody production 
The antigen was synthesised by Active Motif employing the same linkage strategy, which 
was used for raising their very successful DNA modification-specific antibodies, some of which 
are listed in Table 6. Keyhole limpet hemocyanin (KLH) was used as a carrier protein.  
The production of the antibodies was carried out by the Technology Development Lab 
(TDL) at the Babraham Bioscience Technologies (BBT), Babraham Research Campus. Five mice 
were subjected to immunisations for each antigen – labelled in figures as NO01 for mCA and 
NO02 for mCG. The specificities of the sera and subsequent hybridoma clones were tested with a 
quantitative ELISA assay, specifically developed for this purpose (see 4.3.3.3). 
The mouse with the highest serum titre for each antigen was selected for splenectomy and 
hybridoma clones and sub-clones were subsequently screened for specificity. 
 
 
5mC Ab:  5mCA Ab: 
mC 
    




   Currently used 
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4.3.3.2 Validation strategy  
The initial clonal screen was carried out by the TDL in accordance with the collaboration 
agreement; it involved a single positive control and a single negative control. Due to the non-
conventional nature of the antigens, it was necessary to perform further tests after the initial 
screen with more controls in order to assess antibody quality and choose the least cross-reactive 
clones. Two types of tests were performed – ELISA and immunofluorescence (IF).  
Since all eukaryotic cell lines contain predominantly CG context DNA methylation, or 
mixed context methylation, those cell lines cannot be used to evaluate the context specificity. 
None of the existing mES Dnmt-KO lines have only CA or only CG context methylation to make 
their DNA appropriate as a control. Therefore, the initial specificity validation step was performed 
in vitro with a panel of context-specific methylated synthetic oligos. The sequences chosen for the 
oligos are native genomic DNA regions from the major satellite repeat (oligos #1-#8) and the 
LINE1 5’ UTR (L1 #9-#12), which have shown high levels of native 5-methylcytosine in CH 
context as shown in Chapter 3. The panel consists of oligos containing 5mC in all four contexts, 
plus non-methylated oligos in the CA or CG context, as well as two oligos with inverted 
neighbouring sequences – the dinucleotide next to the methylated cytosine is inverted to the 
original positive control. Thus, I ended up with two positive control sequences and ten negative 
control sequences per context (Table 5).  
 
Table 5. Oligonuceotide sequences used for the validation of mCA and mCG sera.  
 
 
# Oligo specificity Name Sequence 
1 mCA positive control   mCA oligo #1 TGAGAAATG[mC]ACACTGAA 
2 mCG positive control  mCG oligo #2 TGAGAAATG[mC]GCACTGAA 
3 CA native sequence, no mC CA oligo #3 TGAGAAATGCACACTGAA 
4 mCC negative control  mCC oligo #4 TGAGAAATG[mC]CCACTGAA 
5 mCT negative control mCT oligo #5 TGAGAAATG[mC]TCACTGAA 
6 inverted dinucleotide for mCA mCCA oligo #6 TGAGAAATGA[mC]CACTGAA  
7 inverted dinucleotide for mCG mCTG oligo #7 CTGTAGGAG[mC]TGGAATAT 
8 CG native sequence, no mC CG oligo #8 TGAGAAATGCGCACTGAA 
9 mCA positive control L1 mCA CAAGCTCTCCTCTTG[MC]AGGGAAGGTGCA 
10 mCG positive control L1 mCG CAAGCTCTCCTCTTG[MC]GGGGAAGGTGCA 
11 CA native sequence, no mC L1 CA CAAGCTCTCCTCTTGCAGGGAAGGTGCA 
12 CG native sequence, no mC L1 CG CAAGCTCTCCTCTTGCGGGGAAGGTGCA 




The context specific oligos were first used to screen a large number of supernatants 
provided by our contractor via the ELISA assay (see 4.3.3.3). The successful candidates from this 
screen were further tested in a biological context via IF.  
 
 
4.3.3.3 Avidin-biotin DNA ELISA 
In order to evaluate properly the specificity of the context-specific animal sera and 
hybridoma supernatants, a more quantitative assay than the standardly used dot blot had to be in 
place. Direct immobilisation of DNA on the polystyrene surface did not produce satisfactory 
results with the context-specific oligonucleotides for specificity validation (Figure 31A) – 400 ng 
of immobilised oligo gave very low signal, only 0.2 OD points above background. This is 
probably due to the very small size of the fragment and a low total amount of antigen: 1 x 5mC in 
an 18 bp long oligo, i.e. 4.5-fold less than in the M13 R2L PCR fragments). Therefore, I tried a 
sandwich ELISA, using an avidin-biotin system. I ordered the same oligos with a biotin 
modification on the 5’ end, and attached them to an avidin-coated plate. For coating the plate I 
used a novel deglycosylated modification of avidin by Pierce, Thermo Scientific called 
NeutrAvidin®, which has the same affinity, but higher specificity and much lower background 
binding than its predecessors. The assay worked really well, it produced three-fold stronger signal 
with only 25 ng oligo per well, which means this system needs 20-fold less oligo (Figure 31B). 
Two pH buffers were tested in case pH mattered in this assay as well, and better results were 
achieved with 1 x PBS, pH ~7.0 (Figure 31B). The NeutrAvidin (Nav) coating was tested with 
dropping amounts of Nav per well at a constant antibody dilution (1:2000) and saturation of the 
well was reached at around 250 ng of protein, after which the signal plateaued and did not change 
(Figure 31C). The strength of the signal was repeatedly the same with 20 ng and 100 ng of oligo 
showing that the binding capacity of the Nav used in this assay is already saturated with 20 ng of 
oligonucleotide (Figure 31C, D), is in agreement with the binding kinetics revealed in Figure 31B. 
All optimisation experiments were done with the 33D3 5mC mAb clone (Eurogentec). Figure 
31D shows that this commercial clone has a higher affinity preference for mCA context in 
comparison to mCG in certain DNA sequences.  
 







Figure 31. Optimisation of the avidin-biotin ELISA assay: A. oligo usage and signal intensity compared 
between direct immobilization in pH 5.0 and biotinylated oligos on the avidin-coated plate; B. Oligo 
binding titration with 500 ng/well Nav and 1:2000 5mC 33D3 mAb; C. Neutravidin titration with fixed 
amounts of oligo (details in figure legend) and 1:2000 5mC 33D3 mAb; D. Antibody titration with two 
fixed oligo concentrations and two methylation contexts at 300 ng Nav/well 
 
4.3.3.4 Results: ELISA screen 
Ten supernatants for NO01 (mCA) were provided by our subcontractor to evaluate with the 
full panel of oligonucleotides, together with the mouse serum. The standardly used anti-5mC 
antibody was included in the analysis for reference.  
 
Six of the tested mCA supernatants showed cross reactivity for mCCA context of 
unmethylated CA (7E1, 7A3, 7A9, 8H8, 8G8, 8G2), one was very specific although weak (2C8), 
and three demonstrated very weak to undetectable activity (5H6, 9H5, 4C10) (Appendix Table 
19). The clone 2C8 was chosen for further evaluation with IF (Figure 32, all mCA supernatants 
are shown in). Five clones were tested for mCG – because of their higher overall specificity and 
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avidity (Figure 32, all mCG supernatants are shown in and Appendix Table 20). The two top 
candidates from mCG were 10E2 and 6F5 due to their high affinity and avidity, although all 
clones showed remarkable specificity and no background in the negative controls. However the 
6F5 clone was lost in subsequent subcloning and only 10E2 was used for further assessment and 
experiments. 
The 33D3 anti-5mC mouse monoclonal antibody again showed preference towards mCA in 
one of the oligo sequences (major satellite, see first repot in Figure 31), but not the other (L1), 
showing that its affinity is affected by the flanking sequences. 
 
Antibody species Oligo panel I Oligo panel II  
 











supernatant 10E2 - 
mCG 
 
























Figure 32. Specificity of mCA (2C8) and mCG (10E2) supernatants in comparison to the commercially 
available 5mC antibody. Graph colour coding: Green – positive control (mCA or mCG respectively), Red – 
opposite negative methylation control: mCG for mCA, and mCA for mCG, Orange – unmethylated DNA, 
Black – other negative methylation controls – mCC and mCT (not biologically relevant) 
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4.3.3.5 Results: immunofluorescence (IF) 
In order to verify that the specificity will remain the same in a more complex environment 
and to test for potential cross reactivity in isolated genomic DNA as well as in a chromatinisied 
DNA template, it was important to test the monoclonal supernatants in biological applications. 
Mouse ES cell lines, and all the known MTase KOs would have both CG and non-CG mixed 
methylation, therefore they are not an ideal model for this validation. The best candidate should 
have either only mCG or only mCA, or even better if the two contexts are present in the same cell 
but can clearly be differentiated, spatially or structurally. Such an ideal candidate cell actually 
exists, and this is the mouse zygote. It has been reported even in the early days of non-CG 
methylation studies, that oocytes have high levels of this type of modification and that it is 
predominantly in CA context (Imamura et al. 2005; Haines et al. 2001). These early observations 
were later confirmed and investigated in more detail, when it became clear that the non-CG 
methylation in the oocyte is as much, if not more, than the CG methylation (Tomizawa et al. 
2011; Shirane et al. 2013). Sperm on the other hand is very highly methylated, but exclusively in 
CG context (Tomizawa et al. 2011; Haines et al. 2001). Therefore, after fertilisation, it is expected 
that the maternal pronucleus will be still very high in non-CG methylation, but will also have 
mCG, while the paternal will have only CG methylation. This has been experimentally shown by 
(Haines et al. 2001) for individual imprinted loci, which retain high levels of mCA methylation 
even during 2-cell stage, and lose the mCA methylation quickly after that, while the paternally 
imprinted loci do not acquire mCA methylation at any stage. We have therefore stained mouse 
fertilised oocytes (performed by Fátima Santos as described in 2.3.17) and the two candidate 
clones were tested alongside the conventional 5mC antibody. The resulting patterns from the two 
context-specific antibodies show remarkable specificity, and behave entirely as anticipated 
(Figure 33). The mCA clone does not show any cross-reactive staining on the paternal pronucleus, 
while the mCG clone stains both pronuclei.  
 
This test demonstrates that the new antibodies are capable of recognising the right target in 
a chromatinised ex vivo environment and are perfectly suitable for experiments requiring direct 
visualisation. It also confirms that the conventional 5mC antibody recognises both mCG and 
mCA methylation in IF experiments, as it has shown with the synthetic ELISA probes (4.3.3.3). 
The maternal pronucleus shows somewhat stronger signal with the commercial 5mC antibody, 
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combining the mCA and mCG signals in one. More importantly, this experiment also validates 
the observations reported by (Haines et al. 2001) that the maternal pronucleus retains its high 
levels of mCA methylation after fertilisation, when the paternal pronucleus undergoes quick 
active demethylation (the paternal demethylation is also seen in the middle and right panels of 
Figure 33). Our observations further this report by showing that mCA methylation is preserved in 
the entire maternal pronucleus, and not only in selected imprinted loci. It has been well 
documented that the majority of 5mC in the mouse maternal pronucleus does not actively 
demethylate after fertilisation (Nakamura et al. 2007; Santos et al. 2013), and our data shows that 




Figure 33. Immunofluorescence of mouse zygotes: left panel shows mCA, middle panel shows 5mC (all 
contexts) and the right panel shows mCG. DNA is in green (top coloured panels only), and the methylation 
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4.3.3.6 Antibody concentration and purification 
After successfully validating the specificity of the two clones, they had to be prepared for 
further use in experiments. Media from hybridoma culturing (here referred to as ‘supernatant’) 
contain very diluted amounts of antibody. They can therefore be used straight or in low dilution 
ratios for ELISA or IF assays, but cannot be used for assays like MeDIP, where the high 
concentration of antibody in a smaller reaction volume is important for its optimal efficiency. 
Therefore, it was necessary to concentrate the supernatant, as described in 2.3.15.  
 




   




Figure 34. Concentration of the supernatant of 2C8 mCA and 10E2 mCG clones and subsequent Protein G 
resin purification (for mCA only). A. mCA, B. mCG. 
 
The purified and concentrated supernatant was tested with an ELISA assay (Figure 34). 
Two fractions were tested – one concentrated supernatant, and one concentrated and subsequently 
purified with a G-resin. The concentrated supernatant showed ~10x higher activity than the 
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original supernatant, slightly lower than expected due to potential loss of protein during 
purification. The purified fractions have lower activity than the concentrated supernatant but 
higher than the original supernatant. Since the concentrated-only supernatant does not show any 
background and is in very high concentration, it seems most appropriate for use directly, 
including methods like MeDIP.  
 
4.3.4 DNA ELISA 
As shown in Table 1, introduction section 1.6.1, there are no easy to use high-throughput 
techniques for the fast measurement of global genomic DNA methylation. In addition, my results 
from chapter 3 make it clear that this is even more complicated when it comes to measuring 
global context specific methylation. For this reason, the development of context-specific 
antibodies provided an impetus to look into quantitative antibody-based methods, which could be 
applied to measure global DNA methylation more accurately than the dot blot technique. Such a 
method, well-established in the research and clinical practice, widely used for the highly sensitive 
and specific detection or quantitation of a given antigen, is the Enzyme-Linked Immuno-Sorbent 
Assay (ELISA) (Engvall & Perlmann 1971; van Weemen & Schuurs 1971). The technique is used 
routinely for both protein analysis and for the detection of pathogens or biomarkers, and has a 
very good quantitative capacity (Lequin 2005). An ELISA protocol for the analysis of DNA 
modifications has not been published in the scientific literature to date, although an antibody 
against 5mC has been available since the early 1980s (Achwal & Chandra 1982). Several 
companies offer ELISA-based kits for the detection of global DNA methylation, but they deliver 
inconsistent results and have therefore struggled to become widely used in the community 
(observations from our lab and personal communication to other scientists). The dot blot on nylon 
or nitrocellulose membranes is still used for the detection of DNA modifications, although it lacks 
a lot on the quantitative aspect for comparisons of varying levels of DNA methylation between 
samples.  
A potential reason for the absence of an ELISA protocol adapted for DNA applications 
might be sought in the first step of the method - the immobilisation of the molecule. An essential 
aspect of the method principle requires that one of the interacting phases (antibody or antigen) is 
immobilised onto a solid surface – the polystyrene bottom of a 96-well microtitre plate. The 
attachment of proteins is due to passive adsorption via hydrophobic interactions, a result of full or 
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partial denaturation of the protein of interest in the alkaline salt-free ELISA coating buffer, and its 
subsequent nonspecific adsorption to the well surface. High-binding surface plates with an 
improved binging capacity have been developed after X-ray irradiation, leading to the exposure of 
negatively charged carboxyl groups on the polystyrene surface. Those groups attract 
electrostatically the charged proteins, in addition to the unspecific hydrophobic interactions, and 
make the adsorption more efficient. DNA is an acid with a significant amount of negative charges 
packed in close proximity, which could potentially affect its binding to the plate in two ways: 1) 
lack of true hydrophobic interactors from the DNA molecule, and 2) repulsion between the 
individual DNA strands leading to less efficient binding. I nevertheless set out to investigate the 
DNA adsorption possibilities.  
 
4.3.4.1 DNA adsorption to the 96-well polystyrene plate 
My search for positively charged plates, which could attract electrostatically the negatively 
charged DNA molecules lead to no success. One technology developed by Corning (DNA-
BIND
TM
) is utilising an N-oxysuccinimide esters modified surface, which can bind covalently to 
terminally aminated DNA oligos. Since it requires a chemical modification of the DNA strands 
prior to the assay, this technology would not be useful for non-amino-modified native genomic 
DNA. I nevertheless decided to try a direct binding of DNA fragments to the ELISA plate surface. 
To address the potential problem with the negative charge of DNA, I tested three types of coating 
buffers: 1) the standard ELISA protein coating 50 mM Carbonate-bicarbonate buffer, pH 9.6; 2) 
50 mM Tris-HCl, pH 7.0, and 3) 50 mM Na Acetate buffer, pH 5.0. I chose pH 5.0 specifically as 
the value pointed out as the isoelectric point (pI) of DNA (Cai et al. 2006) at which the DNA 
molecule will be expected to have a total charge of zero, while it will be negatively charged at pH 
7.0 and even more so at pH 9.6. I chose to test the direct binding on plain non-irradiated ELISA 
plates (i.e. so called ‘medium binding plates’) because the negative charge of the irradiated plates 
would repulse the DNA molecules.  
Double stranded M13-derived DNA fragments obtained in PCR (2.3.6) were used for the 
adsorption tests, with or without DNA modifications in order to test against the relevant 
antibodies (see Table 6). Variable DNA quantities (100 ng and 200 ng) were added to each of the 
buffers, denatured for 5 min at 99ºC and incubated on ice for 10 minutes. The DNA was then 
added to a medium binding plate (two replicate wells and two concentrations), including two 
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control wells with no DNA, and incubated for 1 hour at 37ºC. I first detected the presence of 
attached DNA with a fluorescent single stranded DNA (ssDNA) dye – OliGreen® (Invitrogen) by 
washing and incubating 5 minutes with TE buffer plus 1:200 OliGreen, and reading on a 
CytoFluor II microplate reader. The result showed that DNA was successfully immobilised to the 
plate surface in the buffers with pH 7.0 and pH 5.0 but not with pH 9.6 (Figure 35A left). This 
indicated that the charge of DNA plays a role in its ability to attach to polystyrene. The 
immobilisation of DNA at pH 5.0 and pH 7.0 was further confirmed with an antibody against 
5hmC (the DNA fragment contained 5hmC) as described in 2.3.16, and the wells with pH 9.6 






Figure 35. Optimisation of DNA adsorption. A. three different pH conditions were tested and measured 
with OliGreen (left) and antibody (right); B. Importance of charge for the adsorption was further 
demonstrated by using a negatively charged ‘high bind’ surface plate; C. higher salt was shown not to 
benefit the adsorption of DNA on the hydrophobic surface 
 
In order to verify that indeed the charge makes the difference in the observed results, I used 
a ‘high bind’ negatively charged plate to test if the binding would be weaker. For this, I used the 
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pH 7.0 Tris-HCl buffer in which both the DNA and the ‘high bind’ plate will be negatively 
charged, while the ‘medium bind’ plate will remain uncharged. The result showed that the binding 
of DNA was weaker on the ‘high bind’ surface in comparison to the untreated neutrally charged 
surface and this must be a direct effect of the repulsion between the negative charges of the plate 
and DNA (Figure 35B).  
I tried further optimisation using different salt concentrations. Charged ions can influence 
molecular interactions and therefore can facilitate or decrease the binding affinities. I prepared 
four different NaCl concentrations with both successful pH 7.0 and pH 5.0 buffers. The results 
were assessed only via the complete ELISA protocol with an antibody, as in 2.3.16. Higher salt 
concentrations (300 and 450 mM NaCl) showed marginally less binding at pH 7.0, but a very 
strong negative effect in acetate buffer: 300 mM NaCl leads to a 25% decreased attachment, 
dropping down to zero at 450 mM NaCl (Figure 35C). The highest signal was obtained from 
either no salt at all, or at physiological salt concentration (150 mM NaCl), both for pH 7.0 and 
5.0. The DNA attachment in pH 5.0 was again stronger than in pH 7.0, making the no salt acetate 
buffer the top choice for DNA ELISA coating.  
 
4.3.4.2 Optimising assay conditions for genomic DNA 
After establishing the DNA immobilisation conditions, I tested a panel of antibodies against 
DNA and its modifications to check if they could be used in an actual quantitative assay. Again, I 
used the M13-derived DNA fragments with incorporated 5mC, 5hmC, 5fC or unmodified 
cytosine. Since the incorporation of modified cytosine bases with PCR creates either 100% 
modified or 100% unmodified DNA fragments, one can be confident about the high 
representation of each antigen – in fact many fold higher than in native genomic DNA, which has 
only 3.5% 5mC and 0.1% 5hmC on average. A survey of antibodies revealed that not every 
antibody was appropriate for the assay (Table 6).  
 
The successful antibodies showed good titration and a very high specificity with very low 
background (Figure 36A-E). None of the tested commercial antibodies showed cross reactivity to 
unmodified DNA, or a different DNA modification (Figure 36A-C). Four of the tested antibodies 
– the 5mC, 5hmC, mCA and mCG also showed activity towards native genomic DNA, albeit 
lower, which is expected due to the lower content of modified cytosines. 




Table 6. Antibodies tested for their feasibility for the ELISA assay and the results of their performance 
Antibody Company Appropriate for ELISA 
5mC BI-MECY-100 (33D3)  Eurogentec Yes 
5mC pAb #61255 Active Motif No (results not shown) 
5m-cytidine mAb Cayman Chemical  No (results not shown) 
5hmC pAb #39769 Active Motif Yes 
5fC pAb #61223 Active Motif Yes 
anti-ssDNA IgM MAB3299 Chemicon (Millipore) No (results not shown) 
anti-DNA MAB3034 Chemicon (Millipore) Yes 
 
 
Since this type of assay is strongly dependent on a correct estimation of DNA quantity, I 
have also looked for an appropriate DNA antibody, which can be used for either loading control 






Figure 36. Validation of the ELISA direct DNA binding assay for the different DNA modifications. A. 5mC, 
B. 5hmC, C. 5fC and D. Validation of the use of an ssDNA antibody for loading control. All assays are 
performed with synthetic DNA fragments and trial genomic DNA. 
 





E L IS A  v a lid a tio n   5 m C










D 2 3  E S  1 0 0 n g
R 2 L  m C  5 0 n g
R 2 L  h m C  5 0 n g
R 2 L  C  5 0 n g
B la n k
 





E L IS A  v a lid a tio n  5 h m C










D 2 3  2 0 0 n g
R 2 L  h m C  1 n g
R 2 L  m C  1 n g
R 2 L  C  1 n g
B la n k
 






E L IS A  v a lid a tio n  fC










R 2 L  fC  5 0 n g
B la n k
R 2 L  h m C  5 0 n g
R 2 L  m C  5 0 n g
R 2 L  C  5 0 n g
 







s s D N A  A b  d ire c t b in d in g

































Next, I performed calculations for the expected amounts of gDNA substrate for each 
modification in accordance with the antibody sensitivity, to get an idea about the sensitivity of the 
assay in comparison to dot blot. I compared the amount of cytosine per 100 ng of an R2L M13 
fragment to the amount of each modification in 100 ng of genomic ES cell DNA (Table 7). M13 
values were taken from its sequence (see Appendix Table 13) and the values for mouse gDNA 
have been taken from the annotated mouse genome (NCBI37/mm9). WT ES cell mass 
spectrometry results were: 5mC measured as 3.5% and 5hmC as 0.11% of total cytosine content, 
5fC as 0.1 x 5hmC (Ito et al. 2010), mCA calculated as ¼ of all methylcytosines and mCG as ¾ of 
all methylcytosines in WT ES cells according to (Stadler et al. 2011) (Table 7):  
 
Table 7. Mass comparison of antigen between genomic DNA and the DNA fragment controls for ELISA 
Modification R2L 100 ng WT ES gDNA 
100 ng 
Fold difference 
gDNA vs R2L 
Dot blot ratio 
gDNA vs R2L 
ELISA 
ratio 
C 25.9 ng 20.88 ng - - - 
mC 25.9 ng 0.7308 ng 35 10 x 10-40x 
hmC 25.9 ng 0.023 ng 1126 1000 x 100-1000x 
fC 25.9 ng 0.0023 ng 11260 ? n/a 10 000x 
mCA 7.19 ng ≤ 0.1827 ng ≥ 35 n/a ≥ 10x 
mCG 6.11 ng ≥ 0.5481 ng ≤ 12 n/a ≥ 10x 
 
 
These calculations helped to optimise and standardise the amount of genomic DNA and 
antibody dilution for each assay. For simplicity, and to allow usage of lowest possible amounts of 
gDNA, all antibodies in further chapters were used at a fixed 1:2000 dilution, while the gDNA 
amounts varied. I did not obtain any gDNA signal for 5fC (not shown), most likely due to the low 
representation of the antigen in gDNA and insufficient sensitivity of the antibody. Additional 
optimisation of the sensitivity of the assay might need to be sought for low concentration signals 
like mCA and 5fC modifications, but the current conditions are sufficient for 5mC and 5hmC (the 
Active Motif 5hmC antibody is highly sensitive and useful in this assay despite the lower 
representation of the 5hmC modification in the genomes).  
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4.3.4.3 Quantitative capacity of the DNA ELISA assay 
I next tested the quantitative aspect of the assay. I used genomic DNA samples with known 
absolute amounts of 5mC and 5hmC, measured by mass spectrometry (kindly provided by 
Gabriella Ficz (Ficz et al. 2013)) – I chose four different samples with different amounts of 5mC 
and 5hmC. The relative amounts of 5mC and 5hmC were correctly measured with the ELISA 
assay for both modifications (Figure 37A-B). When the ELISA optical density (OD) signal was 
plotted against the molar 5mC or 5hmC percentage measured by mass spectrometer (LC-MS), the 
correlation coefficient was excellent in both cases ( R=0.9888 and R=0.999) (Figure 37C). It is 
therefore possible to compare ELISA 5mC and 5hmC measurements with published LC-MS or 
HPLC absolute values by including a mass spec-measured standard in the assay. Thus, the query 
samples can be assigned absolute 5mC and 5hmC molar percentages and can be compared to any 
samples measured by HPLC/LC-MS.  
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Figure 37. Mass spec validation of the quantitative potential of direct DNA binding ELISA assay. Four 
gDNA samples were measured by ELISA and compared to their LC-MS measurements for: A. 5mC; B. 
5hmC; C. A direct correlation between ELISA OD (450) and mass spectrometry molar signal, demonstrating 
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As seen in Figure 37C, four data points can be enough for 5hmC but more points would be 
better to use for 5mC. This clearly shows that the quantitative power of each ELISA assay 
depends on the quality of the antibody – the higher the avidity and sensitivity of the antibody, the 
better correlation with LC-MS the assay will have. 
 
4.3.4.4 Enhancing sensitivity and dynamic range of the mCA ELISA assay  
From those first few ELISA tests, it became evident that unless the samples have very 
similar levels of DNA modifications, it was difficult to capture highly variable concentrations 
with one assay, without risking to overexpose or underexpose a sample and thus skew the result. 
It would also be valuable to look into enhancing the sensitivity for mCA, which would be quite 
low in many of the investigated samples in this project, while quite high in the WT ES cell 
controls. One possibility was to use more sensitive HRP substrates, that have a higher dynamic 
range and higher sensitivity than TMB, such as the fluorescent or chemiluminescent substrates. 
After a brief market research, the Thermo Scientific chemiluminescent SuperSignal ELISA Femto 
Maximum Sensitivity Substrate was brought to my attention as the most sensitive, with an 
estimated 10-fold sensitivity increase above TMB’s capacity. 
To compare both substrates I performed the same assay with M13 PCR fragments 
containing 5mC, 5hmC and 5fC at serial dilutions (Figure 38A). Two antibodies for 5fC were 
tested, one of them with weaker sensitivity than the antibody previously tested, in order to 
challenge the method’s sensitivity limits. The overall values for 5hmC, 5mC and the more 
sensitive 5fC antibody were very similar with both substrates, although the R
2
 values of non-
linear correlation were slightly more consistent (around 0.99) for the luminescent substrate 
(referred to as “Lumi”, Figure 38B). The lower sensitivity 5fC antibody however failed to produce 
any signal with the TMB substrate even at 25 ng DNA, equalling background noise, while the 
luminescent substrate showed good titration curve with an R
2
 fit of 0.95 (Figure 38C) with a clear 
signal down to 0.8 ng DNA, accounting for more than 30-fold sensitivity. A remarkable feature of 
this substrate was the ability to expose correctly very low and very high signal at the same time, 
without reaching saturation.  
A similar test was done for mCA with PCR M13 DNA and genomic DNA, where TMB 
failed to register signal at 30 ng DNA while the other substrate was titrating down to 3 ng DNA, 
showing 10-fold higher sensitivity (Figure 38D).  











 hmC mC fC AM fC Dia 
Lumi 0.9890 0.9949 0.9964 0.9534 
TMB 0.9957 0.9829 0.9772 0.1117 
C D 
  
Figure 38. Enhancing the sensitivity of DNA ELISA. A. A comparison between three different antigens and 
four different antibodies performed with both substrates: TMB and Lumi. Detection sensitivities shown in 
corresponding colour for each modification. On both graphs the signal from the Diagenode fC antibody 
looks zero at this scale; B. R square values compared between the two substrates; C. The fC Diagenode 
antibody result scaled down - TMB against the Lumi substrate showing 50-fold increase in sensitivity; D. 
mCA genomic and synthetic DNA fragments showing 10-fold higher sensitivity with the Lumi substrate. 
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In conclusion, the chemiluminescent substrate provided more than 10-fold higher sensitivity 
and a much wider dynamic range for the simultaneous and accurate measurement of highly 
variable samples. This would be very useful for samples with lower abundance of target antigen 




Various possibilities for developing new tools and techniques for the analysis of non-CG 
methylation were addressed. No equivalent of MspI and HpaII enzyme pair was identified for 
non-CG context, although a number of enzymes could be used for selected techniques.  
The MspJI methyl-RRBS technique can deliver very accurate results on CG or non-CG 
context methylation. However, it suffers from low mapping efficiency, which unfortunately 
decreases its applicability. There is a possibility to use the restriction enzyme enrichment 
technique without applying bisulphite conversion, as originally published, although this method is 
not accurate, and would find a better use to validate results obtained from another technique as in 
Shirane et al., 2013.  
Methylation context-specific antibodies were successfully developed, despite the initial 
risks associated with this undertaking. They were shown to have both high specificity and strong 
affinity, which makes them useful for a number of techniques.  
Importantly, a protocol for DNA ELISA has been developed to utilise the quantitative 
capacity of these antibodies for a quick and accurate measurement of CG and CA methylation.  
 
The molecular tools and methods developed here will be useful to the broad scientific 
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 5 Genomic distribution of non-CG methylation: results from novel techniques 
 
5.1 Introduction 
In the previous chapter, I outlined the challenges and current limitations that precluded a 
comprehensive genome-wide analysis of non-CG methylation in the reprogramming cycles during 
mammalian development, according to my general Aims outlined in 1.7. Having developed novel 
tools to allow for this analysis, I proceeded to investigate the genomic distribution of non-CG 
methylation in ES cells, a model of the ICM component of the preimplantation stage mammalian 
blastocyst (Nichols et al. 2009). 
It has been suggested that mCH in mammals is characteristic particularly for ES cells (Lister 
et al. 2009; Ramsahoye et al. 2000; Ziller et al. 2011). However, the multiple reports of such 
methylation in other tissues, as discussed in the Introduction, leave open the question whether or 
not non-CG methylation is present in other tissues, or exclusively in mammalian ES cells, and 
whether ES cells indeed contain the highest genomic content of non-CG methylation. It would 
also be valuable to know more precisely what the dynamics of mCH is throughout early 
development, and whether it is subject to erasure and reprogramming, as its counterpart in CG. It 
is important to find out if it always follows CG dynamics, and is therefore a possible ‘bystander’ 
of the canonical CG methylation activity, or, more importantly, has its own regulated dynamics.  
Establishing quantitative and potentially qualitative values for non-CG methylation would 
lend support to the idea that this genomic signature has the potential for biological significance. 
As the dominant type of CH methylation is actually in CA context (Lister et al. 2009; Ziller et al. 
2011; Chen et al. 2011), in some of the experiments I have investigated CA methylation in 
particular using our newly derived anti mCA antibody, instead of total mCH levels, as the two 
should be tightly linked.  
 
5.2 Aims  
1. To directly compare global CG and CH methylation levels between ES and 
differentiated cells from mouse and human 
2. To address the distribution of CH methylation throughout genomic features and 
compartments in those cells 
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3. To follow the dynamics of CH methylation throughout the ES cell cycle and its 
relation to mCG dynamics 
4. To investigate the levels of non-CG methylation in mouse tissues and map its 
dynamics during early development 
 
5.3 Results 
5.3.1 CH methylation levels in ES and differentiated cells 
To assess the global levels of non-CG methylation I used my context specific antibodies and 
DNA ELISA protocol. To address mouse strain variability I have evaluated both 129-derived 
commercial mES cell lines (J1 and E14), and also B6 mES cells with B6 pMEFs derived in our 
institute. Human cells lines evaluated here have already been subject to genome-wide analysis and 
the results published (Lister et al. 2009). In this assessment, I compared the absolute levels of 
mCG and mCA between the cell lines, but not their proportional levels within each cell line. My 
DNA ELISA-based results showed in all cases that the mCA levels were lower in the 
differentiated cell lines in comparison to ES cells (Figure 39A), ranging between 25 % and 50 % 
of the ES amount for mouse, and more than 60 % for human. It is possible that the difference 
between human and mouse resides with the IMR90 line, which is not equivalent to mouse pMEFs 
(derived from primary tissue), but is a long-standing commercial cell line. Significant variation of 
absolute mCA levels has been observed between the mouse strains, with B6-derived mES cells 
having around 50 % higher mCA levels than the 129-derived lines (Figure 39B). We did not have 
129-derived pMEFs, but I used mixed background pMEFs instead (outlined in Materials and 
methods). However, CG methylation did not vary between mES and pMEF lines (Figure 39C), 
although it was globally lower in mES cells from the B6 background (Figure 39D). mCG 
difference was observed in the human lines, the IMR90 having lower mCG (around 70 % of hES 
value) (Figure 39C). Human DNA is slightly less methylated globally, and my ELISA results 
confirm this observation (also shown by mass spec data from Tamir Chandra, Reik lab). It is 
interesting to note, however, that while human mES cells have slightly above half the CG 
methylation of mES cells, they possess only a third of the mCA methylation of mES cells (Figure 
39B and D). This suggests that the ratio of mCG-mCA is different for mouse and human, the 
mouse ES cells having higher proportion of mCA methylation than the human ESCs, and the 
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difference between context methylation levels in pluripotent cells and foetal fibroblasts is less 






Figure 39. DNA ELISA for global mCA and mCG levels in pluripotent and differentiating mammalian cells. 
A and C. A comparison between ES cells and differentiated cell (embryonic fibroblasts), normalised to the 
ES cells within each sample group for better illustration of the percentage difference. B and D. Same 
samples but normalized to the mouse E14 line, to illustrate the differences in global amounts between the 
cell lines.  
 
5.3.2 Genomic distribution of non-CG methylation 
I next asked what the distribution of non-CG methylation was across the genomic features 
and compartments. I mapped a panel of features against my MspJI meRRBS positive calls, as I 
had done previously for the low coverage BS-seq in Chapter 3. Interestingly, the pMEFs showed 
slightly higher CG methylation in all features, and markedly lower non-CG methylation (Figure 
40). The CGH methylation clearly followed the pattern of CG methylation across the different 































































































































































































Figure 40. Feature enrichment of CG (upper panel), CHG (middle panel) and CHH (lower panel) 
methylation in mES and pMEFs; unmethylated TKO line is used as a background control. The major satellite 
sequences were not filtered out as in previous BS-seq analysis, and the high value reflects the high number 
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CHG methylation was also higher than CHH in ES cells, which is in accord with the published 
data for mammalian ES cells measured by high depth RRBS or BS-seq (Lister et al. 2009; Ziller 
et al. 2011; Chen et al. 2011). CH methylation shows high enrichment in gene bodies (both 
introns and exons) and CGIs outside of promoter regions. Interestingly, tRNA and miRNA 
sequences also showed high values, but not rRNA loci which show higher CG methylation instead 
(Figure 40). From chapter 3 we already knew that mCH is enriched in some repeats and here it 
seemed particularly high in SINE elements. The major satellite sequence showed the highest 
enrichment, as in Chapter 3, although in this case the high value reflects its high repeat numbers 
in the genome as a whole (there was no filtering of the satellite repeats in this analysis), meaning 
it should not actually be so high per monomer, given the large fraction of the genome it occupies. 
As a matter of fact, to validate the amounts of satellite non-CG methylation as shown in Chapter 3 
from the low BS-seq data, this value should have been much higher, provided it occupies 5-8 % of 
the mouse genome (Waterston et al. 2002; Abdurashitov et al. 2009). Finally, the background 
from the unmethylated TKO line was virtually zero, which confirmed the very high accuracy of 
the positive call validation strategy, developed in Chapter 4, without any signal contamination or 
BS-conversion errors. 
The low percentage or low enrichment of non-CG methylation in genome-wide studies of 
pooled DNA would mean that either each cell in the population has very low levels of this 
methylation, homogenously distributed, or it is variable among the cells within the population. To 
assess the variability within the cellular populations I next made use of the new antibodies in 
immunofluorescence (IF). This technique would also help to visually validate the observed feature 
enrichment patterns and similarities between mCG and mCH for mouse and human ES cells and 
embryonic fibroblasts (pMEF or IMR90). Interestingly, mouse ES cells exhibited greater 
variability in their mCA staining in comparison to their CG methylation (Figure 41, upper panel). 
Few cells showed complete nuclear mCA staining, while in most cells the nuclei were fully 
stained for mCG. Few cells did not have any staining, and the rest had partial nuclear staining. 
This effect was not due to the choice of a confocal plane, but was consistent for the whole nuclei. 
Neither of the signals followed the pattern of 5hmC, thus confirming that there is no cross-
reactivity of either antibody for 5hmC. In pMEFs the mCA signal was visibly weaker than the 
signal for mCG (Figure 41, lower panel). A small group of ES cells was included in the image to 
visualise that the microscope settings were the right intensity. The pMEFs had no 5hmC signal as 
expected, and their CG methylation pattern followed the DAPI staining, as for mES cells.  






Figure 41. Immunofluorescence imaging of mouse ES cells (upper panel) and embryonic fibroblasts (lower 
panel). The colours in the merged image are indicated above and below each greyscale panel. Images 
taken by Fátima Santos.  
 
DAPI mCA hmC Merge
DAPI mCG hmC Merge
J1 mES cells
DAPI mCA hmC Merge
DAPI mCG hmC Merge
pMEF cells
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Interestingly, the only nuclear compartment in pMEFs staining for mCA signal were the 
chromocentres. The chromocentres are characteristic of mouse nuclear organisation, and represent 
the dense heterochromatic foci of the chromosomes (Probst & Almouzni 2011). This result 
correlates with our earlier BS-seq observation that non-CG methylation was preserved in pMEF 
major satellites, although in lower levels (3.3.2). In the mESCs, however, very few of the cells 
actually had signal in their chromocentres, a surprising observation after our findings about major 
satellite in Chapter 3. Quantitation of around 800 cells revealed that between 15 and 25 % of 
mESCs showed chromocentre staining for mCA, while between 70-95 % showed chromocentre 
staining for mCG. This result answers an important point about the mCH distribution in the 
satellite, raised in Chapter 3, which could not be answered by BS-seq: the satellite mCH 
methylation is not homogenously low in each cell, it is very heterogeneous and not present in 
every ES cell, not even in every chromocentre in an ES cell. Why the satellites are homogenously 
methylated in CA in pMEFs, however, is not clear, although it seems possible that their CH 
“methylation” might be merely a background signal of both the BS-seq and IF techniques.  
Human ES cells do not have chromocentric foci, and it is therefore more difficult to judge 
the genomic localisation of CA methylation. It was striking that these cells seemed much more 
homogenous for both mCA and 5hmC, unlike the mouse ES cells (Figure 42, upper panel). There 
was no obvious difference in intensity of mCA and mCG signal in the hES cells, similarly to the 
mES cells, and due to the lack of strong cell-to-cell variability, the mCA and mCG signal looked 
overall very similar. A higher magnification view revealed that the mCG signal was denser at the 
DAPI dense regions, while the mCA seemed more homogenous, showing a similar tendency to 
the mouse mESCs. In the IMR90s however, there was clearly lower signal for mCA, and also 
5hmC, as observed with the pMEFs (Figure 42, lower panel). In all cells few dense ‘spots’ were 
staining for mCA, mCG or 5mC (not shown), and provided those resemble heterochromatic 
regions similar to the mouse chromocentres, this would make their pattern very similar to the 
pMEFs’.  
The whole cell approach for antibody labelling of DNA cytosine modifications relies on 
DNA depurination with HCl, and therefore the adenines’ and guanines’ integrity is globally 
affected. The use of this established protocol with our context-specific antibodies, which are 
selected to recognise intact adenines and guanines, unlike the general 5mC antibody, thus raises 
concerns. To confirm our observation, specifically about the major satellite, and thus validate the 
HCl approach for the context-specific antibodies, I prepared metaphase chromosome spreads and 
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Figure 42. Immunofluorescence imaging of human ES cells (upper panel) and embryonic fibroblasts (lower 
panel). The colours in the merged image are indicated above and below each greyscale panel. Images 
taken by Fátima Santos. 
DAPI mCA hmC Merge
DAPI mCG hmC Merge
hES H9 cells
DAPI mCA hmC Merge
DAPI mCG hmC Merge
IMR90 cells




Figure 43. Immunofluorescence imaging of mouse ES metaphase spreads. The satellites are the condensed 
tips of the chromosomes, staining in red with mCG. The rest are the arms of the chromosomes, showing 
staining for both mCG or mCA, and 5hmC. Images taken by Simon Walker, BI Imaging Facility. 
 
The metaphase spreads protocol does not depurinate DNA but denatures it, which ensures 
access to the methylation sites. This result confirmed the strong staining of satellite in CG, and the 
lack of staining for mCA – in this case none of the satellites stained for mCA, which also was 
observed in metaphase chromosomes with the whole cell approach. This observation validated our 
results obtained with the depurination approach, meaning that the overall damage to purines is not 
very high with the milder (2N vs 4N) HCl protocol which has been used.  
 
5.3.3 Dynamics of non-CG methylation throughout the stages of cell cycle 
In order to investigate at a higher level of resolution the connection of non-CG methylation 
to the overall cellular methylation patterns associated with CG methylation, ES cells were sorted 
according to their phase of the cell cycle by fluorescent activated cell sorting (FACS) (Figure 
44A). To better control for S phase cells, I briefly pulse labelled the culture before harvesting with 
the nucleotide analogue EdU (5-ethynyl-2-deoxyuridine), which incorporates in replicating DNA 
and can be visualised by fluorescence. Due to the high rate of ES cell division the FACS success 
was partial, and both G1 and G2 phases contained S-phase cells, although the EdU /+/ cells in 
G2/M could have been cells exiting S within the duration of the EdU pulse (Figure 44B). The 
DNA methylation was then measured in a few different ways for ultimate accuracy and validation 
– dot blot (Figure 44C) and LC-MS (Figure 44D) for total cytosine methylation, and ELISA for 
mCA and mCG methylation (Figure 44E). All results showed consistently a trend for slightly 
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higher methylation in G1 and G2, including both mCA and mCG. Because the differences were 
small overall, due to measurement variability there was no clear-cut statistical significance for the 
individual measurements, but the fact that all methods show the same trend confirms the validity 
of this dynamics. In this regards the mCA seemed to follow closely the mCG accumulation 
dynamics. This result is in agreement with an earlier study in HeLa cells, where the amounts of 
accumulated 5mC were measured during each cell cycle, and was observed that non-CG 
methylation follows the accumulation dynamics of mCG (Volpe 2005).  
 





D E  
   
Figure 44. Methylation dynamics throughout the mES cell cycle. A. FACS sorting of mES cells showing the 
gating over the three cell cycle phases and the extent of phase separation. B. S-phase cells were pulse-
labeled with EdU for 10 min before fixation and subsequently counted in each fraction as a control over 
the FACS-sort. C. Dot blot for 5mC, including M13-derived positive and negative control, and an unsorted 
J1 population. D. Global methylation levels as measured by LC-MS. E. ELISA measurement of relative 
methylation in CA (right) and CG (left) context. Two biological replicates were used, separated in two 
independent sorts.  
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5.3.4 Dynamics of non-CG methylation throughout mammalian development 
The next step was to investigate the dynamic changes of non-CG versus CG methylation 
within the wider framework of mouse development. For this purpose, I first measured mCG and 
mCA methylation in a panel of mouse tissues. As expected, most mouse tissues showed low 
levels of CA methylation, and the brain samples, in line with recent reports (Lister et al. 2013; 
Guo et al. 2014), were the only ones which showed high levels of mCA, comparable with the 
levels in B6 mES cells (Figure 45 upper panel). The CG methylation was much less variable, with 
tissues like placenta and testis having the lowest levels, again in line with published reports (Oda 
et al. 2013; Senner et al. 2012; Oakes et al. 2007) (Figure 45, middle panel). Interestingly, the 
global 5mC methylation (Figure 45 lower panel) showed an averaged value between mCA and 
mCG for all samples, with a couple of exceptions, which might be due to technical errors. This 
result confirms that non-CG context methylation is generally lower in foetal or adult tissues, and 
drops with differentiation.  
My next step was to assess the methylation dynamics before the pluripotency stage and 
during the phases of global erasure and de novo methylation establishment after fertilisation. 
Since IF is not fully reliable for quantification, I used published WGBS datasets instead, a number 
of which had already become available at this stage of my project. To avoid the problem of 
conversion errors and overestimated 5mC levels, I based my quantitation mainly on datasets 
prepared with the amplification-free PBAT library-preparation technique and its modifications 
(Miura et al. 2012; Smallwood et al. 2014). Where this wasn’t possible, I used BS-seq datasets 
with very good conversion values, namely 0.25 for mCG and 0.45 for mCH (L. Wang et al. 2014). 
In order to be able to compare the mCG with mCA, which have very different levels within their 
own context and are hard to compare, I calculated their global levels instead, estimated as a 
percentage from the total cytosine content. In this way, their levels can be comparable within the 
same scale. This is because, despite the fact that CG context is highly methylated, it occupies only 
4 % of total cytosine, and thus its global levels cannot ever be higher than 4 % (this is, if CG is 
100 % methylated, which is biologically impossible). The remaining 96 % of cytosines are in non-
CG context, and even if this context is only 1 % methylated, this already makes a quarter of the 
4 % of global mCG. In reality, mCG is never 100 %, and mCH is often 1-2 % in cells, therefore, 
if presented as global levels , both types of methylation are in essence comparable levels, and can 
be plotted onto the same scale.  







Figure 45. Global methylation in a panel of B6 mouse adult tissues (unless specifically marked otherwise): 
in CA context (upper panel), CG context (middle panel) and global cytosine without context (lower panel). 
















































































































































Figure 46. Global levels of methylation during mouse early development for paternal (upper) and 
maternal (lower) DNA. From the stage of blastocyst into embryonic development, the plot is the same and 
does not distinguish maternal from paternal DNA changes. The datasets used for this plot are listed in 
Appendix Table 21. For the zygote, I have estimated the paternal and maternal levels of 5mC based on 
the ratios given in Santos et al. 2013.  
 
In this analysis, from the lowest methylation point in PGCs (E13.5) up to 4-cell stage, I 
have presented separately the levels of modification for paternal and maternal DNA (Figure 46). 
From zygote to 4-cell stage this separation was not directly obtained from the WGBS-data, from 
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assumption, based on other published data (Santos et al. 2013). Since BS-Seq cannot distinguish 
between a methylated and a hydroxymethylated cytosine as both are resistant to the bisulfite 
treatment (Huang et al. 2010), these values present the levels of both modifications. The levels of 
hmC, however, are not very high outside the zygote, and hence may be overlooked for the 
purpose of this analysis.  
The results for the paternal pronucleus are taken as identical to that for sperm – very high in 
CG methylation, and rapidly demethylated after fertilisation (Figure 46, upper panel). The results 
for the maternal DNA however, were striking for the level of global mCH methylation in the late 
oocyte and zygote, not for its presence in itself, which has been reported, but for the levels, which 
exceed significantly the levels in ES cells (Figure 46, lower panel). While the brain samples 
showed similar or lower levels of mCH in comparison to mES cells, the oocyte has 3-4-fold 
higher levels than mES cells, making it the cell type with the highest amount of CH methylation. 
This argues against the hypothesis that non-CG methylation is a mark of pluripotency, and is 
related to the state of pluripotency (Lister et al. 2009; Chen et al. 2011; Ramsahoye et al. 2000). 
To verify the BS-seq data with our own BS-independent techniques we performed mCA and 
mCG IF on growing oocytes (work by Fátima Santos) (Figure 47). The oocyte indeed showed 
strong staining for both mCA and mCG, but with this technique it is not possible to determine 
which one has higher levels, or how they compare to the levels in ES cells.   
 
 
Figure 47. Immunofluorescence of growing oocyte (GVO), stained for mCA (left panel) and mCG (right 
panel). The cells surrounding the oocyte are cumulus cells, and they stain only for mCG like other tissues. IF 
by Fátima Santos 





After experiencing serious technical difficulties at the early stage of this project, the 
subsequently developed tools and techniques were finally able to help elucidate the levels and 
distribution of non-CG context methylation in early mammalian development. While ES cells 
were confirmed to have high levels of CH methylation in comparison to most types of 
differentiated tissues, they were also shown to possess far from the highest mCH level in 
mammalian development. The cell possessing highest levels of CH methylation is the mature 
oocyte, where the global levels of CH methylation are higher than its global levels of CG 
methylation. Unlike the rapidly dividing ES cells, this is a mitotically arrested cell with a very 
different function, DNA organisation, and DNA methylation machinery. It is perhaps in a way 
more ‘similar’ to the neuronal cells, which, I also confirmed, have very high levels of CH 
methylation (Figure 45). They are post-mitotic and non-dividing long-lived cells, much like the 
oocyte, although with very different DNA organisation and functions. It is an open question 
whether mCH methylation could then be more beneficial in a non-mitotic cell, where the problem 
of its post-replication maintenance is not specifically relevant. Certainly, however, the ES cells 
remain the most accessible model to study non-CG methylation, unlike the oocyte, which is 
significantly more difficult to access, handle and investigate. Therefore, this result could perhaps 
add another perspective into this work, to include questions or analyse further results in a way that 
could be of relevance to the oocyte and the zygote, if not for the ES cell pluripotent system.  
Regarding its cellular localisation and dynamics, non-CG methylation seems both similar 
and different from CG methylation. It is similar in its levels of enrichment within genomic 
features, and dynamics throughout the cell cycle. Nevertheless, the immunofluorescent staining 
highlighted differences, which have been masked by the limitations of the previous molecular 
approaches (Table 8). First, it revealed that mCH methylation has much more heterogeneous 
distribution in the ES cell population than the CG methylation, at least globally. This is a very 
interesting finding, as it has now been well documented that the ES cell population is very 
heterogeneous, at least when grown in classical serum + LIF conditions, and encompasses 
different groups of subpopulations. (Macfarlan et al. 2012; Hayashi et al. 2008). Some of these 
subpopulations are closer to the ground state of pluripotency, while others are primed for 
differentiation (Smallwood et al. 2014). A third group show similarities for even earlier stages, 
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expressing genes characteristic for the 2-cell and 4-cell stages (Macfarlan et al. 2012). It would be 
interesting to know where the ES cells which are high in mCH stand, and whether the mCH mark 
is characteristic for the ground-like (naïve) state or the 2-cell-like state, or is a mark of a primed 
ES cell state, already set on a path of differentiation.  
 
Table 8. Comparison of global differences of mCA and mCG in mESCs revealed by IF.  
 
 
Another aspect of the differences between mCA and mCG relates to the genomic 
localisation (Table 8). Although whole genome feature analysis shows similar enrichment 
patterns, the IF staining of the two types of methylation is very different. First, a limited amount 
of mCA occupies the heterochromatic foci, while they are very dense in CG methylation. Second, 
the overall pattern in both human and mouse ES cells is very homogenous within the nucleus and 
resembles much more the patterns of the transcriptionally active marks like histone acetylation, 
rather than the repressive ones, which cluster around chromocentric foci. This shows that the 
whole genome approach in NGS datasets can potentially give very generalised results, and not 
capture essential differences, unless they are correlated to other functionally meaningful traits like 
histone marks or expression data. The gene body feature for example includes both actively 
transcribed and repressed genes, and the pure association of the methylation marks with gene 
bodies therefore does not give enough information about the actual functional association. While 
CG methylation is generally associated with repressed transcriptional states, the mCH 
methylation, particularly in ES cells, has been associated with actively transcribed genes (Lister et 
al. 2009). Further work will be necessary in order to establish whether there is a clear role of mCH 
in active transcription, whether it is a consequence or a cause of the actively transcribed state, or 
its correlation with it is a result of an unrelated parallel side process.  
Nuclear localisation mCA mCG
1 homogenous homogenous
2 in foci (~20%) in foci (~80%)
3 peripheral (subtelomeric) peripheral (subtelomeric)
1&3: dominant, 2: minor 2: dominant, 1&3: minor
Nuclear distribution 15-25% ESC polulation 70-95% ESC population
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 6 Establishment and maintenance of non-CG methylation 
 
6.1 Introduction 
As discussed in the main Introduction, non-CG context methylation has so far been 
attributed mainly to the de novo Dnmts, although a possible de novo role for Dnmt1 in vivo is still 
disputed. While it is clear that both Dnmt3a and 3b have a low activity towards non-CG contexts 
(mainly CA), both in vitro and in vivo, it is not yet clear whether this activity is specifically 
directed (targeted) or merely a nonspecific (sporadic) activity, which occurs concomitantly with 
the main dominant targeting of CG. The latter possibility is supported by the fact, that the 
presence of non-CG methylation during development occurs within the two phases of 
establishment of methylation marks – in male PCGs and growing oocytes (Shirane et al. 2013; 
Kobayashi et al. 2013), and in pre-implantation embryo (where the ES cells are the ex vivo 
equivalent) (Ziller et al. 2011; Lister et al. 2009). The Dnmt enzymes are ‘error prone’ and as they 
do not have highest fidelity for maintaining the CG methylation state (Jeltsch & Jurkowska 2014; 
Goyal et al. 2006), it is possible that they also exhibit nonspecific side activities, especially when 
expressed at their highest levels and de novo establishment of marks is on the way.  
Additionally, Dnmt2 has remained enigmatic in regard to its role in DNA methylation, and 
its function in methylating tRNAs does not exclude a possibility to also work on a DNA substrate. 
Its preference for methylating non-CG context makes it an appealing candidate for a ‘non-CG 
methyltransferase’ in mammals. It is possible to speculate that its DNA activity could need 
activation from an external signal, and during the de novo methylation establishment, it could be 
receiving the necessary stimulus to switch its substrate towards DNA. Dnmt2 is highly expressed 
in ES cells and Dnmt2 knockout cells are available.  
It has already been suggested that non-CG methylation can be actively removed, potentially 
in a faster and more regulated fashion than mCG (Fuso et al. 2010). In light of recent reports 
regarding the predominance of non-CG methylation in the oocyte (Shirane et al. 2013), depicted 
also in my calculations in Chapter 5 (Figure 46), the mechanisms for demethylation of mCH need 
a closer attention. In the original reports arising from IF, the maternal pronucleus has been 
characterised largely by its passive demethylation post fertilisation, unlike the paternal 
pronucleus, which is an arena of very active demethylation processes. In the absence of a proper 
maintenance mechanism for mCH, a passive removal mechanism seems the most likely pathway 
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for describing the fate of mCH marks. It has been shown that the maternal pronucleus is protected 
by the developmental protein Stella (also known as Dppa3) and the H3K9me2 mark (Nakamura et 
al. 2007; Nakamura et al. 2012). From my calculations in Chapter 5 (Figure 46), it becomes clear 
that the maternal pronucleus has higher global methylation levels than the paternal and indeed 
higher than the levels in subsequent developmental stages, including ESCs and differentiated 
embryonic tissues. Thus, to protect all those methylated sites would constitute a significant 
challenge for any molecular mechanism in place, and even more so when DNA in very close 
proximity, in the same cell, is not afforded this protection, but apparently requires the opposite 
activities leading to DNA methylation loss. The stringent restriction of the activity of any 
molecular mechanism to one pronucleus and not the other would need, in the first place, a very 
well defined ‘labelling’ of identity, which could be provided by mCH.  
It therefore seems justified to investigate the activity of Tet enzymes on mCH context 
cytosines. Interestingly, the human Tet2 enzyme does not show catalytic activity on a mCA-
containing substrate in vitro (Hu et al. 2013). A similar observation has been reported for a highly 
conserved Tet-like enzyme from the amoeboflagellate Naegleria gruberi, which shares high 
similarity with mammals (Hashimoto et al. 2014). If this would be true also for mammalian Tet1 
and Tet3, then the maternal genome could actually be intrinsically ‘resistant’ to active 
demethylation by hydroxylation at the majority of its methylated sites, which are in CH. Whether 
such a property would affect the repair mechanisms participating in active demethylation in the 
zygote, is not known.  
 
6.2 Aims  
In accord with the highlighted open questions, the tasks to be addressed in this chapter are: 
1. To investigate if Dnmt2 has DNA methylating activity in mammals and whether it is 
the enigmatic ‘CH methyltransferase’ 
2. To elucidate which of the canonical Dnmts is responsible for CH methylation in early 
development and if its activity to non-CG context is unspecific or regulated 
3. To investigate the activity of mouse Tet enzymes on mCA and a potential resistance of 
non-CG context methylation to the mechanisms of active demethylation  
 




6.3.1 Investigating a role for Dnmt2 
We have measured global levels of methylation in Dnm2-/- and Dnmt2+/- ES cells, against 
a WT control. We first tested this in IF, which did not show any difference in the methylation 
levels of those three cell lines (Figure 48A). Small differences as we would expect, however, are a 
challenge for this technique and its quantitative capacity, and it is possible that they cannot be 
captured. Therefore, we next measured this with an LC-MS. Surprisingly, our results showed 
around 15 % of decrease in 5mC in the two Dnmt2-/- replicates, in comparison to the Dnmt2+/- 
and the WT control (Figure 48B). The global 5hmC levels did not differ between the -/- and +/- 
clones, although they differed from the J1 WT ESC, and thus they did not follow the pattern on 
5mC. 
In order to confirm that this effect was due to the Dnmt2 and not a decrease of the other 
Dnmts, I surveyed the functional Dnmts in mESCs by RT-qPCR – Dnmt1, Dnmt3a2 and Dnmt3b. 
All three showed normal mRNA levels in the Dnmt2-KO and the TKO ES cell line was used as a 
negative control (Figure 49A). As a verification, Dnmt2 mRNA levels, on the other hand seemed 
normal in a selection of WT cell lines, including MEFs and the Dnmt TKO ES line, but they were 
reduced by 50% in the Dnmt2+/- line, and further reduced in the Dnmt2-/- lines (Figure 49B). 
Because the 5mC decrease observed in our LC-MS data was highly significant, in order to 
exclude any doubt, we did IF staining of the protein levels of the canonical Dnmts in Dnmt2-KO 
cells. The IF showed normal levels of the Dnmts and the variable cellular levels of the Dnmt3s are 
usual (Figure 49C). These results confirmed that the only methyltransferase, which was decreased 
in the Dnmt2-/- cells, was Dnmt2 with no concomitant decrease of canonical Dnmts.  
 
To confirm if indeed the Dnmt2 protein has an activity on DNA in mES cells, and 
contributes towards non-CG context methylation, we used an alternative approach. In order to 
find small genome-wide differences in the methylation pattern of the Dnmt2-KO lines, high depth 
WGBS has to be performed. The cost of this approach could not be justified for a trial experiment, 
and the differences could still be beyond the detection limit when conversion artefacts are taken 
into account. Therefore, I focused my further efforts on the TKO ES cell line, being the only 
mammalian biological system, in which Dnmt2 is the only DNA methyltransferase present. Other 
6: Establishment and maintenance of non-CG methylation 
136 
 





Figure 48. Estimation of global 5mC and 5hmC levels in Dnmt2-KO mESCs. A. Measured by IF. B. 
measured by LC-MS. D2-/-#4 and #7 are two replicates of Dnmt2-/- cells, and D2+/-#9 is their control 
Dnmt2+/- cell line. 
 
mansoni, Entamoeba histolytica, and others (see Introduction). I performed low depth WGBS on 
the TKO ES line (already discussed in Chapter 3). The levels of unconverted cytosine found in the 
TKO line, however, did not differ from the levels of measured conversion artefacts (see Figure 
11C). I then took a more targeted approach and examined the major satellite sequence with a 
classical targeted sequencing, as it was done in Chapter 3 for J1 ES. Due to its importance for the 
overall genomic stability and mitotic fidelity, the pericentric repeat sequence often remains highly 
methylated even during the natural phases of global DNA demethylation in early development, as 








Figure 49. Expression of canonical Dnmts in the Dnmt2-KO ES cell lines. A. RT-qPCR of Dnmt1, Dnmt3a2 
and Dnmt3b, the values are normalised to J1 WT. B. Expression of Dnmt2 in a selection of WT cell lines 
and Dnmt2-KO lines. The TKO line, which lacks the canonical Dnmts expresses WT levels of Dnmt2. C. IF for 
Dnmt1, Dnmt3a (below) and Dnmt3b (above) in Dnmt2-KO mES cells, colours are marked on the image.  
 
 
reported for PGCs (Seisenberger et al. 2012), the paternal pronucleus in the zygote (Salvaing et al. 
2012), and the transition from primed to ground state of pluripotency in mESCs (Ficz et al. 2013). 
If any methylation were remaining in the TKO, then one would imagine it should occupy those 
methylation ‘fortresses‘ which are preserved methylated by the cell even in extreme 
demethylation conditions. Moreover, the major satellite has been shown to have a considerable 
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degree of non-CG methylation relative to the genomic average. My results, however, did not 
reveal any methylation of the TKO line in the major satellite, on either of the strands (Figure 
50A). Few unconverted cytosines were present on the reverse strand; however, they did not 
occupy any of the positions methylated in the J1 WT line, and fall within the expected level of 









Figure 50. Methylation in the Dnmt-TKO mES cell line and other Dnmt2-only species. A. Targeted 
sequencing of the major satellite repeat in TKO mESC. Upper panel is reverse strand, lower panel is 
forward strand. Arrows mark where the 5mC signal is observed in the WT J1 ESC line (Black = CG, red = 
CA). B. Global genomic methylation of Dnmt2-only species measured by LC-MS. Fold-difference in global 
5mC signal is shown for TKO or Drosophila samples in comparison to J1. The signal of Drosophila 
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A final attempt to detect any methylation in other Dnmt2-only organisims, was performed in 
collaboration with Frank Lyko, who provided DNA samples from D. melanogaster and 
Schistosoma mansoni. LC-MS on whole genome DNA from fruit fly and the TKO line revealed 
very low signal, within the detection error of the equipment (B). Schistosoma mansoni had 
significantly higher signals, relative to zero, however the DNA from this parasite is known to be 
contaminated with bacteria and therefore the result could not be accepted as positive, alongside 
the signal from the uncontaminated Dnmt2-only DNA from mouse and fruit fly (Raddatz et al. 
2013). At the same time the Dnmt2 enzymes in all three species were physiologically active and 
successfully methylated its tRNA target as shown in Raddatz et al, 2013. My results confirmed 
that Dnmt2 is not capable of delivering any bona fide detectable levels of DNA methylation. Even 
if very low levels of sporadic methylation occurred as a result of Dnmt2 activity, they would not 
exceed any biologically significant threshold, and would not explain the levels of native CH 
methylation.  
 
6.3.2 mCH contribution of the canonical Dnmts 
My next step was to evaluate the contribution of each of the canonical Dnmts towards CH 
methylation in my mES model system. I used a panel of constitutive knockout cells for each of 
the Dnmts (1-/-, 3a-/-, 3b-/-) and Np95-/-, including a double de novo methylase knockout (3a-/-
3b-/-, or DKO) and TKO (1-/-3a-/-3b-/-). A Dicer-/- mESC line was also included, to evaluate a 
possible role of RNAi pathways in the de novo methylation of CH context. My results confirmed 
a clear contribution of the de novo Dnmt3a and Dnmt3b MTs, which show around 50 % decrease 
of global mCA in both mutants, without a significant quantitative difference between the two 
(Figure 51 left panel). The DKO on the other hand was completely depleted of mCA, reaching the 
absolute zero and background values of the TKO and the unmethylated control DNA. The 
maintenance methylation knockouts Dnmt1-/- and Np95-/- also did not differ significantly 
between each other, fluctuating between 60 % and 100 % of WT mCA values. The Dicer-/- mES 
cells did not show any change in mCA methylation, contrary to expectations, following the 
downregulation of Dnm3a and Dnm3b in Dicer-KO cells (Kanellopoulou et al. 2005; Nesterova et 
al. 2008). The high clonal variability, however, might account for that. The results for mCG were 
in good agreement with previous reports, serving to validate the mCA/mCG antibody ELISA 
approach. The 3a and 3b single knockouts showed a trend for a slight decrease (~15 %), although 
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not quite statistically significant, due to replicate variation; the DKO and TKO mESC lines again 
showed background signal value (our DKO line is high-passage) (Figure 51 right panel). Dnmt1-
/- and Np95-/- showed a marked decrease in mCG levels in comparison to their mCA levels, 
fluctuating between 30 % and 60 % of the WT mCG value. The Dicer-/- line did not show any 
statistical difference in mCG, again due to clonal variation (Figure 51).  
 
  
Figure 51. ELISA for global mCA and mCG levels in a panel of Dnmt KO mESCs and Dicer-KO. Left: mCA, 
right: mCG. All column comparisons not marked as non-significant are significantly different.  
 
 
In summary, these experiments showed:  
1) That both Dnmt3a and Dnmt3b contribute to non-CG methylation, although it is not clear 
whether this result is due to the direct enzymatic involvement of both enzymes, or there is a 
secondary effect due to their tight structural cooperation and functional dimer formation;  
2) Dnmt1 and its partner Np95 do not seem to be directly involved in setting mCA marks, 
although there is a tendency of a decrease in mCA, which might be a secondary effect owing to 
Dnmt1’s cooperation with the de novo Dnmts, as discussed in 1.3.1.  
3) The previously reported decrease of Dnmt3a and Dnmt3b expression in Dicer-/- mES 
cells does not seem to lead to any detectable global decrease in either mCG or mCA levels. If 
RNAi has a role in targeting de novo DNA methylation, and disruption of this pathway would 
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It has been suggested that the presence of non-CG methylation is highly linked with the 
expression of Dnmt3a or 3b, in the sense that its occurrence could be a side effect of their high 
expression, rather than a regulated and biologically meaningful mark. In order to obtain a better 
understanding about the correlation of mCA levels and the occurrence of each Dnmt in the cell 
population, and investigate this possibility, I measured the mRNA expression levels of each of the 
KOs in my panel, and correlated those to global mCA and mCG levels. This correlation should 
replicate the result in Figure 51 to show directly which Dnmt is responsible for which type of 
methylation, since those systems are genetically manipulated to lack particular Dnmts. In 
addition, I have included non-manipulated biological samples, which express variable levels of 
the Dnmts, and have variable levels of methylation in each context. The results from this analysis 
will not necessarily show which Dnmt is responsible for which type of methylation. Their 
correlation, however, could show to what extent the mCA is directly linked to Dnmts’ expression 
levels; whether it is an inevitable, and most likely a nonspecific consequence of the high 
expression of the de novo Dnmts, merely a function of their abundance and high activity at any 
point, or it is, on the contrary, a specific and regulated event.  
The panel of WT samples included the tissues used in Chapter 5, as well as a time course of 
serum > 2i pluripotency ground state transition of an E14 WT mESC line. In this ground state 
transition, the de novo Dnmts quickly reduce their expression levels as a function of Prdm14 
increase (Ficz et al. 2013), which could in turn be correlated with changing (or not) global mCA 
and mCG levels.  
Interestingly, the highest significance correlation for mCA was achieved with Dnmt3b with 
the KO panel of ES cells (p=0.0008), but there was also a clear trend for the entire WT panel of 
samples (p=0.0275, not shown on figure) (Figure 52, upper right). The ES KO panel showed the 
expected link between mCA and Dnmt3a2 as in Figure 51, although significantly lower than with 
Dnmt3b (p=0.0224 with Pearson correlation and p=0.0087 with Spearman correction for non-
Gaussian distribution). There was no correlation for Dnmt3a1, which has low expression in ES 
cells. Dnmt3a1 however showed borderline significance with the WT group of tissues (p=0.0458), 
suggesting it may play a role in mCH levels observed in adult tissues. However, because very few 
tissue types have any significant mCH levels, and for both male PGCs and oocyte it is known that 
the shorter Dnmt3a2 is the de novo Dnmt3a variant (Sakai et al. 2004; Ooi et al. 2009), this 
correlation has to be further verified with more replicates and tissue types. Neither Dnmt3L, 
Dnmt1, nor Np95 showed any correlation with the global levels of mCA, although a Spearman 
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correction for non-Gaussian sample distribution gave a strong correlation for Dnmt3L with the 
group of WT samples (p=0.0091, not shown in figure) (Figure 53, lower panels). Although a 
Dnmt3L knockout line was not included in this study, the rest of the samples showed a variety of 
high and low levels of Dnmt3L expression, but none of those correlated with measured mCA 
levels for the individual groups. In conclusion, these results indicate that the presence of Dnmt3b 
is most tightly related with presence of non-CG methylation, suggesting a lower level of 







Figure 52. Direct correlation between Dnmts’ expression levels and global mCA methylation. Three groups 
of samples were analysed: a panel of Dnmt KO mESCs (Dnmt-KOs), a panel of adult mouse tissues (WT 
tissues), and a serum > 2i reprogramming time course of E14 mESC (WT Ser>2i ES). The group ‘WT’ 
includes both groups of WT samples (tissues and 2i ESCs). The lines represent linear regression; unless 
otherwise stated, the correlation coefficients were calculated with a Pearson two-tailed test in Prism 6.0.  
 
For mCG the results were also quite interesting. Due to the high redundancy between the 
different Dnmts in the maintenance and establishment of CG methylation, it is difficult to get as 
clear correlations for mCG as for mCA and the correlations were not as strong as for mCA. 
Unlike mCA, all de novo Dnmts showed borderline correlations with mCG in all samples 
combined – Dnmt3a1 (the adult Dnmt3a, p=0.0337), Dnmt3a2 (the early development Dnmt3a, 
p=0.0269 with Spearman non-Gaussian correction) and Dnmt3b (p=0.054), while Dnmt1, Np95 
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and Dnmt3L showed no significant correlation for the pooled samples (Figure 53). Within the 
broad correlation, Dnmt3b correlated with the pool of ES cells (p=0.0192) and the pool of WT 
samples (p=0.0192), while Dnmt3a2 correlated with ES cells only (p=0.0334) and Dnmt3a1 with 
WT samples only, including tissues (p=0.312), which matches the known distributions of both 
isoforms of Dnm3a. This could suggest again a less regulated activity for Dnmt3b in comparison 
to the other two members of the de novo Dnmt family. In addition, Dnmt3b showed a correlation 
with CG methylation in the serum to 2i transition of E14 ESCs (p=0.0109), but no such 
correlation was observed for Dnmt3a2, consistent with reported observations that their global 
decrease of methylation is due to a drop in the Dnmt3b expression (Figure 53, upper left panel). 
Dnmt1 is the only enzyme, which showed a correlation for the group of mES Dnmt-KO cells 
(p=0.414) (Figure 53, lower middle panel), potentially due to the lack of a strong redundancy in 
its maintenance role. Interestingly, Dnmt3L showed correlation with mCG in ES cells (p=0.0358) 
unlike mCA, while Np95 showed no correlation with mCG. This might be explained by the low 
number of tissue samples, where Np95 is highly expressed, and points to a lesser importance of 








 Figure 53. Direct correlation between Dnmts’ expression levels and global mCG methylation. Three groups 
of samples were analysed: a panel of Dnmt KO mESCs (Dnmt-KOs), a panel of adult mouse tissues (WT 
tissues), and a serum > 2i reprogramming time course of E14 mESC (WT Ser>2i ES). The group ‘WT’ 
includes both groups of WT samples (tissues and 2i ESCs). The lines represent linear regression; unless 
otherwise stated, the correlation coefficients were calculated with a Pearson two-tailed test in Prism 6.0. 
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Figure 54. Expression of Dnmt3a and Dnmt3b in the different phases of the cell cycle of WT mESCs. Upper 
panel: IF of FACS-sorted cell populations, pulse labeled with thymidine analogue EdU (5-ethynyl-2-
deoxyuridine) as a marker of DNA replication (green), PI (propiduim iodide) as an intercalating DNA 
marker (red) and either Dnmt3a or Dnmt3b (blue) via IF. Significance of peaks is measured with Chi square 
test.  
 
Another way to assess the direct link of mCA methylation and the abundance and activity of 
Dnmt3s was to follow their expression throughout the cell cycle, since I had already measured the 
global mCA and mCG values of cell cycle sorted cell fractions (Figure 44). For this purpose, I 
stained FACS-fractionated mES cell populations for Dnmt3a and Dnmt3b and estimated the 
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relative quantity of stained cells in each population (Figure 54). The EdU pulse labelling was 
again useful to discriminate S-phase cells in the G1 and G2/M fractions. Although the de novo 
Dnmt3s were present in each cell fraction, my results showed a significantly higher expression of 
both Dnmt3a and Dnmt3b in G2/M phase, following DNA replication (Figure 54, lower panel). 
Such a result would make sense in the light of the more recent understandings that the de novo 
Dnmts take an active part in the maintenance of DNA methylation marks. These results also 
highlight the heterogeneity of ES cell populations, in the observation that only 50-70 % of the ES 
cells stained positively for Dnmt3a, while 80-95 % stained for Dnmt3b. This observation supports 
my result, that Dnm3a2 is a more tightly regulated enzyme than Dnmt3b (Figure 52 and Figure 
53). The dynamics of mCA and mCG from my previous measurement in cell cycle sorted ES cells 
does show a potential global methylation increase in the G2/M fraction. However, this result is for 
the global 5mC and the result for mCA in particular shows a significant increase in the G1 phase, 
and not in G2/M. This again would show, that mCA methylation does not strictly follow the peaks 
in expression of the Dnmt3 enzymes, as previously suggested (Ziller et al. 2011), but has an 
independent and regulated dynamics.  
 
6.3.3 Active demethylation of non-CG context 
In order to investigate the sequence specificity of the Tet family enzymes in regard to their 
ability to oxidize 5mC to 5hmC, I have focused on Tet1, due to the commercial availability of 
catalytically active enzyme. As shown in Figure 6 (Introduction, 1.4), the structure of the catalytic 
domain of all Tet family members is highly conserved. Therefore, results obtained for Tet1 in a 
simplified in vitro system, where no potential allosteric regulation by nuclear components would 
take place, is likely to extend to the other Tet members under similar conditions.  
I have performed an in vitro Tet1 oxidation of biotinylated dsDNA fragments (Table 5) 
which contain a single methylated site each, in variable cytosine context, and analysed the 
resulting oxidation products with an avidin-biotin sandwich ELISA system. My results show very 
high Tet1 activity on the symmetrically CG-methylated DNA substrate (‘mCGm’), but much less 
on a hemi-methylated CG substrate (‘mCG’), or on the mCA substrate (‘mCA’) (Figure 55A). 
The amount of 5mC had also changed accordingly on the same fragments (Figure 55B). To 
independently verify these results with a greater degree of stringency, and assess for further 
oxidation products, I also measured the oxidation fragments upon Tet1 treatment with LC-MS 
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analysis. The result was very similar to that of the ELISA in absolute numbers (Appendix Figure 
74. The oxidation kinetics for 5fC accumulation for each substrate followed precisely the 
acquisition of 5hmC (Figure 55C and D). Only a small proportion (6 – 8 %) of 5fC was detected 





C D E 
   
Figure 55. Tet1 activity on 5mC in different context. A and B. Log2 acquisition of 5hmC signal on oxidised 
dsDNA-biotin fragments measured by biotin-avidin ELISA for 5hmC (A) and 5mC (B). C and D. LC-MS 
measurements of absolute oxidation products in same context-specific oxidized dsDNA fragments, 5hmC 
(C) and 5fC (D). Ratio of oxidation products 5hmC and 5fC in each substrate reaction. 5caC was not 
measured with LC-MS, and both 5fC and 5caC were beyond the sensitivity of the ELISA technique.  
 
I next looked at the possibility that non-CG context methylation was able to escape or 
interfere with the repair-based mechanisms of active demethylation. The main proteins, 
implicated in initiating the short- or long-patch BER pathway, are TDG and AID, although for 
TDG it seems more likely to participate downstream of the oxidation pathway, as discussed in 1.4 
of Introduction. It has been shown, that AID-KO fertilised eggs experience less demethylation of 
their paternal pronuclei (Santos et al. 2013), which are exclusively methylated in CG (Figure 33). 
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KO system where active demethylation is happening, we could expect to observe an accumulation 
of mCH. The paternal pronucleus is not a good model because of its virtual lack of non-CG 
methylation, however, mESCs, which have relatively high amounts of mCH, could be an 
appropriate system. AID is expressed in mESCs and is involved in active demethylation during 
the reprogramming towards pluripotency in iPSCs (Bhutani et al. 2010; Bhutani et al. 2013; 
Kumar et al. 2013). I therefore measured global mCG and mCA amounts in iPSCs from WT and 
AID-KO pMEFs (generated in the Reik lab by Inês Milagre). There was no increase of global 
mCA in the AID-KO iPSCs, or the AID-KO pMEFs from which they were reprogrammed (Figure 
56A). The same applied for mCG, however, which is a known target of demethylation by AID-




Figure 56. CA and CG methylation in AID-KO cells. The global methylation in CA (A) and CG (B) context, 
normalized to either B6 WT mESCs or pMEFs. None of the differences between the AID-KO cells and their 
corresponding WT were statistically significant. (note: there is a significance between AID-KO iPSC and 
WT B6 mESC, but not with the BS iPS control line). umDNA is unmethylated DNA control.  
 
This result could potentially indicate that the iPSC reprogramming system was not an 
appropriate approach for assessing the contribution of AID towards 5mC demethylation. None of 
the other systems where active demethylation is taking place however, like the early PGCs and 





























































































































I therefore undertook a different approach, based on bioinformatic analysis of WGBS 
datasets and prediction of outcomes. It was a step forward in the idea that the highly methylated 
maternal genome is ‘protected’ or ‘resistant’ to active demethylation by virtue of its high mCH 
levels. Here it was assessed from the perspective of AID and the repair pathways, and not the Tet 
enzymes, which we already know mCH is not substrate to. The approach was based on the zygote 
as a model, and the known specificity of AID. The consensus sequence of AID is WRC and it is 
known that that its affinity for 5mC substrate (i.e. WR
m
C) is around 10-fold lower than towards 
its natural target – the unmethylated cytosine (Nabel et al. 2012). I reasoned that cytosine 
methylation of this sequence, might be a way to hinder the activity of AID, meaning that the more 
methylated this sequence motif is, the less AID-mediated active demethylation will occur. It 
seems plausible that such a mechanism might be employed by the maternal pronucleus in order to 
‘escape’ active demethylation, especially if this is done by a type of methylation, which is in itself 
resistant to hydroxymethylation. I therefore measured methylation levels of the WRC motif in the 
genomes of oocyte and sperm, from published datasets (L. Wang et al. 2014; Kobayashi et al. 
2012; Shirane et al. 2013; Smallwood et al. 2014). The methylation of this sequence was indeed 
higher in the oocyte genome, as expected, but surprisingly in the paternal pronucleus it was 
actually lower than the global 5mC genomic averages of both MII and sperm (Figure 57A). The 
context composition of the WRC motif is the same as the genomic cytosine composition, meaning 
this effect is not due to underlying sequence biases (Figure 57B). This suggests there might be a 
regulatory mechanism in place, which controls the level of methylation of the WRC sequence 
motif in the oocyte and the sperm.  
Although on a global scale, the methylation of the WRC motif seems low (5.43 % for MII) 
and the majority of WRC sites (> 90 %) remain unmethylated, we should not forget that the 
global methylation levels for the mouse genome range between 3-4 %, and 2-3 % for the human, 
and the CG context alone is around 3% for the mouse genome. Next to those values, which 
undoubtedly have a significant effect on the function of the mammalian genomes, the 5.43 % 
seem a very high value for a single sequence motif. For comparison, the global 5mC change 
between primed (serum + LIF grown) and naïve (2i grown) mESCs is slightly higher than 2-fold 
(3.10 % 5mC primed vs 1.43 % 5mC naïve, Figure 46) and this leads to profound phenotypic 
changes.  
 
6: Establishment and maintenance of non-CG methylation 
149 
 





Figure 57. Methylation in the AID targeting motif WRC. A. Global methylation in the WRC motif for 
oocyte and sperm, in comparison to the global genomic values (left); right: the same figure with sequence 
context proportional values (mCG and mCH). B. Context composition of the mouse WRC motif in 




In this chapter, my experiments addressed the individual roles of all mammalian Dnmts in 
their contribution to non-CG context methylation. Although it might seem that this topic has 
already been addressed substantially in the existing literature, there are a few important findings 
from my work.  
Dnmt2 has been controversial in its role in DNA methylation. Although a number of papers 
have claimed in the past (Lyko, Whittaker, et al. 2000; Kunert et al. 2003), and more recently 
(Takayama et al. 2014; Capuano et al. 2014) such a role, my results could not support such a 
claim (Raddatz et al. 2013). I generated the first WGBS dataset of a Dnmt2-only mammalian 
model organism, and with the conversion rates from my internal spike-in control I could not 
justify that the observed low signal is real. Moreover, data from highly sensitive mass 
spectrometry also could not support the presence of any methylation above background and 
beyond the equipment’s thresholds of detectability. The fact that WT and Dnmt2-KO from 
Drosophila melanogaster DNA did not show any differences, clearly shows that Dnmt2 cannot 
have a role in DNA methylation in the fruit fly. Moreover, the measured fruit fly samples ranged 
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pooled in the figure for clarity. None of the recent papers included a Dnm2-KO DNA in their 
studies, and the compared measurements of global 5mC in the mouse within the range of 7.6 ± 0.8 
% are highly overestimated (Capuano et al. 2014). In addition, one of the studies attributes the 
DNA methylation activity in the fruit fly to a novel unidentified enzyme (Takayama et al. 2014).  
 
The ability of the two major de novo Dnmts to act both in vitro and in vivo on non-CG 
context has been known for a long time (Aoki et al. 2001; Gowher & Jeltsch 2001; Mund et al. 
2004; Lyko et al. 1999). Later, CH methylation has been associated most commonly with the 
presence of Dnmt3a (Lister et al. 2009; Shirane et al. 2013; Lister et al. 2013) or both Dnm3a and 
Dnmt3b (Ziller et al. 2011). Those associations are mainly based on the availability (or highest 
expression) of a particular de novo methyltransferase in the relevant study tissues, and a 
comparable cross-tissue and cross-developmental stages study so far has not been done. Also, the 
fact that under the term ‘Dnmt3a’ there are actually two distinct enzymes is rarely acknowledged. 
On one hand, for some studies this is understandable, because the Dnmt3 isoform in the oocyte 
(Shirane et al. 2013) and mES cells (Stadler et al. 2011; Ziller et al. 2011) is of the same type 
(Dnmt3a2), but it does not become clear which is the main isoform in the mouse brain, when the 
activity is attributed to Dnmt3a (Lister et al. 2013).  
My study evaluated the two isoforms of Dnmt3a independently. Dnmt3a2 showed a strong 
correlation with the presence of mCA, and at the same time suggests a higher level of regulation 
in WT samples, where its presence does not always predict higher mCA levels. Dnmt3b is 
indisputably equally responsible for establishing non-CG methylation marks, and its activity 
seems less regulated for the establishment of both mCG and mCA marks – its presence highly 
correlates with both marks. The fact that Dnm3a2 seems to be under a more stringent regulatory 
control, is also in line with its tightly regulated expression in particular windows during 
mammalian development. It is interesting that Dnmt3a2 is a truncated form of Dnmt3a1, and it 
lacks additional unique regulatory domains that could support an alternative allosteric regulation. 
Therefore it remains an open question how the activity of this isoform is regulated, although a 
likely possibility is that this happens through posttranslational modifications or in an ncRNA 
dependent manner (Jeltsch & Jurkowska 2014). A recent study reported that the activity of 
Dnmt3a2 can be downregulated via phosphorylation by CK2 (Cycline kinase 2), leading to a 
decrease in overall CG methylation levels within particular genomic regions (Deplus et al. 2014). 
It would be interesting to find out if such regulation would also affect non-CG methylation. The 
6: Establishment and maintenance of non-CG methylation 
151 
 
lack of some regulatory domains in Dnmt3a2 might also explain its close cooperation with 
Dnmt3L, which acts as an allosteric regulator. Indeed, it has been shown that the activity of 
Dnmt3a2 rises 20-fold upon cooperation with Dnmt3L (Kareta et al. 2006). Nevertheless, the 
expression of Dnmt3L is even more tightly regulated, and the fact that Dnmt3L showed 
correlation with mCG levels rather than mCA suggests that Dnmt3a2 could also function 
independently, or in a response to stimuli and regulators different from Dnmt3L. Nevertheless, the 
targeting towards imprinting loci in the oocyte and towards repetitive sequences in the male 
PGCs, both of which contain non-CG methylation, has been shown to depend strictly on its 
cooperation with Dnmt3L (Bourc’his et al. 2001; Bourc’his & Bestor 2004; Hata et al. 2002; Hata 
et al. 2006).  
Dnmt3a1 has borderline correlation with non-CG methylation, although this result is 
grounded only in its very high expression in brain cortex (Appendix, Figure 73). On the other 
hand, it is also very highly expressed in other tissues, which do not have high mCH levels, 
suggesting it may not be the factor responsible for high mCH in brain. Clearly, more samples are 
needed to validate this observation. Moreover, it has been reported that the mouse hippocampus 
expresses Dnmt3a2 and its presence is crucial for the proper cognitive function, which declines 
with aging along with the decline in Dnmt3a2 expression (Oliveira et al. 2012). It therefore 
remains an open question whether the high mCA levels in the brain are due to Dnmt3a2, or the 
ubiquitous Dnmt3a1. Interestingly, the same study shows that Dnmt3a2 has been robustly and 
transiently activated by neuronal receptor stimulus, and was partially responsive to nuclear 
calcium signalling, supporting a high level of regulation for this enzyme (Oliveira et al. 2012).  
For Dnmt3b my results indicate that the higher the levels in a cell population or a tissue, the 
higher the presence of the mCH and mCG marks will be. However, the expression of Dnmt3b is 
much more ubiquitous and homogenous within the mES cell population, while the distribution of 
mCA signal is highly variable (Figure 54). This fact may also point towards cooperation between 
Dnm3a and Dnmt3b in establishing the mCH marks. It has been reported that the two work 
synergistically in ES cells and potentially form heterodimers (Li et al. 2007), and while the 
Dnmt3b activity is necessary, it might be modulated by the presence of Dnmt3a2 to drive the 
heterogeneous distribution of mCH. It would be important to co-stain and compare mCA and 
Dnmt3a2 patterns, and determine if the variation in mCA in a mES cell population follows the 
fluctuations of Dnmt3a2 or Dnmt3b expression.  
Regarding the maintenance methyltransferase Dnmt1, my results show a borderline 
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correlation for mCG only. This seems due to the high redundancy with Dnmt3s and it has been 
known, that the maintenance methylation, especially of repeats, is highly dependent on the Dnmt3 
enzymes (Kim et al. 2002; Chen et al. 2003; Liang et al. 2002). In my observations, Dnmt3s 
indeed seem the main driver for DNA methylation. Moreover, it has been shown that Dnmt1 does 
not copy effectively the moderately methylated regions like imprints, and its activity is highest in 
densely methylated sequences, which makes it unreliable at regions with intermediate methylation 
(Lorincz et al. 2002). This suggests that the role of Dnmt3s in maintenance is essential and this is 
not the domain of Dnmt1 only, as has also been proposed recently (Jeltsch & Jurkowska 2014). 
Interestingly, my result argues against any independent purely de novo activity of Dnmt1.  
Dnmt3L shows a definite correlation with mCG in ES cells, and potentially with mCA. No 
correlation with methylation levels was found for Np95, pointing to a weaker role in mES cells, 
which is surprising given their high replication rates, in comparison to adult tissues. However, 
Np95 is a large enzyme, an E3 ubiquitin ligase, with roles outside of DNA methylation, including 
chromatin modifications, heterochromatin reorganisation and DNA damage repair (Mistry et al. 
2008; Nishiyama et al. 2013; Papait et al. 2007). This is a possible reason why its levels could not 
be directly linked with DNA methylation levels.  
 
My findings about the potential resistance of mCH marks to active demethylation are 
intriguing and open new questions and perspectives for follow up work. This is a property that 
currently clearly distinguishes the mCH from the mCG mark, and if it could be validated in vivo 
during the process of active demethylation in the early embryo, this would finally constitute a 
functional significance of non-CG context methylation.  
Although promising, the possibility that mCH methylation affects AID activity in the zygote 
is not clear, given that more than 90 % of the WRC sites remain unmethylated in the maternal 
genome. There are a few ways in which this could affect globally the AID activity, beyond the 
direct physical blockage of preferred target site. It is possible that the AID enzyme, similarly to 
Dnmt1, is sensitive to overall DNA methylation quantities for a wider region, and responds with a 
change in activity if a number of AID sites are methylated above a certain threshold. Another 
option is that the high CA methylation could be changing the physical properties of DNA, by 
making it less accessible for AID. This effect could be achieved with a small number of 
modifications and will affect a wider span of sequences on a global scale. It is known that AID 
works only on single stranded DNA, and hence its activity is high when DNA strand separation is 
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possible and DNA is in an open and accessible state as is the case during transcription (Brar et al. 
2008; Parsa et al. 2012). On the other hand, methylation has been shown to modify very 
dramatically the mechanical properties of DNA, by changing flexibility, stabilising strand 
duplexes and affecting DNA breathing dynamics (Severin et al. 2011; Shimooka et al. 2013). 
Moreover, it is possible that mCH context methylation induces conformational changes (kinks) in 
the nuclear DNA, as it has been shown to do in solution in vitro (Shimooka et al. 2013; Johannsen 
et al. 2014). Such changes will certainly affect the overall DNA properties and local micro-
environment, including strand coiling and tension. Many proteins’ binding capabilities are 
affected by such factors (Alexandrov et al. 2012), and it has recently been shown that AID in 
particular relies on DNA breathing and negative supercoiling to access its single strand substrate 
(Parsa et al. 2012). It is therefore very likely that this scenario of high mCH methylation on the 
maternal pronucleus, but not the paternal, will have an effect on the activity of AID. The 
experimental approaches to address this directly though, remain very challenging due to the 
difficulty to generate a mCH-KO cell without affecting CG methylation.  
 
In summary, I was able to address in higher depth the question about the role of Dnmts in 
the establishment of CH methylation, and showed that this process is regulated rather than 
unspecific. In addition, I uncovered an area of potential distinction between CG and CH 
methylation in their capacity to be (or not) actively removed, which may have profound impact on 
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 7 Functional significance of non-CG methylation 
 
7.1 Introduction 
In this chapter, following the insights from my work on the overall characteristics of non-
CG methylation, I will address the question of its potential biological significance. Since the 
process of its establishment by the Dnmts seems highly regulated, it is also likely that there is a 
functional significance associated with non-CG methylation. So far, CH methylation in ESCs has 
been associated with highly expressed genes (Lister et al. 2009; Ficz et al. 2011), although exactly 
the opposite has been reported for the mammalian brain (Lister et al. 2013; Guo et al. 2014). My 
findings indicated a strong correlation with Dnmt3a2, the so called ‘euchromatic’ 
methyltransferase, supporting an association with gene expression in mESCs, and so do my IF 
results for its nuclear distribution in ES cells (Figure 52 and Figure 41). It would therefore be 
justified to investigate this further, for a validation as well as a deeper insight into this association, 
to correlate the genomic distribution of non-CG methylation with histone marks. It is currently not 
known whether CH methylation is a consequence, an unrelated concomitant event, or a factor 
determining active transcription.  
Because of the strong connection of CH methylation with ES cells, to the extent that the re-
reacquisition of non-CG context methylation is seen as a hallmark of a completed pluripotent state 
reprogramming for iPS cells (Lister et al. 2011), it will be important to find out how depletion of 
mCH affects stem cell pluripotency. This is of course very challenging due to the lack of 
conventional pathways to create mCH knockout systems. If mCH is indeed related to 
pluripotency, this also opens the question of protein binders, which can read this mark, as there 
are such for CG methylation.  
I have therefore incorporated those aspects into my last aims of the project, to address as 
much as technically possible subject to time constraints for this thesis.  
 
7.2 Aims  
5. To correlate the mCH mark with histone modifications and protein binders using 
published ChIP-seq datasets  
6. To look for protein readers of CH context methylation via direct nuclear pull-down 
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7. To analyse the effect of reduced non-CG methylation levels on the pluripotency status 
of mouse ES cells  
 
7.3 Results 
7.3.1 Correlation of mCH with histone marks and pluripotency factors 
In order to gain further insights into the functional significance of non-CG context 
methylation, and be able to add more meaning to my previous findings, I first wanted to correlate 
non-CG methylation with histone marks, and also compare its genomic overlap with the binding 
profiles of proteins of interest. For this purpose, I performed MeDIP-seq with my mCG and mCA 
antibodies for J1 and E14 WT mESCs. Building on the experience from Chapter 3, I modified the 
MeDIP analysis and library preparation procedures in a couple of ways. First, by incorporating 
additional normalisation controls – one ‘Input’ sample (non-precipitated mouse gDNA), and one 
sample of an unmethylated in vitro amplified mouse genomic DNA. Secondly, all samples were 
TrueSeq barcoded and pooled in equal quantities, so that they were subjected to the 
immunoprecipitation together. The idea was to avoid the accumulation of artefacts in the less 
methylated samples, similar to the case with TKO in Chapter 3, by introducing a competition 
between the samples with varying amounts of 5mC. This modified approach ensured that both the 
sequence specificities and antibody pull-down artefacts will be taken into account and subtracted 
by the peak calling algorithm. Additionally, specifically for the mCA MeDIP data, to be extra safe 
Simon Andrews (Babraham Bioinformatics) filtered out the high CA genomic content, which 
seemed to be giving higher false positive signal (> 200 CA per 3kb). During the analysis, the 
mCG data was filtered in the same way, to ensure that I will be comparing the same sequences in 
both datasets, and no technical variability will arise from that.  
I first explored the correlation with histone marks. I retrieved datasets from published 
studies on a selection of histone modifications, for which there were available datasets for 
mESCs. I mapped the localisation of my mCG or mCA peaks by the widely used MACS peak-
caller (Zhang et al. 2008) and saved those genomic locations as genomic coordinates, which were 
then overlayed by the ChIP data. Where possible, more than one dataset was used to ensure a 
higher validity. ChIP-seq peak calling was performed in the same way, with Input or whole cell 
extract (WCE) used as a reference. The histone marks I analysed and the genomic signature they 
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were associated with are listed in Table 9, and the source datasets are listed in Table 22, 
Appendix.  
 
Table 9. Histone modifications analysed and their corresponding genomic signatures.  
 
 
A          H3K4me3 B          H3K4me1 C          H3K27ac D          H3K79me2 
    
    
E          H3K4me3 F          H3K4me1 G          H3K27ac H          H3K79me2 
    
Figure 58. Correlation of mCA (A-D) and mCG (E-H) methylation with active histone modifications. 2kb 
flanking regions are displayed on both sides of the mCA or mCG peak, which is in the middle panel of 
each graph. A, E: H3K4me3; B, F: H3K4me1; C, G: H3K27ac; D, H: H3K79me3. The blue line represents 
the coverage trend plot of each histone mark, and the red line is the control (WCE) for comparison of 
background.  
 
From the active marks, the strongest correlation for mCA was observed with H3K4me3 
(Figure 58A). There was a very slight trend for H3K4me1, as well as H3K27ac, and absolutely no 
Active Signature
H3K4me3 Actively transcribed gene bodies, around TSS and transcriptional initiation
H3K4me1 Inactive/poised enhancers
H3K27ac Active enhancers
H3K36me3 Gene bodies, transcriptional elongation
H3K79me2 Epithelial to mesenchymal transition genes (MEF), some hosuekeepng genes (ES) 
Repressive Signature
H3K9me3 Constitutive heterochromatin
H3K27me3 Facultative heterochromatin, bivalent domains in ESC
H4K20me3 Pericentric heterochromatin, imprinted regions and IAP retrotransposons
H3K36me3 Some constitutive heterochromatic loci
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correlation with H3K79me2 (Figure 58B, C and D). Interestingly, for mCG the trends were 
exactly the opposite: strong negative correlation with H3K4me3, slight negative trend for 
H3K4me1 and H3K79me2, and not for H3K27ac (Figure 58E-H). The H3K36me3 mark, which 
marks both active and repressive chromatin, is analysed with the repressive marks.  
From the repressive marks, there was no correlation for mCA with H3K9me3, a marked 
negative correlation with H3K27me3, and no correlation with either H3K20me3 (borderline 
negative) or H3K36me3, both colocalising with pericentric heterochromatin (Hemberger et al. 
2009; Chen et al. 2008) (Figure 59A-D). This result was surprising given the partial colocalisation 
of mCA with heterochromatic foci in both primed and naïve mESCs. For mCG there was no 
correlation with H3K9me3, nor H3K27me3 and H3K36me3, and a borderline positive one for 
H3K20me3 (Figure 59A-D).  
 
A          H3K9me3 B          H3K27me3 C          H3K20me3 D          H3K36me3 
    
    
E          H3K9me3 F          H3K27me3 G          H3K20me3 H          H3K36me3 
    
Figure 59. Correlation of mCA (A-D) and mCG (E-H) methylation with repressive histone modifications. 2kb 
flanking regions are displayed on both sides of the mCA or mCG peak, which is in the middle panel of 
each graph. A, E: H3K9me3; B, F: H3K27me3; C, G: H3K20me3; D, H: H3K36me3. The blue line 
represents the coverage trend plot of each histone mark, and the red line is the control (WCE) for 
comparison of background. 
 
To validate this result, I co-stained J1 WT mES cells with mCA and the same panel of 
histone marks and DNA binders. Unfortunately, the co-immunostaining worked for few of the 
histone marks, and for none of the proteins. This is because the IF procedure for DNA 
modifications requires treatment with concentrated HCl which denatures all proteins. For this 
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reason the co-staining procedure is in fact two independent IF protocols - first for labelling the 
intact proteins/histone marks and subsequently for labelling the DNA modification. In order to 
avoid degradation of the antibody-labelled protein from the first round, before starting the 
protocol with HCl the fixed cells on the slide are cross-linked with 2% PFA a second time. This 
works in some cases but for many cases it does not give enough protection against HCl and the 
signal from the labelled proteins is destroyed before the final imaging. In other cases, the over-
fixation does not allow the DNA methylation antibody any more access to the chromatin. I 
managed to successfully co-stain with H3K4me3, H3K9me3 and H3K36me3, and the results are 
presented in Figure 60. 
 
 
Figure 60. Immunofluorescence of WT J1 mES cells. Red: mCA, Green: histone mark, as labelled (left 
panels). The colocalisation of both marks was visualised in ImageJ and plotted in yellow over the pattern 
for mCA (right panels). White arrows indicate heterochromatic sites of colocalisation of mCA and the 
histone mark. IF by Fátima Santos.  
 
mCA showed much less overlap with the H3K9me3 and H3K36me3 marks than with the 
H3K4me3 (Figure 60, lower panels). It was interesting to note, that while few of the 
chromocentres which stained for mCA overlapped with H3K9me3, most of them overlapped with 
H3K4me3 or H3K36me3, which are also partially localised in the chromocentres, although not as 
pronounced as H3K9me3. The localisation of H3K4me3 in pericentric foci might explain why the 
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ChIP data did not show strong overlap between mCA, clearly present in the major satellites, and 
other pericentric marks like H3K20me3, pointing out that the localisation of those two marks on 
the pericentric foci could be mutually exclusive.  
Because of the association of mCA with active transcription, I plotted Pol II binding sites, 
and also nascent mRNA transcript coordinates (nuclear run-on, GRO-seq), which correspond to 
sites where Pol II is engaged in nascent transcription or paused (Min et al. 2011). Pol II showed 
an interesting enrichment pattern, on the borders on mCA peaks, and no enrichment for mCG 
(Figure 61A-B). Surprisingly, the GRO-seq nascent RNA transcripts data gave negative 
correlation with mCA, and slightly negative for mCG (Figure 61C-D). 
 
A         Pol II : mCA B         Pol II : mCG C      GRO-seq : mCA D      GRO-seq : mCG 
    
    








Figure 61. Correlation of mCA and mCG methylation with transcription. A, B: Pol II; C, D: GRO-seq; The 
blue line represents the coverage trend plot of each histone mark, and the red line is the control (WCE) for 
comparison of background. E. Scatter plot between H3K4me3 enrichment and peaks of nascent 
transcription. F, G. Enrichment of low-H3K4me3 transcripts (F) and high-H3K4me3 transcripts (G) over mCA 
peaks. The blue line represents the coverage trend plot of the transcripts, and the red line is the H3K4me3 
enrichment, the green is background control (WCE). 
 
The GRO-seq data should correlate quite well with the H3K4me3 mark at the sites of active 
transcription and I looked further into this. Plotting the H3K4me3 enrichment over the nascent 
H3K4me3
GRO-seq
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RNA transcript coordinates, split the group into two types of nascent transcripts – a smaller group 
with high transcription and no colocalisation with H3K4me3, and a bigger highly transcribed 
group, which correlated with this mark (Figure 61E). It is possible that those groups represent the 
paused (no H3K4me3) and actively transcribed (with HeK4me3) PolII sites, which the GRO-seq 
dataset is composed of. The small transcription group without H3K4me3 showed negative 
enrichment for mCA (Figure 61F), while the transcripts marked by H3K4me3 also showed 
enrichment for mCA (Figure 61G). This interesting observation brought further insight with 
which types of transcription the mCA mark specifically correlated. 
 
I next plotted the mCA and mCG marks against different protein binding sites. I first looked 
at four of the major pluripotency related proteins – Nanog, Oct4, Sox2 and Stella (PGC7), the 
latter also implicated in early development and in PGCs. Interestingly, the three of four 
pluripotency factors showed enrichment for mCA but not for mCG, while Stella did not show any 
correlation with either mark (Figure 62A-D). None of the four factors showed any enrichment for 
the mCG mark (Figure 62E-H).  
 
A          Nanog B             Oct4 C           Sox2 D       Stella (Dppa3) 
    
    
E          Nanog F             Oct4 G            Sox2 H       Stella (Dppa3) 
    
    
Figure 62. Correlation of mCA (A-D) and mCG (E-H) methylation with pluripotency factor binding sites. 
2kb flanking regions are displayed on both sides of the mCA or mCG peak, which is in the middle panel 
of each graph. A, E: Nanog; B, F: Oct4; C, G: Sox2; D, H: Stella. The blue line represents the coverage 
trend plot of each histone mark, and the red line is the control (WCE) for comparison of background. 
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It is worth noting that the consensus recognition motifs for the positively enriched Nanog 
and Sox2 contain a CA site (Nanog: G__CATT__C, Sox2: CATTGT (Whyte et al. 2013)), but so 
does the consensus for Stella (CCYCAGSCTSS (Bian & Yu 2014)), verifying that the observed 
enrichments cannot be a sequence-based artefact.  
For comparison, I next analysed two factors unrelated to pluripotency – Tet3, with a role in 
the zygote, and a limited number of tissues such as brain, and the pro-differentiation factor Tcf3, 
which plays a major role in determining tissue-specific cell fate during embryogenesis (Wray et 
al. 2011). Tet3 did not show any correlation with neither mCG nor mCA (Figure 63A, E), while 
the Tcf3 showed enrichment on mCA peaks, and a lower enrichment for mCG peaks (Figure 63B, 
F). While Tet3 is a known CG binder, the binding site of Tcf3 also happens to have a CA motif 
(E-box motif: 5'-CANNTG-3', Uniprot). This time the control showed slight enrichment meaning 
that some of the signal might be sequence background, although the real signal is clearly stronger. 
This result pointed out that mCA correlates not only with pluripotency factors, but also with 
differentiation factors, and this might be related primarily to their consensus binding motifs in 
addition to each protein’s sensitivity towards methylation.  
 
A        Tet3 : mCA B        Tet3 : mCG C        Tcf3 :  mCA D        Tcf3 :  mCG 
    
Figure 63. Correlation of mCA and mCG methylation with early development (Tet3) and differentiation 
factors (Tcf3). The blue line represents the coverage trend plot of each histone mark, and the red line is the 
control (WCE) for comparison of background. 
 
 
7.3.2 Identifying protein binders for non-CG context methylation 
The identification of protein binders for mES cells was done in collaboration with Michiel 
Vermeulen (Utrecht University). They have recently optimised a quantitative SILAC-based 
technique for identification of protein binders from nuclear extracts, explained in detail in 
Appendix Figure 75. The concept is that the nuclear extracts are labelled isotopically prior to their 
incubation with a DNA bait of a chosen sequence, and compared against a control DNA incubated  













Figure 64. Validation of a second bait for a protein binders experiment. A. Identification of L1_Mus1 in 
the MspJI meRRBS datasets (left) and validation in high depth WGBS dataset. B. Methylation rate of the 
same CAG position #16 in all L1_Mus1 motifs within the mouse genome. C. A genomic distribution of 
instances of L1_Mus1 which show methylation at #16 CAG. D. Methylation percentage binning for the 
L1_Mus1 CAG position, a comparison with CG is shown, demonstrating a predominant CHG methylation of 
this region. GAII and HiSeq are two parallel datasets for WT mESC (Stadler et al. 2011).  
 
with unlabelled extracts (forward reaction). This is done twice per bait, and in the second reaction 
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allows a precise quantitative comparison of the bound proteins to the bait, and also the 
identification of proteins repelled by the bait (bound to the control) with high statistical 
confidence.  
For statistical validity, our experiment was performed with two DNA baits – one sequence 
from the major satellite repeat, with a previously validated in vivo methylated CHH (CAC) 
position, used also in the validation of the mCA monoclonal antibody in Chapter 4. The second 
one was chosen specifically for this study. For this purpose I used my MspJI meRRBS dataset and 
identified top positions with highest number of methylation calls (>20). Not surprising, one of 
them was the major satellite, as discussed also in Chapter 5 (Figure 40), and several more 
candidates, out of which the LINE L1_Mus1 element was the only one which belonged to a 
known genomic feature and was ES cell specific (not enriched in pMEFs) (Figure 64A, left). It 
was also in the CHG (CAG) context, which was desirable provided my other bait was in CHH, 
especially since CHG is more highly methylated in ES cells (Lister et al. 2009; Ziller et al. 2011). 
Moreover, I was able to successfully validate the methylation of this position on the same locus in 
a high depth WGBS from mESCs (Stadler et al. 2011) (Figure 64A, right).  
Additionally, I used the BS-seq data to also analyse the genomic occurrence of the 
L1_Mus1 element and calculate the genome-wide methylation rate of this repeat, on that same 
CHG position (Figure 64B). More than 6000 sequences containing this 28 bp consensus were 
present in the mouse genome (Figure 64C) and more than 10 % were methylated on this CHG 
position, reaching a maximum of 60 % methylation in a selection of ~20 motifs (Figure 64D).  
 
Next, the protein pull down was performed by our collaborators with the two mCA 
methylated baits, and their corresponding unmethylated controls (Table 5, rows 1,3, 9 & 11). We 
were hoping that both baits would show, to some extent, similar results, so we could identify 
universal mCA binders, alongside the sequence-specific readers, which will have preference for 
the flanking sequence. At this first round of pull down, we identified a few sequence specific 
binders, enriched for the methylated control (readers), and a few which were clearly repelled by 
the methylation (repellers). Interestingly, the proteins differed for the L1 and major satellite probe, 
demonstrating that most proteins would have flanking sequence preferences, and, most likely, 
there were no universal mCA readers. For the major satellite probe the definite binders were 
MeCP2, Foxk1, Foxk2 and an unknown zinc-finger protein Zfp646, and the repellers were three 
zinc-finger proteins (Zscan4f, Zbtb43 and Zbtb22) (Figure 65, upper panel). The primary function 





Figure 65. Protein pull-down result for the major satellite (upper panel) and L1_Mus1 probe (lower panel), 
in an ‘mCA against CA’ experiment. The top right corner shows the specific mCA readers, while the bottom 
left corner shows the proteins repelled by mCA. 95 % confidence intervals are shown by the box plots 











































and information about those proteins are summarised in Appendix, Table 23 and Table 24. With 
marginal statistical significance among the binders were the pluripotency factor Oct4, an RNA Pol 
I and II subunit Polr1c, a splicing factor Puf60 (Poly-(U)-binding-splicing factor), and a 
homeobox protein Six4. This result was interesting and validated my bioinformatic observation 
for mCH enrichment over Oct4 binding sites, while Sox2 was also among the mCA binders 
although it did not reach statistical significance. Interestingly, as statistically marginal repellers 
we found all three subunits of RPA (Replication protein A), the well-described cofactor of AID, 
which facilitates its deamination function during the somatic hypermutation in B cells (Chaudhuri 
et al. 2004; Weill & Reynaud 2004). RPA has an important role in UNG2-mediated BER also as a 
direct recruiter of UNG2 to facilitate the fast removal of uracil from AID-mediated deamination 
sites (Otterlei et al. 1999; Dianov et al. 1999; Doseth et al. 2012). This finding is very appealing 
in the light of my hypothesis for the role of mCH in inhibiting active demethylation through BER. 
The L1_Mus1 probe gave much fewer interactors, Zbtb10 as a single reader above the 
significance threshold (unknown function), and Pcpb3 (Poly-(C)-binding protein 3), as a single 
repeller (Figure 65, lower panel). With marginal significance were the pluripotency factor Dppa2 
(Developmental pluripotency-associated protein 2), and the mitochondrial Dlst (function in 
oxoglutarate-succinate metabolism). A marginally significant repeller was the splicing factor 
HnrpII (Appendix, Table 23 and Table 24).  
 
I then did a functional association analysis of the reader and repeller groups of proteins for 
both probes, including the statistical marginals, and performed clustering on the DAVID web 
server (http://david.abcc.ncifcrf.gov/) (Huang et al. 2007) for the given gene ontology (GO) and 
association terms. Interestingly, the mCA readers grouped in one big cluster, strongly associated 
with positive transcriptional regulation and alternative splicing (Figure 66, left panel; raw data in 
Table 25, Appendix). In addition, there was a small cluster for DNA binding-associated GO terms 
without any particular known function. The annotations of the repellers however clustered into 
more groups – the two highly scored groups were for replication and DNA repair, and 
transcriptional regulation (not specifically positive in this one) (Figure 66, right panel; raw data in 
Table 26, Appendix). Two smaller groups formed for non-DNA related GO terms in cluster #3 
and one group of unclustered terms, mainly associated with DNA and RNA binding.  
 





Figure 66. A schematic representation of biological function associations for the mCA binders and 
repellers. The full lists of GO terms and associations can be found in Appendix Table 25 and Table 26. 
 
It was curious that MePC2 was pulled down as a mCA binder, being also one of the main 
mCG binders. In order to validate this result I performed an in vitro binding assay between 
MeCP2 (methyl-binding domain only) and the same major satellite probe, in an avidin-biotin 
ELISA format.  
 






Figure 67. In vitro binding assay of the recombinant MeCP2 protein and DNA fragments with varying 
methylation context. Only the methyl-dinging domain (MBD) of MeCP2 was used. A. Kinetic curve of the 
binding to the WT MeCP2 in variable amounts, and a section at 0.5 ug/well with statistical significance of 
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My result confirmed the binding towards mCA, and importantly, this was the preferred 
substrate in comparison to symmetrically and hemi-methylated mCG substrate (Figure 67A). The 
background binding to unmethylated CG-containing fragment was low, but the binding towards 
CA-containing unmethylated oligo was higher. To test the validity and specificity of this 
interaction an inactive R111G MeCP2 mutant (Free et al. 2001) was used in the assay and found 
not to show any residual background binding to any of the fragments (Figure 67B). This would 
suggest that the CA vs CG underlying sequence might be the reason, and not the methylation 
itself, towards the highest affinity to mCA. For that matter, the crystal structure of MeCP2 bound 
to DNA shows that MeCP2 introduces bending to the DNA upon its binding, and the possibility 
that CA context might be slightly curved (Shimooka et al. 2013) could give an explanation for this 
result and MeCP2 binding preference (Ho et al. 2008).  
 
7.3.3 Effect of global mCH decrease on pluripotency in mESC 
In order to test how the loss of mCH would affect ES cells, we would need to abolish the 
function of the enzyme(s) responsible for its establishment, according to the classical approach. 
However, in the case of non-CG methylation this poses an immense challenge because abolishing 
the activity of Dnmt3a or Dnmt3b, the enzymes responsible for its establishment, results in a 
strong decrease of CG methylation. However, it is known that Dnmt3a/3b-DKO cells lose their 
methylation progressively and early passage cells have considerable CG methylation (Chen et al. 
2003). Based on my results in Chapter 6, I hypothesised that the CH methylation will decrease 
faster upon their simultaneous knockout, than the CG methylation, because of the mCG 
maintenance role of Dnmt1. This means, that there will be a window immediately after knockout 
where the CG methylation is unchanged but the non-CG is decreased or completely abolished. We 
therefore obtained Dnm3a and Dnmt3b conditional DKO mES cells, inducible upon tamoxifen 
treatment. After knockout induction, the cells grew very slowly and were terminated at day nine 
post knockout, with three time points taken in total – at day 3, day 6 and day 9. The global 
methylation estimates for CG and CA at each time point revealed that the mCG indeed did not 
change even until day #9 (Figure 68A). mCA, on the contrary, decreased and reached a stable but 
not zero level at day #6 after induction of  deletion. Provided there is no maintenance of mCA, 
and the ES cells divide at their usual rates of every 16 hours, by day #3 (72hr) CA methylation 
should have reached levels less than 10% of its original amount. The cells, however, grew much 
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slower, and they reached their lowest point at day #6, which is not too surprising given the very 
slow growth rate. It is disappointing that the decrease did not continue after day #6. Nevertheless, 







                           C 
 
Figure 68. Dnmt3a and Dnmt3b double knockout (DKO) inducible mES cell line – time course post KO-
induction. A. Global mCG (left panel) and mCA (right panel) levels, compared with a control from non-
induced cells grown in parallel. B. RT-qPCR of the three time course points for all Dnmt enzymes and Np95 
(without Dnmt2). C. RT-qPCR for all Dnmt enzymes and Np95 (without Dnmt2) of constitutive Dnmt3a and 
Dnmt3b single- or double-KO, together with E14 mES cells grown in 2i (with or without VitA). 
 
I next measured the expression of all Dnmts and the other proteins involved in DNA 
methylation, including Dnmt3L and Np95. As expected, both Dnmt3s were downregulated, 
although this was much more pronounced for Dnmt3b (Figure 68B). This might mean that there is 
still mRNA remaining from Dnmt3a, since both transcripts (3a1 and 3a2) did not drop more than 
4-fold from WT levels. I therefore compared with the expression levels in our constitutive Dnmt-
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68C), provided we have all evidence that the proteins are not there (results not shown). 
Interestingly, Dnmt3b levels were slightly higher than in the constitutive knockouts, ranging 
between 2^-(6÷8) log scale values, rather than 2^-(8÷10), which might explain why the decrease 
in mCA levels was not 100% complete. In my comparison I also included ground state ES cells, 
grown for a week in 2i, which have been shown to downregulate both de novo Dnmts upon 
ground state reprogramming (Ficz et al. 2013; Leitch et al. 2013; Habibi et al. 2013; Hackett et al. 
2013) (Figure 68C). Reprogramming from the primed ES cell state to ground (naïve) pluripotency 
is achieved after swapping culture media from classical serum + LIF ES medium, to a 
standardised medium containing two inhibitors for the Erk1/2 and Gsk3β signalling pathways 
(henceforth termed ‘2i’) (Nichols et al. 2009; Wray et al. 2011).  
The original 2i medium contains Vitamin A, which generates retinoic acid, one of the 
known differentiation and growth factors. To assess whether or not this makes a difference, I also 
included in the comparison also cells grown in medium without Vitamin A, together with cells 
grown in the original medium (marked as ‘+Vit A’). The levels of decrease of Dnmt3a2 but not 
Dnmt3b transcripts in my conditional 3ab-KO on days #6 and #9 seemed very similar to the levels 
of Dnmt3a2 in ground state ‘2i’ ES cells (~2-fold decrease on a log2 scale). However, Dnmt3b 
was much more downregulated in the DKO, and the characteristic downregulation of Dnmt3L in 
the naïve state (Leitch et al. 2013) was not observed in the conditional DKO (neither in the 
constitutive KOs).  
 
I next wanted to evaluate how a decrease of mCH would affect the pluripotency state of the 
conditional DKO mES cells. Because of the similarity with ground state ES cells in the 
downregulation of Dnmt3 expression, I measured the mCA and mCG levels in the naïve ES cells 
for comparison. It is known that naïve ES cells decrease mCG quite drastically during their 
transition to ground state, but it has not been clear whether this is the case with their mCH levels.  
Since the demethylation of naïve ES cells is due to a downregulation of the de novo 
machinery and not the maintenance (Ficz et al. 2013; Leitch et al. 2013; Habibi et al. 2013; 
Hackett et al. 2013), which is also confirmed in my experiment (Figure 68C), the expectation was 
that mCH will also be down, if not completely abolished. However, my ELISA measurements 
showed, that while mCG was decreasing in the time course of serum to 2i, the mCA levels 
fluctuated but did not decrease (Figure 69A and B). There was a slightly more pronounced 
decrease of mCG in the cells grown in the original 2i medium, than the cells without Vit A, but  









Figure 69. Global mCG (A) and mCA (B) levels in E14 WT cells’ time course towards ground state 
reprogramming. The fluctuation in mCA was estimated as not statistically significant with 1way ANOVA 
applying Dunnett's Multiple Comparison Test for each value against the Control value. C. mCH levels 
measured in published WGBS datasets; the conversion controls and the MII oocyte values are given for 
reference. D. IF for mCG (left panel) and mCA (right panel) on E14 WT mESC grown in Serum/LIF and 2i 
(~1week). IF by Fátima Santos. 
 
there was no significant change in mCA in either case. I estimated mCH values in two sets of 
published datasets for WT mES cells in primed (serum) and ground (2i) state and although the 
datasets from pooled DNA did not show any difference (Ficz et al. 2013), the single cell 
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(Figure 69C). This difference might be due to culturing conditions or more likely to the nature of 
the methylome data – single cell versus pooled ES population, and nevertheless, due to a high 
inter-cell variability and value overlap, the overall difference in 2i vs serum is not high. I 
validated those results with IF, and again a decrease in mCA was not observed, on the contrary to 
mCG (Figure 69D). Notably, the pattern of mCA was as heterogeneous as for primed ES cells, 
observed also in the single cell methyomes in Figure 69C. The nuclear distribution was quite 







Figure 70. Expression of pluripotency factors and developmentally related genes. A. Expression in the 
panel of Dnmt3a/b constitutive KOs, the inducible 3ab-DKO (day #9) and naïve ES cells grown with or 
without Vitamin A. Arrows point to genes in which the inducible DKO behaves like 2i cells (blue arrows) or 
like the constitutive de novo KOs (purple arrows). B. Changes in expression during the three time points 































I next analysed the expression of a panel of transcription factors in my conditional DKO 
time course and all of the constitutive KOs, and compared those against the 2i (1 week) cells. I 
chose a selection of pluripotency related genes, including a group of Tet1/2-regulated genes (Ficz 
et al. 2011). All constitutive Dnmt-KOs showed similar patterns of expression within their group, 
but there were also clear similarities to the 2i ground pluripotency state, mainly in the 
upregulation of Stella and Prdm14 (Figure 70A). The rest of the pluripotency factors, however, 
showed some major differences arising from the overall upregulation in 2i but not in the 
constitutive Dnmt-KOs (like Nanog, Klf4, Esrrb, Klf2, F6xo15), while the Tet enzymes were 
generally downregulated in 2i but not in the constitutive KOs.  
It was therefore interesting to observe, that the long-term conditional DKO (day #9) showed 
more similarities to the 2i cells than the other Dnmt-KOs (Figure 70B). It was probably due to the 
fact that its mCG levels were completely normal (at least equal to primed pluripotent WT ES 
cells) and therefore gene expression will not be aberrantly affected as in the constitutive KOs. 
However it was very intriguing to observe that the 60 % overall downregulation of mCH alone is 
driving this effect. In terms of global cellular methylation levels, this decrease amounts to roughly 
15 % overall decrease of methylation; for comparison, the global decrease of methylation in long 
term 2i cells (>3 weeks) is around 50 % (Ficz et al. 2013). However, the main difference here, in 
addition to the 3-fold difference in overall levels, is the fact that in 2i this decrease comes from 
the CG context, while in my conditional DKO it is solely due to non-CG context.  
 
7.4 Discussion 
In this chapter, I undertook a few different approaches in order to investigate the functional 
significance of non-CG methylation. Each approach was successful in revealing a different aspect 
of the functional potential of the mCH mark.  
My findings from the correlation with histone marks confirmed the strong connection 
between mCH methylation and transcription. Moreover, they revealed that there are functional 
sub-regions within the mCH ‘domain’ and they correlate with different and potentially non-
overlapping marks. mCH has been previously associated with gene bodies (Lister et al. 2009; Ficz 
et al. 2011). However, the strongest correlation according to my MeDIP versus ChIP comparison 
was not with the typical gene body modification H3K36me3, but with H3K4me3. H3K4me3 is 
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also an active mark, and it localises to transcription start sites of active genes (Okitsu et al. 2010; 
Lauberth et al. 2013). Together with H3K27me3 it defines the so called ‘bivalent’ loci 
characteristic for ES cells only, which define genes as temporarily paused for transcription 
(Bernstein et al. 2006). However, mCH shows a strong negative correlation with H3K27me3, 
suggesting that it is not characteristic for the bivalent genes, but only the actively transcribed 
genes with H3K4me3. In addition, the overlap with the nascent strand enrichment showed that not 
all H3K4me3 associated genes overlap with CH methylation either, but only the actively 
transcribed group, and not the paused genes. The IF co-staining profiles revealed that large 
sections of mCA remain not correlated with H4Kme3. Some of the pericentric staining 
colocalised with H3K36me3, which is known to localise to pericentric chromatin in addition to 
gene bodies. 
There was no positive correlation observed for mCA with neither of the repressive marks, 
apart from a slight overlap with H3K9me3 at some of the pericentric loci, as shown by IF (Figure 
60). This is interesting, given that in plants non-CG methylation correlates most strongly with 
H3K9 methylation, and inversely with active marks like histone acetylation, as discussed in 1.5 
(Stroud et al. 2014). For these features and its overall correlation with active transcription, non-
CG methylation in mammals, or at least in ES cells, seems unrelated to its counterpart in plants.  
Positive correlation was observed for major pluripotency factors, as well as proteins 
involved in differentiation, potentially governed by the consensus recognition motif of each 
protein. Indeed, our IF co-staining attempts failed to produce meaningful results for a validation 
of these observations, although the positive link between our protein pull down experiment and 
the MeDIP/ChIP overlap was very encouraging and strengthens the observations. Also, the two IF 
co-staining experiments which worked entirely support the MeDIP/ChIP result. However, it is 
undoubtedly necessary to validate further those correlations experimentally either by more 
attempts for co-localisation in IF, co-IP experiments or in vitro binding assays.  
 
With the help of our collaborators, we further identified experimentally a panel of proteins, 
which either bind with high affinity or are repelled by mCA. The strongest amongst the binders 
was the known methyl-cytosine reader MeCP2, which surprised with its high in vitro affinity to 
mCA. A recent study confirmed its binding to non-CG context methylation in neuronal cells, 
where MeCP2 is very highly expressed and important for differentiation (Guo et al. 2014). It is 
important to note that MeCP2 is implicated in various pathological conditions, if mutated, which 
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opens the intriguing possibility that its binding to mCA contributes to any of those conditions. In 
addition, MeCP2 has been very well investigated and several mutants have been characterised, 
which affect its DNA binding capacity or its downstream effector functions (Free et al. 2001; 
Baker et al. 2013). It will be valuable to analyse those mutants for their ability to bind mCA, with 
the possibility to find a mutant, which binds only to mCA but not mCG or vice versa, and could 
serve as a very valuable tool for the functional study of non-CG methylation.  
The rest of our binders were, like MeCP2, strongly related to tissue differentiation (Foxk1, 
Foxk2, Six4, Creb1), or pluripotency, like the classical pluripotency marker Oct4 and the 
pluripotency and cancer associated Dppa2. It is interesting that all binders clustered within one 
group of active transcriptional regulators, supporting my numerous previous associations of mCA 
with active transcription. A number of proteins, both among the binders and the repellers (Puf60, 
HnrpII, Ptbp1), were related to splicing, which is interesting in the light of reports, which connect 
CH methylation to mRNA splicing (Guo et al. 2013). As a whole, all of these proteins fall into the 
wider area of transcriptional control, including the PolI and III subunit Polr1c, which implies a 
role of the mCH mark in transcriptional regulation. Among the repellers, three showed a 
connection to telomere maintenance and a role in telomere elongation in early development 
(Zscan4f, Hnrnpd and RPA), which is globally related to the fine-tuning of the maintenance of the 
pluripotency state and developmental progression. All of these point to a potential role of mCH in 
the regulation and diversification between pluripotency and differentiation. 
It is curious to note, that the major satellite probe yielded a higher number of both readers 
and repellers, despite its shorter size, which demonstrated that the major satellite is a potentially 
stronger recognition target for many proteins. This is probably due to its high abundance in the 
nucleus, and importance for global genomic organisation and stability. It also revealed that DNA 
binding proteins are in general very sequence specific, even if they are sensitive to DNA 
methylation.  
Among the repellers, the presence of the AID cofactor RPA with all of its three subunits 
was undoubtedly the most exciting result. This result strengthens the hypothesis of mCH-
dependent resistance to demethylation by AID-mediated BER, and sheds another perspective, by 
showing that AID itself might not be the only protein in the pathway which is affected by high 
levels of mCH. If mCH prevents DNA binding of more than one of the initiator proteins for BER, 
then it is very likely that the process will be affected. Moreover, RPA has been shown to assist the 
BER helicases in the unwinding of a short stretch of nucleotides upon long-patch BER initiation 
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(Ahn et al. 2009), which means that not just a methylated AID recognition WRC sequence could 
cause an inhibitory effect, but also if the mCA site is in a close proximity to the BER initiation 
site. Also, the RPA was repelled by an 18-bp long DNA fragment with an mCA site in the middle, 
meaning that the effect of one methylation site spreads across a longer stretch of sequence. It is 
intriguing to know how far this effect spreads on the neighbouring sequence. This finding already 
supports a previously predicted pathway (in Chapter 6), by which ~5 % of mCH in the female 
pronucleus could affect BER in a global genome-wide scale, by also affecting the accessibility of 
neighbouring DNA sequences. However, RPA has not been the only repeller associated with 
replication and repair in the nuclear pull-down, and the second largest repeller functional cluster 
was associated with transcriptional regulation, although not specifically in positive way as the 
result was for the mCA binders. 
 
My experiment with the conditional 3ab-DKO revealed that changes of mCH methylation 
on a global scale trigger phenotypes similar to phenotypes resulting from the global changes in 
CG context methylation. This overall loss triggered changes in gene expression, which are very 
similar to the effects resulting from global mCG loss, and in fact, it is very likely that the 
equivalent loss of 15 % mCG would have the same effect, if not even less pronounced. It has 
previously been reported that hypomethylation of ES cells leads to pluripotency ground state 
(Leitch et al. 2013), but it is novel to reveal that loss of mCH methylation alone can trigger such 
an effect. This demonstrates, that non-CG context methylation is not a ‘second class’ methylation 
mark, neither a mere meaningless result of a Dnmt3-mediated sporadic activity. For the ES cell, 
mCH methylation seems to be as meaningful as CG methylation, and the global loss of one or the 
other, leads to similar consequences. The notion of lack of function for mCH comes from the fact 
that direct locus-specific effects cannot be observed in the same way as for mCG, because of its 
very low sequence-specific enrichment levels (typically 2-10% vs 80% for mCG). This makes it 
very challenging to study in a cell population context, but for an individual cell each cytosine 
signal is binary – it is either methylated (100%) or not (0%), and this is irrespective of context. 
Whether the observed effect will also be true for the other mCH-high cell types, like oocyte and 
neurons, is not known.  
In addition, my observations show that naïve mES cells have a heterogeneous distribution of 
mCA. It has been reported that ground state mES cells represent a mixed population of pluri- and 
toti-potent cells (Morgani et al. 2013) and it would be important to find out if the mCA-high cells 
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fall exclusively within one of those two groups, or belong to both sub-populations.  
Lastly, it has been proposed that Prdm14 is the main negative regulator of Dnmt3b, which 
drives the global demethylation in serum>2i transition (Leitch et al. 2013). My result shows that 
the opposite could also be true and the depletion of Dnmt3b can lead to upregulation of Prdm14 
and trigger a naïve-like state. Certainly, more extensive genome-wide work would have to be 
carried out in order to compare comprehensively the mCH-knockdown state with the pluripotency 
ground state, including analysis on imprinted loci. For this purpose, it would be helpful to obtain a 
higher passage culture of the 3ab-inducible KO, at a point where mCH drops down to zero while 
mCG remains constant.   
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 8 General discussion and future perspectives 
 
Asymmetric non-CG methylation has long been recognised in the mammalian genome but 
its distribution, quantity and biological significance have remained very elusive. While a lot of 
work has been published in recent years, the majority of the focus has addressed the distribution 
and abundance of non-CG methylation. A lot has also been done in regard of the factors involved 
in its establishment, with most of the published data indicating Dnmt3a, one of the de novo 
methylases, as the main enzyme responsible for its occurrence. My work attempted to build on the 
current knowledge, by addressing the occurrence, quantity and its establishment mainly from the 
perspective of justifying a functional significance.  
 
Non-CG methylation is a very challenging biological phenomenon, veiled in mystery due to 
technical difficulties in studying it, masked by BS-conversion artefacts, and with a tendency to be 
ignored because of its very low context numbers, which for the most part look insignificant. 
Furthermore, the information which has been revealed so far, describes some conflicting 
characteristics, which have made it difficult to assign one clear function. Its highest distribution in 
mammals has been confirmed for four cell types: early maturation stage of paternal PGCs (E16.5) 
(Seisenberger et al. 2012; Kobayashi et al. 2013), maturing (late) and ovulated MII oocyte 
(Shirane et al. 2013; Tomizawa et al. 2011), embryonic stem cells (ECSs) (Lister et al. 2009; 
Stadler et al. 2011; Ziller et al. 2011) and the adult mammalian brain (Lister et al. 2013; Guo et al. 
2014). Among those, the ES cells have the lowest absolute and relative mCH amounts (Table 10). 
In addition, while in mESCs mCH has been associated with actively transcribed genes, in the 
brain it has been associated with transcriptional repression, in both cases as a function of its gene 
body distribution. In the ESCs and E16.5 male PGCs the mCH is a highly transient mark, while in 
non-replicating cells like the oocyte and the adult neuron it is a lasting long-term mark (if not 
permanent). It is not clear how this mark can be of potential equal importance both to the non-
replicative and to the highly dividing cells, especially when in the latter it is a very transient 
phenomenon, observed within a very short developmental window. A possible answer to this 
could be that there are a few different functional roles of non-CG methylation, a direct 
consequence of its molecular characteristics, which distinguish it from CG methylation.  
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Table 10. Summary of main characteristics of non-CG methylation according to cell type. 
Feature  \\  Cell type ESCs  16.5 PGCs Oocyte Brain (Neuron) 
Cell cycle positioning Replicating Replicating  Pre-replicative Post-replicative  
Potency Pluripotent Differentiating Totipotent 
 Terminally 
differentiated 
mCG (% CG)  60-70% 50%  40%  >90% 
mCH (% of all mC)  25 % 50%  65 %  35 % 




Methylase  Dnmt3a2 + Dnmt3b Dnmt3a2 + 3L  Dnmt3a2 + 3L  Dnmt3a 




8.1 A role in transcriptional regulation 
In agreement with the previously published observations (Lister et al. 2009), my results 
strongly point to a direct association of non-CG context methylation with active transcription, at 
least in mESCs.  
First, in both the germline and in mESCs, and most likely in the brain, mCH is established 
by the ‘euchromatic’ isoform of Dnmt3a – the shorter Dnmt3a2. Its nuclear localisation in mESCs 
looks also very euchromatic, much like the nuclear distribution of Dnmt3a2, spread throughout 
the whole nucleus with a very small proportion associated with heterochromatic foci (Figure 41). 
It remains to be established whether the mCH heterogeneity in the mESC population follows the 
heterogeneity of Dnmt3a2. Moreover, a comparison of genome –wide ChIP-seq data sets against 
my results links mCH most strongly with H3K4me3, including in the majority of instances where 
it localises to heterochromatic foci (Figure 60). It is somewhat surprising that it does not show any 
significant correlation to the four repressive histone marks I looked into. In contrast, there is a 
positive correlation with the two modifications associated with active enhancers - H3K27ac and 
H3K4me1. This behaviour is the opposite of what has been shown for non-CG methylation in 
plants, which is quite surprising, and could be interpreted as both did not have a common 
evolutionary origin and drivers.   
These associations are strongly supported by our protein binders assay, where all of the 
identified readers and repellers are related to transcriptional regulation, and the readers - to 
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positive regulation in particular (Figure 66). This is an important point, demonstrating that the CH 
methylation may not be merely a consequence of a more accessible to the MTases open DNA 
structure during transcription, but could be a factor in itself affecting the gene activity.  
More specifically, our mCA readers and repellers are related to the transcriptional control of 
either pluripotency or differentiation-related developmental processes, pointing towards a role in 
the diversification between the two states. These observations are functionally exemplified with 
our mCH-knockdown system, where a 60 % loss of global mCH triggered changes in gene 
expression, which resemble elements of a transition towards the ground state of pluripotency. This 
result is not very intuitive, given that naïve mESCs, reprogrammed in the classical way by 
switching serum/LIF to 2i conditions, do not lose their CH methylation. Its levels remain almost 
as high, and as similarly heterogeneous as in primed mESCs. This in itself is very surprising, 
given that naïve mESCs are known to be more homogeneous in their phenotype than the primed 
mES cell population. My results show that, while other aspects of the ground state favour a more 
uniform behaviour and quantitative distribution of pluripotency factors, they do not become 
homogenous in regard to their mCH methylation levels and distribution. The mCH values from a 
recent single cell whole-genome bisulphite analysis of ESCs grown in serum and 2i (Smallwood 
et al. 2014) confirm this observation (Figure 69C). The single cell analysis, however, shows a 
slight decrease in global levels of mCH methylation in the ground state, which will be beyond the 
sensitivity of the ELISA and IF employed here, and is not observed in other WGBS reports (Ficz 
et al. 2013).  
These observations together with earlier associations of mCH methylation with transcription 
would suggest a role in creating epigenetic heterogeneity and diversity in the ES cell population, 
similar to the heterogeneity of primed state mESCs, but occurring at an earlier developmental 
window. Whether this initial mCH heterogeneity contributes to a transition into the primed mESC 
state, later defined by changes in their CG methylation marks, is not known and could be the next 
question to address. This finding would suggest that an initial state of ‘priming’ could exist also in 
the naïve pluripotent state, and therefore may be part of the very definition of pluripotency, 
underlying the intrinsic ability of pluripotent cells to undertake diverse differentiation pathways.  
Naïve pluripotency is characterised by protection from de novo methylation (Leitch et al. 
2013). This definition could be adapted to include a low but important level of de novo 
methylation, maintained by the remaining low Dnmt3 levels, which create initial diversity and set 
the ground state for subsequent full-scale priming for future developmental events.  




8.2 Global methylation buffer 
While the individual mCH position seems an entirely valid methylation signal for the ES 
cell, due to the very low level of mCH methylation per single locus it seems that the effect of this 
methylation on a population level seems minimal, in comparison to the effect CG methylation 
could have. This suggests that one of the effects of non-CH methylation is in its ‘bulk’ levels, 
contributing to a globally higher state of methylation. On a genome-wide scale, the saturation 
capacity of the CG context is very low, since it occupies just 4 below % of the total cytosine pool 
in the mouse and human genomes. This means that the greatest quantitative effect of CG 
methylation could not exceed 4 %. In fact, this value would be somewhat less than a theoretical 
maximum owing to the need to factor in the majority of CGIs which need to remain 
unmethylated. The rest of the individual or non-promoter CGIs are normally methylated in most 
cell types, and therefore there is very little capacity for creating a change in global methylation 
levels, if the cell is restricted only to its CG context. In addition, these specificities of the CG 
context, together with its evolutionarily controlled genomic distribution, strongly limit the 
possibilities of creating diversity through the CG context methylation, except during large-scale 
reprogramming phases. Therefore, the nature and ‘power’ of non-CG methylation could reside in 
its absolute numbers, and its ubiquitous and unrestricted genomic distribution. As my IF (Figure 
41) and meRRBS feature enrichment results show (Figure 40), non-CG methylation is ubiquitous, 
and apart from CGIs and transcription start sites, it occurs everywhere throughout the genome. As 
such, this may offer a few benefits to the cell, especially to serve as an epigenetic buffer in 
instances when DNA methyl-transferase activity may be particularly high, such as in the oocyte 
and in ESC and during the re-acquisition of DNA methylation in foetal male germ cells. In those 
situations, CH context can take up a high extent of methylation activity on a global scale, without 
affecting significantly the expression levels of individual genes.  
Keeping global genomic methylation levels high is very important for the cell, with a few 
notable exceptions. The global decrease of methylation in somatic cells is implicated as an early 
event in carcinogenesis (Friso et al. 2013), and is a hallmark of all cancer cells, also serving as an 
accurate predictor of cancer aggression and metastatic capacity (Li et al. 2014). This is 
undoubtedly linked to their high capacity to proliferate, as a common feature cancer cells have 
with ESCs, especially in the ES naïve state, is the lower global methylation levels. Elevating non-
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CG methylation and increasing overall genomic stability, while keeping CG methylation down 
and maintaining proliferation capacity, might be another way for the ES cells to keep the genome 
under check, same applying for E16.5 male PGCs. On the contrary, any levels of non-CG 
methylation have rarely been associated with cancer, and generally it is known as a non-cancer 
related phenomenon.  
All developmental stages associated with de novo methylation maintain very high levels of 
methyltransferase expression. Their activity must be highly regulated, and while in the ESCs and 
E16.5 male PGCs those developmental windows are quite short, the timeframe for the maturing 
oocyte is very long, spread out over many years. To keep CG methylation low and avoid 
epigenetic ‘errors’ for such a long time, while maintaining the Dnmt3a2 levels very high, could be 
a real challenge. Therefore, ‘side-tracking’ Dnmts’ activity towards the CH context, which has a 
weak effect on individual loci and can act as a global methylation ‘sponge’, could be the long-
term solution.  
In this way, while the methylation in CG context can have a real effect on individual genes 
or repetitive sequences, it seems that the true asset of non-CG context methylation lies in its 
numbers and contribution to the body of ‘bulk’ methylation, rather than to the gene-specific or 
locus-specific methylation.  
 
8.3 Resistance to active demethylation 
An important and novel characteristic of non-CG context methylation, which has emerged 
from my work, is the potential to resist the known mechanisms of active demethylation.  
My results for mouse Tet1 (Figure 55) and a published in vitro study for human Tet2 (Hu et 
al. 2013) clearly show, that loss of DNA methylation mediated by the Tet family of enzymes via 
the oxidative pathway does not happen outside of the CG context. In addition to this, I have 
explored the possibility if CH context is also resistant to the second major pathway implicated in 
active demethylation, which involves the components of base excision repair (BER) (Hajkova 
2010; Santos et al. 2013; Popp et al. 2010). The AID deaminase is involved in the highly 
controlled somatic hypermutation (SHM), happening only in maturing B-cells, which leads to the 
immunoglobulin class switch, necessary for the progression towards an adaptive immune 
response during infection. In addition, it has been found important also for the phase of global 
methylation erasure in developing PGCs, as well as for the paternal pronucleus in the zygote 
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(Popp et al. 2010; Santos et al. 2013). Although 5mC is a known substrate of AID (Morgan et al. 
2004), it has been reported that AID is 10-fold less active on methylated cytosines, within its 
recognition sequence WRC (Nabel et al. 2012). In addition, my protein pull down results show 
that the AID cofactor RPA is also strongly repelled by CH methylation. Given the unusually high 
level of global methylation on the maternal pronucleus, found both on CG and CH context, it is 
tempting to speculate that it can function to inhibit the BER activating mechanism, thus 
conferring intrinsic resistance of the maternal DNA to both major pathways of active 
demethylation. Such resistance would not exclude the currently accepted mechanism by which the 
maternal pronucleus escapes active demethylation, mediated by the developmental protein Stella 
(Nakamura et al. 2007), but will only reinforce it and act in parallel. Stella has recently been 
shown to interact directly with Tet3 to block its activity (Bian & Yu 2014), meaning it might have 
more relevance for CG context methylation, but remain irrelevant for mCA, which is the 
predominant form of methylation on the maternal DNA. In addition, it is possible that those two 
pathways could cooperate, although no association with either mCG or mCA was observed in my 
Stella ChIP colocalisation analysis.  
In order to validate the model of mCH-conferred resistance to active demethylation, 
however, more details must be investigated about the long-patch BER-mediated mechanism in the 
zygote. It is intriguing to address also if RPA is indeed a factor in BER together with AID during 
the paternal reprogramming in the zygote. According to the most recently proposed mechanism 
for BER-mediated demethylation in the zygote (Santos et al. 2013), AID does not act on 
methylated cytosines, as previously presumed, but induces deamination on its original B-cell 
substrate – the unmethylated cytosines, thus creating uracils. This could potentially trigger long-
patch BER, which removes longer stretches of DNA (up to 13bp), including methylated cytosines, 
rather than a single nucleotide via the short-patch BER. In this recent model, it has been proposed 
that AID initiates BER on its own, and its activity is coupled with replication, when single 
stranded DNA substrate becomes accessible on the paternal pronucleus. UNG2, on the other hand, 
has been pointed as the most likely enzyme, implicated in the uracil removal down the line 
(Santos et al. 2013). However, on its own AID has been shown to have activity towards single 
strand DNA substrate only in vitro (Pham et al. 2003; Brar et al. 2008). In vivo it has been 
established that it works together with its cofactor RPA (Chaudhuri et al. 2004), which can 
facilitate AID-mediated deamination on actively transcribing double-stranded DNA (Chaudhuri et 
al. 2003). Subsequently RPA recruits UNG2 (Otterlei et al. 1999), thus bridging the activity of 
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AID and UNG2 together in BER. RPA-independent activity of AID would depend on the 
availability of single strand substrates, which have been suggested to form spontaneously as a 
result of negative supercoiling (Parsa et al. 2012) or the activity of the RNA exosome (Basu et al. 
2011). Whether any of those mechanisms or coupling with DNA replication, as suggested, are 
functional in vivo, however, is not known, but it has been shown that AID can function in an 
RPA-independent manner by associating with the stalled Pol II transcriptional complex (Yamane 
et al. 2011). This single in vivo example of an independent function of AID, however, does not 
trigger BER, but it is mutagenic and claimed to contribute to B-cell carcinogenesis. UNG2, 
however, can be recruited to DNA independently of RPA, to active replication foci through the 
replication factor PCNA for a post-replicative U:G mismatch repair. It has been shown, 
nevertheless, that this activity cannot substitute for the RPA-mediated UNG2 BER since the 
targeting sites by PCNA and RPA do not overlap (Torseth et al. 2012).  
As any other replication, repair and recombination related protein, RPA is highly expressed 
in both human and mouse oocytes (Roig et al. 2004; Carofiglio et al. 2013), and is hence present 
in zygotes. It is therefore very likely that the oocyte RPA is involved in the proposed pathway, 
working as a cofactor for AID in the zygote, similarly to their concerted function in SHM. Unlike 
the situation in SHM in B-cells, there is no active transcription on the paternal pronucleus before 
its DNA undergoes replication. Therefore the AID and UNG2-mediated BER could indeed 
happen together with RPA during the replication, as suggested by the current model from Santos 
et al. However, it is important to also note that the AID-RPA-mediated SHM is an error-prone 
BER, while the proposed mechanism by Santos et al. regards an error-free BER, which might also 
imply a different mechanism. Nevertheless, RPA has also been known as a processivity factor for 
the BER helicases (Ahn et al. 2009), and it is therefore possible that long-patch BER cannot at all 
proceed without RPA. Moreover, the RPA-AID binding has been very evolutionary conserved, 
and precedes other regulating mechanisms in the SHM process (Basu et al. 2008), suggesting that 
the AID-RPA cooperation might be universal and extend beyond their role in SHM. 
Immunofluorescence for RPA and other BER components in the zygote could help elucidate this 
relationship, and methylation analysis of fertilised oocytes maternally knocked-out for RPA (if 
viable) could show if the extent of demethylation is affected as it is in the AID and UNG2 KO 
zygotes. More importantly, analysis of the AID and UNG2 KO zygotes with the context specific 
antibodies could elucidate if the amount of CA methylation on the maternal pronucleus remains 
indeed unchanged after the knockout, and if the increase in methylation on the paternal 
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pronucleus, observed by Santos et al., is due to mCG only. Similarly, quantitative IF of the Tet3 
KO zygotes for mCA and mCG will also help validate the current in vitro observations that mCA 
is resistant to active demethylation by the Tet enzymes.   
In addition, the association of mCH methylation with actively transcribed TSS and stalled 
polymerases as revealed by the GRO-seq analysis (Figure 61) could also interfere with the 
reported sporadic and mutagenic activity of AID on those exposed ssDNA strands, and therefore 
implicate an anti-mutagenic role of mCH. Similarly, if the methylated WRC sites are localised 
near the imprinted DMR regions in the oocyte, this could also ensure their targeted protection 
from active demethylation in the zygote. All of these possibilities could be investigated 
bioinformatically.  
 
It is understandable that the biological implications of a mechanism for resistance to active 
DNA demethylation might be quite substantial. In addition to its importance in the zygote, it 
might explain the lack of methylation erosion in the oocyte during the long period of its 
maturation, a phenomenon which has been reported for other non-replicating mCH-high cells 
such as neurons (Oliveira et al. 2012). It could also explain the ‘necessity’ for high levels of mCH 
in the neurons themselves, which, unlike oocytes, also have very high levels of mCG and very 
active Tet-dependent hydroxylation mechanisms. The high Tet levels in neurons could be a factor 
in the reported neuronal methylation erosion, which makes the mCG a less long-lived or less 
‘durable’ mark in non-dividing cells. The mCH on the other hand could be the virtually 
permanent molecular mark, which is not propagated through cell divisions into the cell 
population, but is a stable epigenetic memory of individual DNA molecules until the death of the 
cell, thus representing a ‘molecular epigenetic memory’. This would be especially relevant, if the 
presence of mCA affects permanently the binding properties of transcription factors or other 
chromatin regulators. Such property clearly differentiates mCH from mCG, which has the role to 
set the cellular identity, not allowing it to change through cell divisions, but can be erased and 
eroded in non-dividing cells with high Tet activity. This positions mCG and mCH in different 
planes, with virtually opposite properties, that could serve contrary roles in the cell.  
 
In summary, the currently presented results characterising non-CG context methylation, 
provide insights into its specific properties and unique features, and demonstrate that it could have 
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 10 Appendix 
 
10.1 Additional tables 
 













   
  
base percent total  word percent absolute relative 
T 29,13  CA 7,45 35,70 
A 29,11  CT 7,35 35,22 
G 20,88  CC 5,24 25,11 
C 20,88  CG 0,83 3,98 
 
Base composition of the mouse genomic sequence 





Table 12. Table of used oligonucleotides  
qPCR primers   
Gene Forward primer Reverse primer 
Hspcb GCTGGCTGAGGACAAGGAGA CGTCGGTTAGTGGAATCTTCATG 
Atp5b GGCCAAGATGTCCTGCTGTT GCTGGTAGCCTACAGCAGAAGG 
Dnmt2al ATGACCGATCCAAGGACAAC TTCAAAACCTTTGACATTTTCT 
Dnmt2pro AACCAGGACGCCACAGTAGT GCCATTGATCAGGCCTTAAA 
Dnmt1s GGGTCTCGTTCAGAGCTG GCAGGAATTCATGCAGTAAG 
Dnmt3a1 AGAACAGAAGCAGACCAACATCG TGGAAGGTGAGTCTTGGCATG 
Dnmt3a2 GGCTCACACCTGAGCTGTACTG GCCTGGTTCTCTTCCACAGC 
Dnmt3b TGGTGATTGGTGGAAGCC AATGGACGGTTGTCGCC 
MajorSat GAAAATGAGAAATACACACTTT GTCAAGTGGATGTTTCTCATT 
U1 CTTACCTGGCAGGGGAGATA CAGTCCCCCACTACCACAAA 
Maj GACGACTTGAAAAATGACGAAATC CATATTCCAGGTCCTTCAGTGTGC 
Min CATGGAAAATGATAAAAACC CATCTAATATGTTCTACAGTGTGG 
DNA primers   
Region Forward primer Reverse primer 
Dnmt2genot TTTTAATGAGCCCTCCATGC TTTTCCCTTCTCCTTTCTTTCC 
IRES-R (mDnmt2) - GAAAGAGGGCTCTGTCCTCCAGTCTC 
M13 2kb ATTTCCATGAGCGTTTTTCC GCAAGGCAAAGAATTAGCAA 
M13 RT1 GCTCCCGCTCTGATTCTAAC TTAGAGCTTGACGGGGAAAG 
M13 RT2 GACAGGTTTCCCGACTGG GGGTAACGCCAGGGTTTT 
M13 R3 CCAGACGCGAATTATTTTTG GATGAACGGTAATCGTAAAACTAGC 
M13-R5 GGCGTTACCCAACTTAATCG AAAGCGCCATTCGCCATT 
MSatFor BS AAATGAGAAATATATATTTTAGGA CAAATAAATATTTCTCATTTTCC 
MSatRev BS AAATAAAAAATACACACTTT GTTAAGTGGATGTTTTTTATT 
Sequencing primers   
Region Forward primer Reverse primer 
M13 (F-40 & R) GTTTTCCCAGTCACGAC CAGGAAACAGCTATGACC 
pQE (FOR-REV) CCCGAAAAGTGCCACCTG GGTCATTACTGGAGTCTTG 











Table 13. M13-derived PCR fragments. The sequences of the M13 fragments used for a variety of 
experiments such as NNA standards, fragments with variable cytosine content for BS-degradation or for 
the analytical test digest of variety of restriction enzymes. For NNA, the base for which the fragment was 
used is indicated in the ‘Name’ column as well as capitalised in the actual sequence, and the DpnII 
restriction site is underlined.  
Name Length Sequence 5’ > 3’ 





































Table 14. Table of used antibodies 
Target (Antigen) Company Clone 
5-methylcytosine Eurogentec BI-MECY-0100, clone 33D3 
5-hydroxymethylsytosine Active Motif cat # 39769 rabbit polyclonal 
5-formylcytosine  Active Motif pAb #61223 
ssDNA  Chemicon (Millipore) MAB3034 
Dnmt1 Santa Cruz H-300 sc-20701 rabbit polyclonal 
Dnmt3a Abcam ab13888 [64B1446] (Imgenex - IMG-268A) 
Dnmt3b Abcam ab13604 [52A1018] (Imgenex - IMG-184A) 
Oct3/4 Santa Cruz sc-5279 (C10) mouse monoclonal 
H3K9me3 Active Motif mouse monoclonal 
Anti-His 6x Pierce MA1-21315 (HIS H8)  
Anti-mouse HRP  Southern Biotech 1030-05 Goat Anti Mouse IgG HRP 1.0 mL 
Anti-mouse HRP NA931VS ECL Mouse IgG, HRP-linked whole Ab 
(from sheep) 




Table 15. Illumina adapters and primers  
Name Sequence 5’ > 3’ 
PE adapter 1 P-GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
PE adapter 2 ACACTCTTTCCCTACACGACGCTCTTCCGATCT 
PE PCR Primer 1.0 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCT
TCCGATCT 
PE PCR Primer 2.0 CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCTGCTGAACCGC
TCTTCCGATCT 
PE PCR Primer 2.0 indexed 
(Quail et al. 2012) 
CAAGCAGAAGACGGCATACGAGATXXXXXXXXGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATCT 
Sequencing primer PE 1.0 ACACTCTTTCCCTACACGACGCTCTTCCGATCT 
Sequencing primer PE 2.0 CGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATCT 
Sequencing primer PE 2.0 







Table 16. Table of consensus repeat sequences 

















































Table 17. Unspecific cutters (target CN). The enzymes in red colour are methylation-dependent (cut only 
methylated sites): 
 FokI SgeI MnlI FspEI MspJI 
Sites cut total 
(out of) 
5.4 x 10
6 ~10.5 x 106 
(203 x 106) 
23 x 10












1 : 476 ~1 : 252 
(1 : 12.6) 
1 : 111 
 
~1 : 240 
(1 : 12) 
~1 : 125 
(1 : 6) 
C’s detected 0.22% 0.43% 0.87% 0.42% 0.81 % 






Table 18. Specific cutters (target a specific dinucleotide – CA, CT or CG) 




XspI (CTH) MspI/HpaII 
(CG) 
Sites cut total 5.4 x 106 7.65 x 106 12.5 x 106 8 x 106 1.6 x 106 
% CHG/CHH/CG 1 : 476 6.79% 4.56% 2.96% 7.47% 
C’s detected 0.22% 2.86 % 4.66 % 3.02 % 0.6 % 






Table 19. Full screen of mCA monoclonal supernatants 
 
Graph colour coding: 
Green – positive control (mCA or mCG respectively) 
Red – opposite negative methylation control: mCG for mCA, and mCA for mCG 
Orange – unmethylated DNA 














3 3 D 3  m C  s p e c if ic ity
m C A  o lig o  # 1
m C G  o lig o  # 2
C A  o lig o  # 3
m C C  o lig o  # 4
m C T  o lig o  # 5
m C C A  o lig o  # 6
B la n k







































































































































m C A  2 C 8  c lo n e  s p e c if ic ity  II
L 1  m C A
L 1  m C G
L 1  C A
C A  o lig o  # 3
m C C A  o lig o  # 6
m C T G  o lig o  # 7
B la n k















































































































































































































































inv mCCA oligo #6
































m C A  5 H 6  c lo n e  s p e c if ic ity
m C A  o lig o  # 1
m C G  o lig o  # 2
C A  o lig o  # 3
m C C  o lig o  # 4
m C T  o lig o  # 5
B la n k










m C C A  o lig o  # 6L 1  m C A
L 1  m C G
L 1  C A























m C A  9 H 5  c lo n e  s p e c if ic ity
m C A  o lig o  # 1
m C G  o lig o  # 2
C A  o lig o  # 3
m C C  o lig o  # 4
m C T  o lig o  # 5
B la n k










m C C A  o lig o  # 6L 1  m C A
L 1  m C G
L 1  C A


















m C A  8 G 8  c lo n e  s p e c if ic ity
m C A  o lig o  # 1
m C G  o lig o  # 2
C A  o lig o  # 3
m C C  o lig o  # 4
m C T  o lig o  # 5
B la n k










m C C A  o lig o  # 6
L 1  m C A
L 1  m C G
L 1  C A






















m C A  8 G 2  c lo n e  s p e c if ic ity
m C A  o lig o  # 1
m C G  o lig o  # 2
C A  o lig o  # 3
m C C  o lig o  # 4
m C T  o lig o  # 5
B la n k










m C C A  o lig o  # 6L 1  m C A
L 1  m C G






















m C A  4 C 1 0  c lo n e  s p e c if ic ity
m C A  o lig o  # 1
m C G  o lig o  # 2
C A  o lig o  # 3
m C C  o lig o  # 4
m C T  o lig o  # 5
B la n k










m C C A  o lig o  # 6L 1  m C A
L 1  m C G

























































































































































































































































































































































































Table 21. Datasets used for the calculation of global mCG and mCH levels in mouse early development.  
 
Developmental stage Dataset/s 
13.5 fPGC Wang 2014 
NGV Shirane 2013 PBAT 
GVO Shirane 2013 PBAT, Kobayashi 2012, Wang 2014 
Sperm Kobayashi 2012, Wang 2014 
M II oocyte Smallwood 2014 (scPBAT) 
Zygote Peat 2014 PBAT  
2-cell Wang 2014 
4-cell Wang 2014 
Blastocyst Kobayashi 2012 
ICM Wang 2014 
mESC 2i Smallwood 2014 (scPBAT) 
mESC serum Kobayashi 2012, Smallwood 2014 (scPBAT) 
Epiblast E6.5 Wang 2014 




























Oct  4 Marson_2008 mES
Tcf3 Marson_2008 mES
Stella (PGC) Bian_2014 mES
Tet3 Bian_2014 mES
Tet 1 Williams_2011 mES








Table 23. Statistically significant and marginally significant mCA protein readers and their major functions 







Binds both 5-mC and 5hmC-containing DNA, no flanking preference. Mediates 
transcriptional repression; seems to regulate dendritic growth and spine 
maturation
Foxk1 P42128
Transcriptional regulator that binds to the upstream enhancer region (CCAC box) 
of myoglobin gene. Has a role in myogenic differentiation 
Foxk2 F8VPY3
Recognizes the core sequence 5'-TAAACA-3'. At E12.5, expressed ubiquitously in 
the developing central nervous system. 
Zfp646 Q6NV66 N/A
Oct4 P20263 Pluripotency factor
Six4 Q61321
Involved in skeletal muscle development. Also implicated in retina and kidney 
development
Puf60 Q3UEB3 Plol(U) binding splicing factor





Developmental pluripotency-associated protein, may be involved in the 
maintenance of the active epigenetic status of genes
Dlst Q9D2G2
Mitochondrial, 2-oxoglutarate dehydrogenase complex catalyzes the overall 
conversion of 2-oxoglutarate to succinyl-CoA and CO2
Creb1 Q01147
Cyclic AMP-responsive element-binding protein 1, transcription factor that 
stimulates transcription upon binding to the DNA cAMP response element 
(CRE), involved in the differentiation of adipose cells.






Table 24. Statistically significant and marginally significant mCA protein repellers and their major functions 









Acts as an activator of spontaneous telomere sister chromatid exchange (T-SCE) 
and telomere elongation during early development (ES, Blastocyst)
Zbtb43 G3X9N4 May be involved in transcriptional regulation.
Zbtb22 Q9Z0G7 May be involved in transcriptional regulation.
Rpa1 Q5SWN2
Replication protein A complex, binds and stabilizes single-stranded DNA 
intermediates upon replication and repair
Rpa2 Q3TE40
Plays also a role in base excision repair (BER) probably through interaction with 
UNG. May also play a role in telomere maintenance .
Rpa3 Q9CQ71 The RPA complex controls DNA repair and DNA damage checkpoint activation.
Hnrnpd Q60668
Binds telomere ssDNA and even stronger telomere RNA, might have a role in 
telomere elongation. 
Patz1 Q5NBY9 DNA binding protein, role in spermatogenesis, T-cell differentiation
L1 probe
Pcbp3 P57722
Single-stranded nucleic acid binding protein that binds preferentially to oligo dC, 
iron chaperone for ferritin
Hnrnpll Q921F4
RNA-binding protein that functions as regulator of alternative splicing for multiple 
target mRNAs
Ptbp1 Q922I7
Plays a role in pre-mRNA splicing and in the regulation of alternative splicing 






Table 25. GO and functional terms for nuclear pull-down identified mCA binders. Clustering was 





Enrichment Score: 2.48 Count P_Value Benjamini
SP_PIR_KEYWORDS nucleus 9 0,000031 0,001100
SP_PIR_KEYWORDS dna-binding 6 0,000290 0,004900
GOTERM_MF_FAT sequence-specific DNA binding 5 0,000790 0,028000
SP_PIR_KEYWORDS Transcription 6 0,000850 0,009600
GOTERM_BP_FAT positive regulation of transcription, DNA-dependent 4 0,001400 0,340000
GOTERM_MF_FAT DNA binding 7 0,001500 0,026000
GOTERM_BP_FAT positive regulation of RNA metabolic process 4 0,001500 0,190000
GOTERM_BP_FAT transcription 6 0,001500 0,140000
GOTERM_BP_FAT positive regulation of transcription 4 0,002100 0,140000
GOTERM_BP_FAT positive regulation of gene expression 4 0,002300 0,130000
GOTERM_BP_FAT positive regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process4 0,002600 0,120000
GOTERM_MF_FAT transcription factor activity 5 0,002700 0,032000
GOTERM_BP_FAT positive regulation of nitrogen compound metabolic process 4 0,002800 0,110000
GOTERM_BP_FAT positive regulation of macromolecule biosynthetic process 4 0,002900 0,100000
GOTERM_BP_FAT positive regulation of cellular biosynthetic process 4 0,003200 0,100000
GOTERM_BP_FAT positive regulation of biosynthetic process 4 0,003300 0,093000
GOTERM_BP_FAT regulation of transcription 6 0,004300 0,110000
GOTERM_BP_FAT positive regulation of macromolecule metabolic process 4 0,004700 0,110000
SP_PIR_KEYWORDS transcription regulation 5 0,004900 0,033000
GOTERM_BP_FAT regulation of transcription, DNA-dependent 5 0,006600 0,140000
GOTERM_BP_FAT regulation of RNA metabolic process 5 0,007000 0,140000
SP_PIR_KEYWORDS phosphoprotein 8 0,012000 0,065000
GOTERM_MF_FAT transcription regulator activity 5 0,013000 0,110000
SP_PIR_KEYWORDS repressor 3 0,016000 0,073000
GOTERM_BP_FAT regulation of transcription from RNA polymerase II promoter 3 0,048000 0,620000
SP_PIR_KEYWORDS alternative splicing 6 0,050000 0,190000
UP_SEQ_FEATURE splice variant 6 0,074000 0,990000
Enrichment Score: 0.49 Count P_Value Benjamini
INTERPRO Zinc finger, C2H2-like 3 0,074000 0,930000
INTERPRO Zinc finger, C2H2-type 3 0,075000 0,730000
SMART ZnF_C2H2 3 0,190000 0,910000
GOTERM_MF_FAT zinc ion binding 3 0,540000 1,000000
GOTERM_MF_FAT metal ion binding 4 0,660000 1,000000
GOTERM_MF_FAT transition metal ion binding 3 0,670000 1,000000
GOTERM_MF_FAT cation binding 4 0,670000 0,990000






Table 26. GO and functional terms for nuclear pull-down identified mCA repellers. Clustering was 




Enrichment Score: 3.25 Count P_Value Benjamini
KEGG_PATHWAY Mismatch repair 3 0,000014 0,000056
KEGG_PATHWAY Homologous recombination 3 0,000021 0,000043
KEGG_PATHWAY DNA replication 3 0,000036 0,000048
KEGG_PATHWAY Nucleotide excision repair 3 0,000055 0,000055
INTERPRO Nucleic acid-binding, OB-fold 3 0,000370 0,010000
SP_PIR_KEYWORDS dna replication 3 0,000790 0,007500
GOTERM_BP_FAT DNA replication 3 0,003300 0,180000
GOTERM_BP_FAT DNA metabolic process 3 0,024000 0,510000
SP_PIR_KEYWORDS phosphoprotein 5 0,400000 0,590000
Enrichment Score: 1.71 Count P_Value Benjamini
INTERPRO Zinc finger, C2H2-type/integrase, DNA-binding 4 0,001800 0,024000
INTERPRO BTB/POZ 3 0,001800 0,016000
INTERPRO BTB/POZ-like 3 0,003500 0,023000
INTERPRO BTB/POZ fold 3 0,003500 0,023000
INTERPRO Zinc finger, C2H2-like 4 0,003900 0,021000
INTERPRO Zinc finger, C2H2-type 4 0,004000 0,018000
SMART BTB 3 0,005500 0,038000
COG_ONTOLOGY Transcription / Cell division and chromosome partitioning 3 0,005900 0,012000
SMART ZnF_C2H2 4 0,006800 0,024000
SP_PIR_KEYWORDS zinc 5 0,010000 0,038000
GOTERM_MF_FAT zinc ion binding 5 0,026000 0,350000
GOTERM_BP_FAT regulation of transcription 5 0,029000 0,440000
SP_PIR_KEYWORDS metal-binding 5 0,034000 0,090000
SP_PIR_KEYWORDS transcription regulation 4 0,037000 0,085000
SP_PIR_KEYWORDS Transcription 4 0,052000 0,110000
GOTERM_MF_FAT transition metal ion binding 5 0,053000 0,450000
GOTERM_BP_FAT transcription 4 0,075000 0,680000
SP_PIR_KEYWORDS zinc-finger 3 0,120000 0,210000
GOTERM_MF_FAT transcription regulator activity 3 0,160000 0,680000
GOTERM_MF_FAT metal ion binding 5 0,180000 0,650000
GOTERM_MF_FAT cation binding 5 0,180000 0,610000
GOTERM_MF_FAT ion binding 5 0,190000 0,570000
Enrichment Score: 1.34 Count P_Value Benjamini
GOTERM_CC_FAT chromosome 3 0,002700 0,065000
GOTERM_CC_FAT non-membrane-bounded organelle 3 0,063000 0,560000
GOTERM_CC_FAT intracellular non-membrane-bounded organelle 3 0,063000 0,560000
SP_PIR_KEYWORDS phosphoprotein
Count P_Value Benjamini
GOTERM_MF_FAT DNA binding 8 N/A 0,000180
SP_PIR_KEYWORDS nucleus 8 N/A 0,009000
SP_PIR_KEYWORDS acetylation 6 N/A 0,019000
SP_PIR_KEYWORDS dna-binding 5 N/A 0,016000
SP_PIR_KEYWORDS rna-binding 3 N/A 0,072000
GOTERM_MF_FAT RNA binding 3 N/A 0,390000








10.2 Additional figures 
 
 
Figure 71. A schematic representation of the conservation of strand information in paired end NGS 
datasets. Adapter sequence from the original strands differs from the adapter sequences of their PCR 
products, making it possible to map original forward amd reverse strands. Figure borrowed from Ficz, 





Figure 72. Log2 expression of Dnmts and Np95 in a panel of Dnmt-KO and Np95-KO mES cell lines used 
for this project. The Dnm3a, Dnm3b, Dnmt3ab and Dnmt1 KOs were normalised to J1 WT, Np95-KO to 







Figure 73. Log2 expression of Dnmts and Np95 in a panel of tissues. All were normalised to J1 and E14 


















































Figure 74. A comparison between ELISA and LC-MS measurements of absolute gained levels of 5hmC 





















































Figure 75. A schematic representation 
of the SILAC-based technique 
workflow for identification of nuclear 
protein binders.  
Bait and control DNA are separately 
incubated with light and heavy nuclear 
extracts (NE) from cells grown in light 
or heavy SILAC media. Bait DNA 
incubated with heavy NE is combined 
with control DNA incubated with light 
NE (forward experiment) and bait 
DNA incubated with light NE is 
combined with control DNA incubated 
with heavy NE (reverse experiment). 
The two experiments are fractionated 
using 1D SDS-PAGE, followed by in-
gel digestion and mass spectrometry. 
The results can be visualised in a 
scatterplot. Specific interactors of the 
bait DNA are located in the lower 
right quadrant (high forward ratio, 
low reverse ratio) whereas proteins 
that are repelled by the bait DNA end 
up in the upper left quadrant (low 
forward ratio, high reverse ratio). 
High-abundant background proteins 
and nonspecific DNA binders cluster 
together around the origin of the 
graph.  
Adapted from (Spruijt et al. 2013). 
 
 
